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An investigation into BK Polyomavirus and host-virus interactions 
The potentially oncogenic human pathogen BK Polyomavirus (BKPyV) was first identified in 1971 and 
has since been associated with a number of diseases primarily in immunosuppressed patients. 
Infection is established in early life and by adulthood up to 90% of populations show seroconversion 
for the major capsid protein VP1. Despite this infections are rarely cleared, maintaining a silent 
asymptomatic persistence punctuated with periods of viral shedding in the urine. The virus is non-
enveloped and comprises a simple ~5.2 Kb dsDNA genome which expresses just seven known proteins, 
necessitating a heavy reliance on, and interactions with, host mechanisms in order to efficiently 
replicate and disseminate within a population.  
The poorly understood lifelong persistence and failure to clear infection highlights our lack of 
understanding of the viral life cycle and viral interactions with host processes and responses to 
infection. Indeed, non-enveloped viruses are thought to spread solely through infected cell lysis but 
such large-scale lysis should trigger an acute inflammatory response, which is rarely seen in healthy 
immunocompetent individuals.  
The research conducted for this thesis first investigates the egress of BKPyV in a non-lytic manner, 
presenting evidence for an active non-lytic method of viral egress that is dependent on cellular anion 
homeostasis. Moreover, data generated for this thesis suggests that virions egress via an 
unconventional secretion pathway which traffics directly from the endoplasmic reticulum (ER) to the 
plasma membrane in single-membraned vesicles.  
Further research undertook a whole cell quantitative temporal viromic (QTV) approach, post-
experimentally tagging whole cell lysate peptides with isobaric labels (Tandem Mass Tagging, TMT) to 
provide a greater understanding of host cell proteomic changes throughout BKPyV infection in two 
primary human cell types over 72 hours of infection. Such an approach identified ~9000 cellular 
proteins, of which a surprisingly small number changed significantly in abundance in response to 
BKPyV infection. Of those that were changed in abundance a large proportion were related to cell 
cycle, revealing that BKPyV infection induces a pseudo-G2 arrest, similar to the G2/M checkpoint. 
Validation of TMT results in both cell types provided confidence in this robust data set, and further 
studies highlighted the importance of not only cell cycle status, but the activity of CDK1 for efficient 
viral infection and replication. Additionally, TMT generated data emphasised the lack of innate 
immune induction in response to BKPyV infection, suggesting BKPyV exhibits a sophisticated evasion 
of pathogen recognition.  
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The potentially oncogenic human pathogen BK Polyomavirus (BKPyV) was first identified in 1971 and 
has since been associated with a number of diseases primarily in immunosuppressed patients. 
Infection is established in early life and by adulthood up to 90% of populations show seroconversion 
for the major capsid protein VP1. Despite this infections are rarely cleared, maintaining a silent 
asymptomatic persistence punctuated with periods of viral shedding in the urine. The virus is non-
enveloped and comprises a simple ~5.2 Kb dsDNA genome which expresses just seven known proteins, 
necessitating a heavy reliance on, and interactions with, host mechanisms in order to efficiently 
replicate and disseminate within a population.  
The poorly understood lifelong persistence and failure to clear infection highlights our lack of 
understanding of the viral life cycle and viral interactions with host processes and responses to 
infection. Indeed, non-enveloped viruses are thought to spread solely through infected cell lysis but 
such large-scale lysis should trigger an acute inflammatory response, which is rarely seen in healthy 
immunocompetent individuals.  
The research conducted for this thesis first investigates the egress of BKPyV in a non-lytic manner, 
presenting evidence for an active non-lytic method of viral egress that is dependent on cellular anion 
homeostasis. Moreover, data generated for this thesis suggests that virions egress via an 
unconventional secretion pathway which traffics directly from the endoplasmic reticulum (ER) to the 
plasma membrane in single-membraned vesicles.  
Further research undertook a whole cell quantitative temporal viromic (QTV) approach, post-
experimentally tagging whole cell lysate peptides with isobaric labels (Tandem Mass Tagging, TMT) to 
provide a greater understanding of host cell proteomic changes throughout BKPyV infection in two 
primary human cell types over 72 hours of infection. Such an approach identified ~9000 cellular 
proteins, of which a surprisingly small number changed significantly in abundance in response to 
BKPyV infection. Of those that were changed in abundance a large proportion were related to cell 
cycle, revealing that BKPyV infection induces a pseudo-G2 arrest, similar to the G2/M checkpoint. 
Validation of TMT results in both cell types provided confidence in this robust data set, and further 
studies highlighted the importance of not only cell cycle status, but the activity of CDK1 for efficient 
viral infection and replication. Additionally, TMT generated data emphasised the lack of innate 
immune induction in response to BKPyV infection, suggesting BKPyV exhibits a sophisticated evasion 
of pathogen recognition.  
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In summary, the research in this thesis has established a novel transmission pathway for BKPyV, along 
with providing a greater understanding of the interactions between virus and host throughout the 
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1.1 An Introduction to Polyomaviridae 
1.1.1 Classification and History 
The family Polyomaviridae are a group of species-specific ubiquitous pathogens, known to cause cell-
tropism dependant infection. Originally part of the family Papovaviridae, which contained both 
Papillomavirus and Polyomavirus genera, Polyomaviridae have been identified as a distinct virus family 
since 1999. In 2011 the single family was divided into three genera, the Orthopolyomavirus and 
Wukipolyomavirus genera containing mammalian viruses, while the Avipolyomavirus genera 
containing those viruses which infected birds (Johne et al., 2011, Schneider et al., 2014). This 
classification has been further updated by the International Committee on Taxonomy of Viruses 
(ICTV), and as of 2018 there are four distinct genera of polyomavirus based on their Large T Antigen 
(TAg) sequence similarity (Calvignac-Spencer et al., 2016). 
The largest of these new genera containing more than 30 members, Alphapolyomavirus, encompasses 
a number which infect humans and other mammals, including the oncogenic Merkel Cell Polyomavirus 
(MCPyV), Murine Polyomavirus (MuPyV) and Raccoon Polyomavirus (RacPyV). With more than 20 
species Betapolyomavirus is the next largest genus and, similar to Alphapolyomavirus, its members 
infect humans and other mammals. Both BK Polyomavirus (BKPyV) and JC Polyomavirus (JCPyV) are 
members of the Betapolyomavirus genus, as well as the primate polyomavirus Simian Vacuolating 
Agent 40 (SV40). Gammapolyomavirus includes fewer than 10 species, all of which infect only birds. 
While Gammapolyomaviruses are generally not thought to be oncogenic, disease presentations can 
be severe and at times fatal in various avian species. Deltapolyomavirus encompasses just four 
exclusively human tropic strains whose disease presentations are less apparent than either 
Alphapolyomavirus or Betapolyomavirus (Calvignac-Spencer et al., 2016, Moens et al., 2017). 
The first polyomavirus to be identified was MuPyV in 1952, and this virus was shown to be the 
causative agent of tumours in newborn and immunocompromised mice (Gross, 1953). In 1960 SV40 
was found to be a contaminating agent in several batches of the human oral poliovirus vaccine Sabin, 
which had been grown in monkey kidney cell cultures (Sweet and Hilleman, 1960). While SV40 has 
also been shown to cause tumours in mice, extensive cohort studies following large-scale exposure to 
humans in 1960 showed no increased risk of oncogenesis, thus SV40 shows inadequate evidence as 
the definitive causative agent of carcinoma in humans (Bouvard et al., 2012). It must be noted, 
however, SV40 viral gene products have been identified in a number of different tumours, suggesting 
a potential co-infectious association (Lowe et al., 2007), and most recently SV40 has been associated 
with malignant pleural mesothelioma (Thanh et al., 2016). 
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It was not until 1971 that the first human polyomaviruses were discovered. Named for the individual 
in which they were identified, BKPyV was isolated from a male Sudanese 39-year-old kidney transplant 
patient who had been suffering serious pyelonephritis and renal failure (Gardner et al., 1971), while 
JCPyV was isolated from the brain tissue of a patient that had suffered progressive multifocal 
leukoencephalopathy (PML) (Padgett et al., 1971). Since 2007 a further twelve human polyomaviruses 
have been discovered (Table 1.1), many of these have not yet been associated with disease and in a 
number of these a human host may not be the primary source of infection. One such example is Lyon 
IARC Polyomavirus (LIPyV), which shares 65% sequence similarity with RacPyV of raccoon origin (Gheit 
et al., 2017). 
 
1.1.2 Human Polyomaviridae and Associated Disease 
Table 1.1: An overview of all 14 human polyomaviruses discovered to date 





BKPyV Beta 1971 Haemorrhagic cystitis (HC); 
polyomavirus associated 
nephropathy (PVAN); 
Prostate cancer; Meningitis 
and encephalitis; Human 
Immunodeficiency Virus 
(HIV)-associated salivary 
gland disease; Retinitis; 
pneumonitis 
Urine (Erard et al., 2004, 
Hirsch et al., 2005, 
Keller et al., 2015, 
Chittick et al., 2013, 
Burger-Calderon et 
al., 2014, Reploeg 
et al., 2001, 
Hedquist et al., 
1999)  
JC Polyomavirus JCPyV Beta 1971 Progressive multifocal 
leukoencephalopathy 
(PML); Multiple sclerosis; 
Colon cancer 
Urine (Gheuens et al., 







KIPyV Beta 2007 No clear disease 
correlation, may be 




(Gaynor et al., 





WUPyV Beta 2007 No clear disease 
correlation, may be 




(Allander et al., 




MCPyV Alpha 2008 Merkel cell carcinoma Skin lesion (Feng et al., 2008) 
Human 
Polyomavirus 6 
HPyV6 Delta 2010 Pruritic dermatoses and 
dyskeratosis 




HPyV7 Delta 2010 Pruritic dermatoses and 
dyskeratosis 













(Scuda et al., 2011) 





MWPyV Delta 2012 No clear disease 
correlation 




STLPyV Delta 2013 No clear disease 
correlation 
Stool (Lim et al., 2013) 
Human 
Polyomavirus 12 
HPyV12 Alpha 2013 No clear disease 
correlation 
GI tract (Korup et al., 2013) 
New Jersey 
Polyomavirus 













(Gheit et al., 2017) 
       
 
1.2 BKPyV 
1.2.1 Seroprevalence, Disease and Treatment 
BKPyV has been divided into four major subtypes, grouped by genetic heterogeneity. The worldwide 
distribution of subtype I means that it is also the most prevalent subtype, while subtype IV is found 
only in Europe and East Asia. Subtypes II and III are seldom isolated in any general population (Yogo 
et al., 2009). From these subtypes, five separate serotypes have been described; subtypes II, III, IV and 
the further subdivided subtype Ib1 and Ib2 (Pastrana et al., 2013). A high seroprevalence in a 
population is maintained throughout life. By the age of four 50% of children are thought to be infected, 
rising to more than 60% by the age of ten and continuing to rise into adulthood, by which time up to 
90% of populations show seroconversion for at least one BKPyV serotype (Shah et al., 1973, Kean et 
al., 2009, Viscidi et al., 2011). Such high rates of seroconversion in a population must be treated with 
caution however because these studies have used seroconversion against the BKPyV major capsid 
protein VP1 as an indicator of prior infection, but there is known to be a high level of cross-reactivity 
between many polyomavirus VP1 motifs, notably between JCPyV and BPKyV VP1 which show 78% 
similarity (Moens et al., 2013). 
Although the route of transmission of BKPyV is unclear, typically primary infection is thought to occur 
in the tonsils, through a respiratory or faecal-oral route, after which infected monocytes traffic the 
virus to various tissues and organs throughout the body (Hirsch and Steiger, 2003). This initial infection 
is largely asymptomatic and BKPyV maintains a silent persistence in the renourinary tract epithelium, 
where minimal episomal replication occurs. It has been suggested that this state represents a ‘true 
latency’ by BKPyV (Helle et al., 2017).  
It is thought that once lifelong asymptomatic viral persistence is established in the renourinary tract 
the patient is unlikely to suffer any adverse clinical effects until such time that they may become 
immunosuppressed. Immune suppression, particularly by strong immunosuppressive therapies but 
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also clinical conditions such as Acquired Immuno-Deficiency Syndrome (AIDS), leads to a dramatic 
increase in BKPyV lytic replication. Viral loads over 104 copies/ml detected in patient urine by 
polymerase chain reaction (PCR) are indicative of ‘reactivated infection’ (Hirsch and Steiger, 2003). It 
is the large scale lysis of cells caused by virus replication from which many of the cytopathic effects 
(CPE) occur. Kidney transplant patients are particularly prone to polyomavirus associated nephropathy 
(PVAN), in which CPE are characterised by interstitial nephritis caused by breakdown of the infected 
epithelial layer of graft tubules, after which BKPyV gains access to the bloodstream. The resultant 
influx of inflammatory cells may lead to atrophy of the renal tubules and fibrosis. Up to 10% of 
transplant patients can be affected within the first two years post-transplant, of these up to 80% can 
result in graft failure (Egli et al., 2007). There is little treatment available for treatment of PVAN in 
patients. It is generally recommended that the immunosuppressive drug regimen is reduced to allow 
the host immune system to control viraemia levels as the currently available anti-viral drugs that show 
inhibitory effects on BKPyV replication, cidofovir and leflunomide, have very serious side effects 
including nephrotoxicity (Johnston et al., 2010). Graft failure, therefore, may be due to direct damage 
caused by viral replication and lysis or due to graft rejection caused by reduction of 
immunosuppression, or a combination of both. 
In 10-25% of haematopoeitic stem cell transplant (HSCT) patients increased BKPyV-induced cell lysis 
due to immunosuppression can lead to haemorrhagic cystitis (HC) (Hingorani, 2016) Although not 
usually life threatening, HC can lead to greatly reduced rates of recovery from HSCT and in exceptional 
circumstances blood clots have been known to block the urinary tract, resulting in renal failure (Jiang 
et al., 2009a). It has also been noted that BKPyV has been found in the salivary glands of AIDS patients, 
causing Human Immunodeficiency Virus (HIV)-associated salivary gland disease (Burger-Calderon et 
al., 2014), the retina of AIDS patients with ophthalmological complications (Reploeg et al., 2001) and 
in the upper respiratory tract of children suffering interstitial pneumonitis (Hedquist et al., 1999), 
illustrating that BKPyV is an opportunistic pathogen with the potential to cause clinical disease at a 
number of sites in immunocompromised patients. While these disease presentations can be more 
effectively treated with anti-viral drugs they further demonstrate why a greater understanding of the 
interactions between virus and host is needed and may lead to a more effective treatment of BKPyV 
either pre- or post-transplant, with the potential to save lives and improve the clinical outcomes of 
many more. 
BKPyV, like many polyomaviruses, has oncogenic potential and has been shown to transform Baby 
Hamster Kidney 21 (BHK-21) cells in vitro (Major and Dimayorc.G, 1973) and hamster kidneys in vivo 
(Takemoto and Martin, 1976). In humans however, while gene products have been found in a number 
of tumour tissues, most notably the prostate (Chittick et al., 2013), there is a great deal of variation 
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between studies as to levels of viral gene expression, or even the presence or absence of detectable 
virus in carcinomas, and there is currently little evidence of a causal of BKPyV infection with 
carcinogenesis; reviewed extensively in (Abend et al., 2009a). As such BKPyV is characterised as a 
group 2B carcinogenic biological agent, i.e. possibly carcinogenic to humans (Bouvard et al., 2012). 
The viral gene products TAg and small t antigen (tAg) have been shown to have oncogenic properties 
through their action of cell cycle deregulation and p53 induced apoptosis, which is discussed more 
extensively later. 
 
1.2.2 Genome Organisation 
BKPyV are small circular dsDNA viruses with a genome of ~5kb, whose bidirectional transcription is 
controlled by a non-coding control (NCCR) region of around 400bp. The principal early transcribed 
genes are TAg and tAg, which are splice variants of a single mRNA transcribed from the same genomic 
region and are named for the size of protein produced by said splicing (DeCaprio and Garcea, 2013). 
A truncated form of TAg has also been described (truncTAg) (Abend et al., 2009b), which initially goes 
through normal TAg splicing, but undergoes a secondary splicing event leading to a frameshift that 
introduces a stop codon in frame soon after the second splice acceptor site. The late region encodes 
for the structural capsid proteins, VP1, VP2 and VP3, and agnoprotein (Agno), a small multifunctional 
non-structural protein. VP3 is homologous to the C-terminus of VP2, originating from an alternative 
start site within the VP2 open reading frame.  
While the transcribed portion of BKPyV is largely conserved throughout strains, the NCCR region is 
highly variable. Containing the origin of replication (Ori) with more than 30 transcription factor binding 
sites, the archetype strains contain ‘blocks’ of base pairs (designated as O, P, Q, R, S) that can be found 
to be rearranged, duplicated or lost in strains other than archetype, leading to differential effects on 
cell tropism, oncogenicity and preferential transcription of early or late genes (Bethge et al., 2015, 
Johnsen et al., 1995, Moens et al., 1995, Gosert et al., 2008). These rearrangements are often 
identified in patients with increased levels of viral replication, who frequently shed archetypal strain 
in urine while blood plasma virus is rearranged (Gosert et al., 2008). The reason for such variations in 
patients remains unclear, however such NCCR rearrangements may play a role in virus adaptation to 
different types of cell in vitro. 
  












Figure 1.1: A schematic view of BKPyV circular dsDNA genome.  
Dark blue regions represent early genes, while light blue regions represent late genes. 
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1.2.3 Virion Structure 
Polyomaviruses such as BKPyV are small 45 nm non-enveloped virions comprising 72 VP1 pentamers, 
each associated with a single VP2 or VP3 on their inner cavity surface. The pentamers form a capsid 
with T = 7 icosahedral symmetry; sixty pentamers have six adjacent pentamers, while the remaining 
twelve have five adjacent pentamers. Each pentamer is stabilised by the C-terminal arms of VP1, while 
the capsomer as a whole is stabilised by both disulphide bonds and calcium ions. The N-terminal arm 
of VP1 is associated with the viral genome, condensed within the capsid by ~20 nucleosomes 





















Figure 1.2: Cryo-EM structure of BKPyV virion.   
A 40-Å-thick cross section of the virion highlights the VP2/3 attachment to the inner pentamer void, shown in 
blue/green, contour level 0.0032 (a). Under each VP1 pentamer a VP2/3 is associated. Condensed dsDNA can be 
seen in two layers of density (b). Image taken from (Hurdiss et al., 2016); used with permission.  
(a) (b) 
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1.2.4 Viral Proteins and Known Functions 
Table 1.2: An overview of BKPyV viral proteins and their known functions 
Viral Protein Early/Late Expression 
Size 




Early 20  The first protein, along with TAg and truncTAg to be 
expressed during infection through alternative 
splicing of the full length T-antigen mRNA. 
Modulates host replication processes to drive viral 
replication. tAg binds protein phosphatase 2A 
(PP2A), inhibiting it’s enzymatic activity. 




Early 80  The first protein, along with tAg and truncTAg to be 
expressed during infection through alternative 
splicing of the full length T-antigen mRNA. Contains 
an LXCXE motif allowing it to bind Rb, p107 and 
p130, stimulating cell cycle progression. TAg also 
functions as a helicase, forming a double hexamer to 
unwind viral DNA at the Ori, subsequently recruiting 
host DNA replication proteins. TAg can also bind p53, 
further modulating host cell cycle progression and 
apoptosis. Contains a nuclear localisation sequence 
(NLS). 
(Stubdal et al., 
1997, Sowd and 
Fanning, 2012, 
Lilyestrom et al., 






Early 17  The first protein, along with TAg and tAg to be 
expressed during infection through alternative 
splicing of the full length T-antigen mRNA. Contains 
the LXCXE motif identified in TAg, allowing it to bind 
Rb, p107 and p130, stimulating cell cycle 
progression. Contains a nuclear localisation 
sequence (NLS). 
(Abend et al., 
2009b) 
VP1 Late 42  A common feature of all polyomaviruses, the VP1 
structural protein forms the main constituent 
protein of the virus capsid and comprises 5 surface 
exposed loops; BC, DE, EF, GH and HI. Five copies of 
VP1 form a pentamer stabilised by C-terminal arms 
of each VP1, while the N-terminal arms mediate DNA 
binding. 72 pentamers form each capsid, stabilised 
by Ca+ cations and disulphide bonds.  
(Liddington et al., 
1991, Hurdiss et al., 
2016) 
VP2 Late 38  Minor capsid protein located on the internal side of 
the capsid. Structurally similar to VP3, sharing the C-
terminus but has a longer N-terminus. One copy of 
VP2 or VP3 is associated with each VP1 pentamer via 
a hairpin loop inserted into the central pentamer 
cavity. May have a role in uncoating and targeting to 
the nucleus via an NLS. 
(Chen et al., 1998, 
Hurdiss et al., 2016, 
Bennett et al., 
2015) 
VP3 Late 27  Minor capsid protein located on the internal side of 
the capsid. Structurally similar to VP2, sharing the C-
terminus but has a truncated N-terminus in 
comparison. One copy of VP2 or VP3 is associated 
with each VP1 pentamer via a hairpin loop inserted 
into the central pentamer cavity. May have a role in 
uncoating and targeting to the nucleus via an NLS. 
(Chen et al., 1998, 
Hurdiss et al., 2016, 




Late 8  A small protein of 66 amino acids in length. Thought 
to colocalise with lipid droplets, and interact with 
PCNA in an inhibitory manner. Its exact function is 
unknown. 
(Gerits et al., 2015, 
Unterstab et al., 
2013)  
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1.3 Lifecycle of BKPyV 
1.3.1 Attachment and Entry 
The capacity to reduce infectivity of BKPyV after neuraminidase treatment along with the 
haemagglutination of erythrocytes after exposure to BKPyV lead to the discovery that virions, and 
specifically VP1, are able to bind sialic acid residues on the surface of target cells (Seganti et al., 1981, 
Sinibaldi et al., 1990). In culture BKPyV has been shown to bind a number of b-series gangliosides 
including GD3, GD2, GD1b and GT1b (Low et al., 2006, Neu et al., 2013). Those cells which do not 
express these gangliosides are resistant to BKPyV infection however these same cells, if induced to 
express GD3, GD2, GD1b or GT1b, become permissive to infection. It has been suggested that both 
the α(2,3)-linkage of sialic acid to galactosyl residues and the α(2,8)-linked sialic acid residues play an 
important role in the binding of BKPyV to the cell surface; enzymatic removal of these linkages was 
shown to reduce infection, whilst reinstatement of them once again caused cells to be permissive to 
infection (Dugan et al., 2005, Low et al., 2006).  
Cell tropism differences have been noted for different BKPyV serotypes (Pastrana et al., 2013) and it 
is suspected that there may be more than just interaction with sialic acid residues required for 
infection. It has been shown for MCPyV that sialic acid binding is secondary to a potential 
glycosaminoglycan binding (Schowalter et al., 2012).  
Once bound to a receptor, BKPyV has been shown to enters African Green Monkey Kidney (Vero) cells 
by caveolin-mediated endocytosis  (Eash et al., 2004) although renal proximal epithelial tubule (RPTE) 
cells, a human primary cell type which better represents in vitro infection sites, show a cell entry 
mechanism which is both clathrin and caveolin independent (Zhao et al., 2016). Once endocytosed 
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1.3.2 Transport to the Nucleus 
Once internalised it has been shown that in RPTE cell vesicles containing BKPyV are trafficked along 
microtubules and as such, infection can be disrupted with the use of the microtubule depolymerising 
drug nocodazole. Vesicle bound BKPyV are targeted to the endoplasmic reticulum (ER), avoiding the 
Golgi apparatus, in a dynein independent manner (Moriyama et al., 2007, Moriyama and Sorokin, 
2008). There is also compelling recent evidence that BKPyV entry involves Rab18 positive endosomes 
(Zhao and Imperiale, 2017). Delivery to the ER along this pathway is thought to take 8-12 hours 
(Moriyama and Sorokin, 2008). It is interesting to note that in Vero cells vesicle trafficking does not 
show the same dependency on microtubule dynamics (Eash and Atwood, 2005), further illustrating 
the importance of conducting experiments in cell types which most closely align with those of natural 
infection sites. 
Upon reaching the ER BKPyV virions are deposited into the ER lumen through fusion of the host vesicle 
and ER membrane. It is thought that capsid disassembly begins in the ER through disassociation of 
VP1 disulfide bonds (Jiang et al., 2009b) exposing VP2 and VP3 hydrophobic residues that embed into 
the ER membrane. The ER associated protein degradation (ERAD) and proteasome pathways, both 
primarily used by cells to recycle misfolded proteins, are then hijacked to allow transport of the 
partially disassembled capsid out of the ER and to the nuclear pore via the targeting of the exposed 
NLS regions of VP2 and VP3 (Bennett et al., 2013). There is evidence that partially disassembled capsids 
are then imported into the nucleus by the α/β1 importin pathway (Bennett et al., 2015). It is generally 
considered to take 12-18 hours before the viral capsids reached the nucleus and the genome is fully 
uncoated. 
 
1.3.3 Gene Expression and Genome Replication 
BKPyV relies on host machinery for protein synthesis, regulated tightly by host transcription factors 
recruited to the bidirectional NCCR transcription factor binding sites, of which there are more than 30 
(Moens et al., 1995, Johnsen et al., 1995). At around 12-24 hours after viral entry to the cell such 
transcription factors are recruited to the NCCR. The early genes are the first to be transcribed, which 
comprise primarily of TAg and tAg, as well as the lower abundance additionally spliced TAg transcript 
that encodes for truncTAg (Abend et al., 2009b). Each of the early proteins are translated from 
alternatively spliced T-antigen mRNA (DeCaprio and Garcea, 2013). The early proteins are essential 
for viral replication, working to promote cell growth, cell cycle checkpoint bypass, apoptotic resistance 
and thus stimulating a cellular environment favourable for viral DNA replication. Most studies into the 
effects of these early genes have been conducted in other human and primate polyomaviruses., 
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however, due to extensive sequence homology between genomes one may tentatively extrapolate 
the data to encompass BKPyV. After its synthesis the NLS of TAg causes it to be quickly transported to 
the nucleus, where it plays a multifunctional role (Doherty and Freund, 1997). The binding of TAg to 
p53 has been shown to lead directly to apoptotic resistance, while also stimulating cell cycle 
progression through reduced checkpoint arrest signalling in response to any DNA damage in SV40 
(Lilyestrom et al., 2006). In JCPyV, MCPyV and SV40, TAg has been shown to bind pRB family proteins, 
preventing early cell cycle arrest and stimulating progression from the early cell cycle growth phase 
(G1) to synthesis (S) phase, known as the G1/S checkpoint (Bollag et al., 2000, Borchert et al., 2014, 
White and Khalili, 2006). This is further enhanced in SV40 by TAg binding to Hsc70, an ATPase-
containing chaperone protein which triggers the disassociation of pRb and E2F, allowing TAg to bind 
pRb directly (Sullivan et al., 2000). Cell growth in BKPyV infected cells has been shown to be stimulated 
by an activated MAP kinase pathway, stimulated by TAg (Seamone et al., 2010). The SV40 tAg, in 
contrast, has a more minor role in cell cycle progression. It binds and inhibits the enzymatic activity of 
protein phosphatase 2A (PP2A), a protein phosphatase which has more than 300 cell cycle regulatory 
targets (Skoczylas et al., 2004). BKPyV tAg also contains the Retinoblastoma (Rb) binding motif LXCXE 
suggesting it may, like TAg, also lead to bypass of the G1/S checkpoint, although this has yet to be 
formally demonstrated (Ehlers and Moens, 2014). 
TAg also acts as a viral helicase, the only viral protein identified to be involved in viral genome 
replication. Forming a dimeric hexamer, TAg binds GAGGC motifs found at the Ori in the NCCR of the 
viral genome. Host replication factors are then recruited to the Ori, leading to viral replication at 
around 18-24 hours after infection (Bennett et al., 2012). During viral genome replication the host 
DNA damage response (DDR) pathway is activated, preventing BKPyV-induced damage to host DNA 
(Verhalen et al., 2015). 
Late genes are transcribed and translated from around 24 hours after infection from a common pre-
messenger RNA (pre-mRNA) which is alternatively spliced to form individual messenger RNA (mRNA) 
transcripts which are then transported from the nucleus (Huang and Carmichael, 1996). Transcribed 
from the complementary viral DNA strand, mRNA transcription is driven by both the increased copies 
of viral genomes and TAg induced changes in transcription factor binding in the NCCR (Moens et al., 
1997). The late genes comprise the structural proteins VP1, VP2 and VP3 which make up the viral 
capsid, and also Agno, which may play a regulatory role in replication. Agno is known to bind 
proliferating cell nuclear antigen (PCNA) in an inhibitory manner, suggesting a role in reducing viral 
genome synthesis and promoting viral capsid assembly (Gerits et al., 2015). The roles of Agno are 
thought to extend beyond this, and it has also been shown to bind N-ethylmaleimide-sensitive 
factor Attachment Protein Alpha (α-SNAP), suggesting a role in trafficking (Panou et al., 2018). 
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However, point mutations of Agno in BKPyV genomes that prevent synthesis of Agno, have shown 
virus is still infectious in Vero cells (Johannessen et al., 2011). Furthermore, in RPTE cells infected with 
mutant BKPyV in which wild-type Agno expression is eliminated genome levels are comparable, and 
may even exceed, that of cells infected with wild type BKPyV (Panou et al., 2018).  
 
1.3.4 Virion Assembly 
Once synthesised in the cytoplasm VP1 forms pentamers, each associated with a single VP2 or VP3 on 
what will become the innermost surface (Lin et al., 1984). These are quickly transported into the 
nucleus due to NLS. Capsid assembly has been found to spontaneously occur with overexpression of 
VP1 alone, in this instance leading to virus-like particles (VLPs), although stability of VLPs is greatly 
increased in the presence of VP2 and VP3 (Teunissen et al., 2013).  
Imported pentamers are transported to nuclear ‘viral factories’ which are located near promyelocytic 
leukaemia nuclear bodies (PML-NB), although these are not essential for viral replication and 
encapsidation (Erickson et al., 2012). For MuPyV the encapsidation of non-viral vector DNA was found 
to be dependent on total amount of vector DNA in the proximity of the virus factory and not sequence 
specific (Spanielova et al., 2014), however mutations in the N-terminus of SV40 TAg lead to less 
efficient viral assembly, suggesting a role for TAg in DNA encapsidation (Spence and Pipas, 1994a, 
Spence and Pipas, 1994b). Furthermore in JCPyV heat shock protein 70 (Hsp70), typically involved in 
protein folding and prevention of protein aggregation (Mayer, 2005), has been shown to mediate 
capsid DNA binding to TAg and VP2/3 (Saribas et al., 2014). Interestingly, Hsp70 is an essential viral 
replication factor recruited by not only Polyomaviridae but also Adenoviridae, Poxviridae and 
Orthomyxoviridae among others (Mayer, 2005).  
In BKPyV the known DNA binding region of VP1 N-terminus is thought to stimulate encapsidation of 
viral genomes, ultimately leading to the completed synthesis of progeny virions in the nucleus (Hurdiss 
et al., 2016). 
 
1.3.5 Lytic Virion Release 
As a non-enveloped virus it has been commonly accepted that the primary method for viral release 
from an infected cell is through cellular lysis after rupturing the nuclear membrane. The swollen nuclei 
of infected cells are a distinctive infectious marker and tightly packed virions within the nucleus at late 
stages of infection in transplant patient derived renal tubular cells can be seen with transmission 
electron microscopy (TEM) (Drachenberg et al., 2003). In JCPyV it has been shown that neither VP1 
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nor Agno alone were capable of causing cell lysis, although Agno was found to act as a viroporin which 
may, in the context of late stage infection and swollen nuclei, contribute to nuclear membrane failure 
and rupture (Suzuki et al., 2010).  
 
1.3.6 Non-Lytic Virion Release 
There is little data that has been published on the mechanisms of polyomavirus release from infected 
cells. It has been postulated that a method of non-lytic release for polyomavirus may exist. The 
establishment of lifelong infections, coupled with minimal inflammatory responses to such an 
infection, suggests that cell lysis may not be occurring in this silent yet persistent stage of infection. 
Furthermore, evidence for non-lytic release of other non-enveloped viruses has been identified. The 
parvovirus Minute Virus of Mice (MVM) has been shown to be trafficked along cytoskeleton filaments, 
bound by vesicles, and that this process is necessary for effective viral release (Bar et al., 2008). 
Hepatitis A (HAV), a pathogenic picornavirus, appears to acquire host membranes prior to non-lytic 
release from an infected cell, cloaking the virus from recognition and neutralisation by host antibodies 
(Feng et al., 2013). Yet another non-enveloped virus, poliovirus, has been shown to require 
microtubules for extracellular release in a non-lytic manner (Taylor et al., 2009). Most notably the 
polyomavirus SV40 has been shown to be released from the apical surface of primate kidney epithelial 
cells without cell lysis, and that this release could be inhibited with monensin, a sodium ionophore 
which blocks the transport of secretory vesicles from the trans-Golgi network (Clayson et al., 1989).  
In addition to evidence on non-lytic release in other non-enveloped viruses, it has been shown that 
JCPyV Agno mutant progeny are less able to egress the nucleus and release (Ellis et al., 2013). The role 
of BKPyV Agno interaction with α-SNAP has been suggested to play a role non-lytic egress, affecting 
the exocytosis pathway (Johannessen et al., 2011). Most recently BKPyV Agno has been shown to be 
an essential factor for nuclear egress in non-lytic infections (Panou et al., 2018). Our lab has also 
provided evidence for a non-lytic release mechanism for BKPyV (Evans et al., 2015), which will be 
discussed further as the basis of Chapter 2 of this thesis.  
  






























































































































































































































































































































































































































































































































































































































































































































































Chapter 1. Introduction 
16 
 
The work detailed in this thesis relates to a number of different host processes that appear to be 
involved in BKPyV release and/or modified during infection. The relevant host pathways are 
introduced below. 
 
1.4 Eukaryotic Secretory Pathways 
1.4.1 Conventional Secretion 
Proteins that are secreted from cells, be they soluble extracellular proteins or residents of the cell 
surface membrane, can be transported via a number of routes. The same is also true for non-lytic 
release of viruses. The best understood and studied of these pathways is conventional vesicular 
egress, a pathway which traffics cargo from ER lumen through the Golgi and on to the cell surface, 
either by the constitutive secretory pathway or the regulated secretory pathway.  
Constitutive secretion is the direct trafficking of vesicle bound proteins from the trans-Golgi network 
(TGN) directly to the cell surface, where the contents are released upon fusion of vesicle and cell 
surface membranes (Fig. 1.5). Cellular proteins known to traffic by the constitutive secretory pathway 
include serum proteins such as immunoglobulins and transferrin, and extracellular matrix proteins 
such as collagen and proteoglycans (Lodish et al., 1995). In contrast to this, upon vesicle budding from 
the TGN, regulated secretion pathways see proteins stored in immature secretory vesicles which 
mature and concentrate cargo until such time that a signal or cellular environmental change triggers 
release. Proteins known to release in this way may be peptide hormones, such as endorphins, 
digestive enzymes, such as ribonuclease or trypsin, or milk proteins such as casein or lactalbumin 
(Lodish et al., 1995). Another example of a regulated secretion protein is insulin. Within the pancreas 
reside β-cells which secrete insulin in response to high concentration of glucose which stimulate an 
action potential within the cell. Until such time as a high glucose concentration signal is received, 
insulin is stored and secretion regulated by inhibitory signals that control exocytosis (Rorsman and 
Braun, 2013). 
The pathways for both constitutive and regulated conventional secretion begin in the same manner. 
The membrane-bound or soluble secreted proteins are translocated into the ER during synthesis, this 
is directed by the presence of a 5-16 amino acid signal peptide located towards the N-terminus of the 
nascent protein (Walter and Lingappa, 1986). If correctly folded by molecular chaperones found in the 
ER, the target protein will dock with membrane-bound receptors, which stimulate COPII vesicle 
formation. COPII coated vesicles are targeted to the endoplasmic reticulum Golgi intermediate 
complex (ERGIC) by Rab1, a small GTPase of the Ras superfamily, leading to fusion of vesicles with the 
ERGIC (Allan et al., 2000, Lodish et al., 1983).  
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The ERGIC organelle is situated between the ER and the Golgi, directing vesicles containing proteins 
between the two, thus any misfolded proteins may be transported back to the ER for re-folding in 
COPI coated vesicles. Correct folding in the ER may feature additional post-translational modifications 
such as disulphide bridge formation and N-linked glycosylation. Should refolding in the ER prove 
unsuccessful the misfolded protein will be retro-translocated from the ER back into the cytoplasm by 
the ERAD pathway, where they are ubiquitinated and targeted for proteasomal degradation (Kostova 
and Wolf, 2003). Correctly folded proteins are trafficked along microtubules from the ERGIC to the 
TGN in COPII coated vesicles, then on through the TGN in a targeted cis to trans manner in COPI 
vesicles. During transport through the TGN proteins may undergo further post-translational 
modification of glycans. Once protein synthesis and post-translational modification has been 
completed target proteins can be secreted (Munro, 2011).  
In the constitutive secretory pathway cargo-containing vesicles that bud from the trans-Golgi can be 
trafficked directly to the plasma membrane, where upon docking they undergo membrane fusion 
resulting in the enclosed cargo being released directly into the extracellular space. Proteins that are 
transported via the constitutive secretory pathway are thought not to have specific secretory signals, 
instead large tethering complexes interact with the vesicle coat to target contents to the plasma 
membrane or other subcellular locations. Tethering complexes are Rab effectors/exchange factors, 
thus it is the interaction of specific tethering complexes and Rabs which direct intracellular trafficking 
(Cai et al., 2007). One example of tethering regulating vesicle targeting is the golgin tether GM130 
which interacts with Golgi-reassembly stacking protein of 65kDa (GRASP65; also known as GORASP1), 
itself an effector of Rab1, leading to stacking of Golgi cisternae and regulation of COPII vesicle targeting 
to, and fusion with, the TGN (Barr et al., 1998).  
There are ~70 human GTPases which form the well conserved family of Rab proteins. Membrane-
bound through a covalently linked lipid-anchor, Rabs cycle between active guanosine triphosphate 
(GTP) and inactive guanosine diphosphate (GDP) states through the activity of GDP/GTP exchange 
factors (GEFs) and GTPase activating proteins (GAPs). Active Rabs facilitate membrane budding in 
response to cargo selection and tethering complex binding, followed by trafficking to target 
membranes. Once membranes fuse and cargo is released, Rabs become inactive and cycle back to 
their original cargo selection membrane. Each Rab shows a specific subcellular localisation and 
effector target membrane, for example Rab5 is found on the membranes of early endocytic cargo, but 
as the endosome matures it is replaced with Rab7 which targets vesicle contents to lysosomes (Rink 
et al., 2005). It must be noted however that there may be some overlap in function and/or partial 
redundancy that is not fully understood (Zhen and Stenmark, 2015).    
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Once brought into proximity with one another by tethering complexes and Rabs, soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins mediate fusion of 
membranes and release of vesicle contents (Sollner et al., 1993). SNARE proteins are present on both 
vesicle (v-SNARE) and target (t-SNARE) membranes, anchored to membranes by their N-terminus with 
a SNARE-specific 60-70 amino acid cytosolic region that forms coiled-coil helices through heptad 
repeats (Rothman and Warren, 1994). Further classification of SNAREs can be made by the key amino 
acid residues which form the centre of the helical bundle, R-SNAREs contain an arginine (R) in the 
helical bundle, while Q-SNAREs contain a glutamine (Q) (Fasshauer et al., 1998). Current 
understanding of SNARE complexes suggests that membrane fusion occurs entirely by mechanical 
force, once one v-SNARE and three t-SNAREs are brought into contact with one another the tightly 
formed four helix bundle draws opposing membranes together until the lipid bilayers merge and a 
fusion pore is made, spilling the vesicle contents through (Sudhof and Rothman, 2009).  
In this way tethers, Rabs and SNAREs work in conjunction with one another to mediate complex and 
multifaceted trafficking pathways directing secretory cargo to their appropriate destination.  
  











Figure 1.5: The ERGIC and ERAD both work as protein quality control pathways.  
(1) The ERGIC directs proteins between the ER and Golgi, only allowing correctly folded and glycosylated to traffic 
onwards to the Golgi. Should proteins be incorrectly folded they are directed back towards the ER. (2) Further 
glycosylation occurs as proteins traffic from the cis to trans face of the Golgi, incorrectly glycosylated and processed 
proteins can still be trafficked back to the ER to allow correct processing. (4) Should folding and glycosylation fail 
repeatedly, proteins are trafficked out of the ER by the ERAD pathway, ubiquitinated and transported to the 
proteasome for degradation. 
 
 
Proteins that are foreign, mis-glycosylated or incorrectly folded are sorted and removed from the ER by ERGIC and 
ERAD pathways, but this process can be evaded or hijacked by a number of viruses. 
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1.4.2 Unconventional Secretion 
Unconventional secretory pathways are an umbrella term for those vesicular and non-vesicular 
secretory pathways which do not traffic from the ER to the Golgi, then via secretory vesicles to the 
plasma membrane, but utilise other methods to reach the extracellular space. First identified when 
Brefeldin A (BFA), an inhibitor of the small GTPase ADP-ribosylation factor 1 (ARF1), induced inhibition 
of Golgi trafficking yet still failed to prevent secretion for a number of cellular proteins (Nickel and 
Rabouille, 2009). At least four of pathways have thus far been described and it seems likely that there 
are others which are yet to be discovered.  
The first of these suggested pathways, termed Plasma Membrane Pore Formation (PMPF), is the 
translocation of non-vesicular proteins into extracellular space through lipidic pores. These pores may 
either be constructed through oligomerisation of the protein being translocated, or of other cellular 
components which transiently form pores. In the first example certain fully-folded cytoplasmic 
proteins bind phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) enriched in inner plasma membranes, 
forming a pore through self-oligomerisation. Once oligomerised they insert into the plasma 
membrane, then translocate to the extracellular membrane. They then dissociate and are able to able 
to enter the extracellular space (Rabouille, 2017). This pathway is not only identified in the secretion 
of cellular protein fibroblast growth factor 2 (FGF2) (Steringer et al., 2015), but also secretion of the 
viral HIV protein, transactivator of transcription (TAT) (Debaisieux et al., 2012), illustrating that viruses 
are able to subvert different secretory pathways. 
Another example of PMPF is seen during inflammation, where inflammation itself drives pore 
formation. In macrophages it has been shown that IL-1b release can be triggered by the 
hyperpermeabilisation of the cell plasma membrane, suggested to utilise pores formed by gasdermin-
N which is cleaved by caspase 1 in times of inflammation (Ding et al., 2012, Rabouille, 2017).  
The second described pathway of unconventional protein secretion can occur for proteins targeted to 
late endosomal or lysosomal compartments forming Multi Vesicular Bodies (MVB). These endo-
lysosomal compartments can be induced to fuse with the plasma membrane and their contents are 
released, allowing both organelle contents and any intraluminal vesicles, also known as exosomes, 
contained within to be released. Exosomes, small extracellular vesicles carrying various forms of cargo 
such as mRNA, proteins and even viruses, were once thought to bud directly from the plasma 
membrane. Exosome formation occurs through Endosomal Sorting Complex Required for Transport 
(ESCRT)-mediated budding events into the late endosomal or lysosomal compartments which go on 
to become MVBs (Kowal et al., 2014). This allows both free and membrane bound proteins to be 
released into the extracellular space. Both membrane bound and free IL-1b and Caspase 1 have been 
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shown to be released in this way in times of inflammation (Qu et al., 2007, Andrei et al., 2004). 
Targeting of MVBs to the plasma membrane has been shown to be mediated by Rab11, Rab27a, 
Rab27b and Rab35 (Zhen and Stenmark, 2015). Both HAV and the parvovirus MVM have evolved to 
hijack this secretory pathway to aid their release from cells, bound in exosomes such viral transmission 
likely reduces extracellular detection of viruses by both the innate and adaptive immune systems 
(Jackson et al., 2005, Feng et al., 2013). Norovirus and rotavirus, both non-enveloped enteric viruses 
appear to be released from cells in a non-lytic manner contained within large extracellular vesicles. 
Such vesicles, when shed in stool, were more infectious than free virus found within the same stool. 
These vesicles were proposed to be exosomal or potentially derived directly from plasma membrane 
budding, however a specific pathway remains to be elucidated (Santiana et al., 2018). 
Times of stress may also lead to the third type of unconventional protein secretion, Autophagy 
Induced Protein Secretion (AIPS). In AIPS, autophagy derived membranes form vesicles termed 
‘secretory autophagosomes’, comprising curved tubular double membranes which fuse with the 
plasma membrane, thus trafficking autophagic membrane bound proteins to the plasma membrane. 
In one such case, upon cellular starvation the Golgi-Associated Stacking and Reassembly (GRASP) 
family protein Grh1, a Rab1 interactor and yeast homolog of mammalian GRASP65 (also known as 
GORASP1), is relocated from the ER/Golgi to tubular membranes which are autophagy derived, 
although they may fail to form complete autophagic vesicles, these membranes go on to fuse with the 
plasma membrane (Bruns et al., 2011). One protein to be secreted by this pathway in Dictyostelium is 
Acb1, which is thought to be concentrated in the tubular membranes or within the lumen of the 
autophagosome itself and is released when the autophagic membrane fuses with the plasma 
membrane (Duran et al., 2010). Acquisition of these autophagic membrane and subversion of this 
unconventional secretion pathway has been described variously for varicella zoster virus (VZV), 
Epstein Barr virus (EBV) and poliovirus among others (Buckingham et al., 2014, Nowag et al., 2014, 
Jackson et al., 2005). 
The fourth described pathway is termed Golgi-bypass and is the direct trafficking of proteins from the 
ER to the plasma membrane in small ER-derived vesicles. This is driven by ER stress and has been 
described in such circumstances where the ERAD pathway is unable to cause degradation of mis-
folded proteins. In the case of F508-deleted Cystic Fibrosis Transmembrane Conductance Regulator 
(*CFTR) ER stress leads to S441 phosphorylation of GRASP55 (also known as GORASP2), causing it to 
monomerise and relocate to the ER where it interacts with the *CFTR cargo. Single membraned 
vesicles containing the membrane-bound *CFTR are formed, which traffic to the plasma membrane 
(Gee et al., 2011). A similar process has been described for H723R pendrin (*pendrin), whose over-
abundance in the ER leads to increased expression of DnaJ homolog subfamily C member 14 
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(DNAJC14), and along with its co-chaperone Hsp70, traffics the membrane-bound protein directly to 
the plasma membrane (Jung et al., 2016).  
  
































Figure 1.6: Unconventional secretion pathways.  
Unconventional secretion pathways described so far include (1) direct translocation through pore formation, 
either by cellular stress or by the translocated proteins themselves. (2) MVBs of late endosomal or lysosomal 
origin fuse with the plasma membrane spilling the organelle contents, including exosomes, into the extracellular 
space. (3) Autophagy driven double membrane formation around cytoplasmic proteins lead to their delivery to 
the extracellular space. Autophagy membrane bound proteins are also secreted in this way. Grh1, a yeast 
homolog of mammalian GORASP1, is often translocated from the Golgi and found in these autophagy driven 
membranes. (4) Golgi bypass in times of ER stress leads to single membranes pinching off from the ER and 
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1.5 Eukaryotic Cell Cycle Regulation 
1.5.1 General Overview of Cell Cycle Regulation 
Eukaryotic cell growth and division is universally represented as a cyclical process that is controlled by 
the organised accumulation, activation, deactivation and breakdown of the regulatory proteins, in 
particular cyclins and cyclin dependant kinases (CDKs). First identified in yeast in 1976 (Nurse et al., 
1976) these regulatory proteins have been the subject of much research ever since. The cell cycle itself 
has four key distinct phases; G1, the first growth phase, is a cell which contains a single complement 
of chromosomes (2n), undergoing normal metabolic activity and growth. After G1 cells may enter S 
(synthesis) phase, in which a new complement of genomic material is synthesised. Once the genomic 
content of a cell reaches 4n cells enter G2, the second growth phase. During G2 cells continue to grow 
rapidly, duplicating organelles and preparing cell content to enable division, which occurs when cells 
enter M (mitosis) phase. M phase is the organisation and division of cell content into two distinct 
compartments which actively splits the cell into two daughter cells, whereby this process may begin 
again, or allow cells to exit the cell cycle, entering G0. 
There are checkpoints within the cell cycle which are able to prevent a cell progressing through the 
cycle should insufficient growth signals or too many inhibitory signals be received (indicated with 
orange flashes in Fig. 1.7), and again it is through the activity of cyclins and CDKs that it is possible for 
these checkpoints to be implemented. 
The first of these checkpoints is the G1 restriction checkpoint. Cells will only progress from G1 to S 
phase when the correct growth signals are received along with intracellular cues, such as the 
availability of sufficient cellular energy resources. Until the G1 checkpoint the transcriptional 
activators E2F1-3 are bound to and repressed by Rb protein, which prevents entry into S phase. This 
is further enhanced by the binding of p107 to E2F4 and p130 to E2F5 ensuring these transcriptional 
repressors located in the nucleus. As a cell progresses through G1 and upon receiving correct growth 
signals the levels of cyclin D increase and binds either CDK4 or CDK6. The cyclin D:CDK4/6 complex is 
active and phosphorylates Rb, p107 and p130. This phosphorylation releases the transcriptional 
activators E2F1-3, allowing them to translocate to the nucleus and drive transcription of S phase 
genes, while phosphorylated p107 and p130 release E2F4 and E2F5 which are transported to the 





















































Figure 1.7: Cell cycle, cyclins and cyclin dependant kinases.  
The cell cycle progresses from G1 through to S upon release of the transcription factors E2F1-3 (and associated 
removal of E2F4 and E2F5 repressors). Once DNA has been correctly synthesized in S phase cells can move into 
G2. Finally progressing onto M phase. The mitotic checkpoint ensures chromosomes are lined up on the mitotic 
spindle, sufficient organelles exist, and cells separate correctly. This process is completed through the cyclical 
synthesis, recruitment and degradation of cyclins and their binding partners, CDKs.  
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Among the genes transcribed by E2F1-3 is cyclin E that binds CDK2 and further enhances transition 
into S phase, forming a positive feedback loop. Later cyclin A, also transcribed by E1F1-3, preferentially 
binds CDK2, forming a complex that phosphorylates E2F1-3, preventing further transcription of S 
phase genes. E2F6-8, other transcriptional products of E2F1-3, also repress transcription of S phase 
genes, giving rise to an overall negative feedback loop, causing cells to exit S phase and enter G2 
(Bertoli et al., 2013, Skotheim et al., 2008). 
The second checkpoint occurs at the G2/M transition, where during the start of G2 phase cyclin A 
binds CDK1. During G2 the levels of cyclin B increase, but the protein remains inactive and cytoplasmic 
until it is phosphorylated by polo-like kinase 1 (Plk1) or CDK1, which allows cyclin B to translocate to 
the nucleus and act as a transcription factor for mitotic genes when in complex with CDK1, having 
displaced cyclin A. Upon displacement cyclin A is ubiquitin tagged for degradation (Hagting et al., 
1999). CDK1 itself is held inactive throughout S phase through its phosphorylation by Wee1 kinase. 
Upon signalling to pass the G2/M checkpoint Wee1 is tagged for ubiquitination and degradation by 
phosphorylation by Plk1. Plk1 also phosphorylates cdc25, itself a phosphatase, and in doing so causes 
cdc25 to dephosphorylate CDK1, thereby activating CDK1 (Guardavaccaro and Pagano, 2006). Once 
cells have divided cyclin B is ubiquitinated and tagged for degradation by anaphase promoting 
complex (APC) allowing cells to exit M phase, returning to G1. Cell cycle de-regulation and inefficient 
checkpoint regulation can result in uninhibited proliferation of cells, this could be due to self-
sufficiency in growth signals or insensitivity to anti-growth signals, both of these features are two of 
the key hallmarks of cancer. As such, it is easy to see how de-regulation of the cell cycle have wide 
ranging implications in the field of tumour growth and cancer development (Hanahan and Weinberg, 
2000). 
 
1.5.2 Polyomaviruses, BKPyV and Cell Cycle Deregulation  
Members of the polyomavirus family have long been implicated in cell cycle manipulation and 
deregulation, indeed MCPyV is thought to be the primary causative agent of over 80% of Merkel Cell 
carcinoma (MCC) through clonal integration of the viral genome into the host, and the resultant 
effects of constitutive TAg and tAg expression on both the Rb-family and p53 proto-oncogenes. It has 
been shown that removing the effects of TAg and tAg by knocking down with short hairpin RNA 
(shRNA) can not only prevent MCC positive cells from replicating, they in fact go on to die, while those 
cells without viral clonal integration do not (Houben et al., 2010). As stated previously, SV40 TAg has 
been shown to carry a LXCXE motif which binds to Rb, p107 and p130, this has an effect similar to the 
phosphorylation of these proteins by the cyclin D:CDK4/6 complex, thus causing cells to bypass the 
G1/S restriction checkpoint even in the absence of the correct proliferation signals (Decaprio et al., 
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1988, Stubdal et al., 1997). In addition to this, when TAg combines to its dimeric hexamer helicase 
form, the outer surface can bind p53. A tumour suppressor protein, p53 usually responds to ATM/ATR 
DNA damage signals by transcribing a number of genes which induce the cell cycle to be stalled at the 
G2/M phase checkpoint. Stalling of the cell cycle allows time for DNA repair to take place, should DNA 
repair not occur in a timely manner apoptosis is triggered. Inactivation of p53 therefore allows the cell 
cycle to progress through checkpoints, where it may normally be halted under such a circumstance 
(Lilyestrom et al., 2006). The overall effect of these interactions is to forcibly drive the cell cycle 
onward in the absence of the correct cues, and to override DNA damage signals which would cause 
the cell to exit the cycle and undergo apoptosis. 
Furthermore, tAg is able to bind PP2A regulatory subunit A and catalytic subunit C. This causes the 
substrate adaptor subunit B to be substituted by tAg and so the activity and specificity of the whole 
PP2A holoenzyme is altered. The effect of this is wide ranging as PP2A has a large number of targets, 
however many of the effects are through proliferative signalling cascades such as the MAPK/ERK and 
AKT pathways, thus providing further cell cycle deregulation (Pallas et al., 1990). 
It has further been shown that TAg must be phosphorylated to become active and able to form the 
dimeric hexamer helicase capable of unwinding viral DNA for replication. In SV40 this phosphorylation 
site has been shown to be T124, while in JCPyV it is T125 (McVey et al., 1996, Swenson and Frisque, 
1995). Mutation of these residues prevents viral replication and these have been shown to be CDK 
recognition sites (Swenson et al., 1996, McVey et al., 1996). Furthermore it has been suggested that 
cyclin A:CDK2 and cyclin B:CDK1 complexes can efficiently phosphorylate TAg threonine residues (Li 
et al., 1997). 
Unlike MCPyV, BKPyV and other non-integrating polyomaviruses have yet to be shown as the 
causative agent of any cancer. However BKPyV-induced cell cycle deregulation may contribute to its 
role as a suggested cofactor in a number of cancers induced by other oncoviruses such as Human 
Papilloma Virus (HPV), EBV and Human Herpes Virus 8 (HHV-8), having been isolated from tumours in 
tandem with these viruses (Moens et al., 2014). 
BKPyV TAg and tAg carry the same motifs described for SV40 which would enable them to bind p53, 
Rb-family proteins and PP2A, thus indicating that they have the same activities; being able to de-
regulate cell cycle check points (Moens et al., 2007, Harris et al., 1998). It has also been shown that 
increased MAPK/ERK signalling is able to increase levels of BKPyV replication in vivo (Seamone et al., 
2010) suggesting that proliferative signalling is beneficial for BKPyV viral replication.   
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1.6 Innate Immunity 
1.6.1 General Overview of Innate Antiviral Immunity 
Viral infection can be detected by cells in a number of ways, triggering an antiviral immune response 
intended to reduce virus replication and reinfection rates. Cellular sensors may detect viral RNA, viral 
DNA or other pathogen associated molecular patterns (PAMPs), activating mitochondrial antiviral 
signalling protein (MAVS) and stimulator of interferon genes (STING) mediated pathways that 
culminate with the transcription of type I and III interferon (IFN), along with pro-inflammatory 
cytokines (Liu et al., 2015). In response viruses, due to their extensive co-evolution with hosts, have 
developed a variety of ways in which to evade activation of cellular antiviral responses. 
Viral RNA can be sensed when it forms double strands (dsRNA), not normally found in host cells. 
Protein kinase R (PKR) upon sensing of dsRNA inhibits eukaryotic initiation factor 2D (eIF2D), 
preventing cap-dependant translation of both host and viral RNA, leading to reduced rates of 
replication. In addition, stimulated PKR can also induce autophagy and cause activation of 
inflammasomes, protein complexes which are able to recognise a variety of stressors and activate the 
pro-inflammatory IL-1β and IL-18, leading ultimately to pyroptotic cell death (Pindel and Sadler, 2011). 
Another sensor of dsRNA, oligoadenylate synthase (OAS), can directly bind dsRNA and activate RNase 
L, through production of 2’-5’-linked oligoadenylate. Ribonuclease L (RNase L) degrades both cellular 
and viral RNA, inhibiting viral replication. Furthermore the resultant RNA fragments are PAMPs, acting 
as ligands for retinoic acid-inducible gene-I (RIG-I) proteins, whose downstream signalling leads to the 
production of IFN (Chakrabarti et al., 2011).  
Viral DNA is most often sensed in the cytoplasm, a subcellular location in which endogenous DNA is 
not usually found. The cytosolic DNA sensor, DNA-dependent activator of IFN-regulatory factors (DAI), 
senses poly dA:dT and induces the translocation of nuclear factor-NB (NF-NB) and IFN regulatory factor 
3 (IRF3), which go on to transcribe type I IFNs (Takaoka et al., 2007). Both DNA-dependant protein 
kinase (DNA-PK) and meiotic recombination 11 homolog A (MRE11) can bind cytoplasmic DNA, 
triggering IRF3-mediated type I IFN transcription (Chu et al., 2000, Kondo et al., 2013). Cyclic GMP-
AMP synthase (cGAS) directly binds the sugar-phosphate backbone of cytoplasmic dsDNA in a 
sequence independent manner, again causing the transcription of type I IFN, driven by IRF3 
translocation (Sun et al., 2013). In the nucleus viral dsDNA, whose origins of replication tend to be AT-
rich and serve as binding and recognition sites for TAg, are recognised and translated by RNA 
polymerase III (Pol III) into small RNA fragments, leading to the production of IFN through RIG-I 
activation as seen with RNA viruses (Chiu et al., 2009). Interferon-J (IFNJ)-inducible protein 16 (IFI16) 
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can also sense nuclear viral DNA, leading to the activation of inflammasomes triggering inflammatory 
responses (Unterholzner et al., 2010).  
PAMPs can also include 5’-triphophate or 5’-diphosphate RNA, not found in host cellular RNA, or poly-
U/UC both recognised by RIG-I, while melanoma differentiation protein 5 (MDA5) recognises an 
improperly methylated 5’-cap of RNA along with high molecular weight dsRNA. These both lead to 
transcription of IFN (Kato et al., 2006).  
In addition to these pattern recognition receptors (PRRs) another family of proteins, toll-like receptors 
(TLRs), mount an effective response to viral and other pathogens. TLRs are membrane bound dimeric 
receptors which recognise a number of PAMPs, leading to the expression of IFNs and proinflammatory 
cytokines via NF-NB, IRF3 or IRF7 mediated pathways. Most anti-viral TLRs are located within 
endosomal membranes, TLR3 can recognise endocytic dsRNA, TLR7/8 recognises ssRNA, while TLR9 
recognises unmethylated CpG DNA often found in DNA viruses. TLR2 and TLR4 are found on the cell 
surface and can recognise viral haemagglutinin and envelope proteins (Akira and Hemmi, 2003). 
Leucine-rich repeats (LRRs) allow TLRs to recognise their specific substrates, going on to signal via the 
cytoplasmic Toll/interleukin-1 receptor (TIR) interactions with the cytoplasmic adaptor proteins 
MyD88 or TRIF (Yamamoto et al., 2003). 
Coevolution of viruses with innate immune systems has resulted in the emergence of a plethora of 
evasion mechanisms. For example, many flaviviruses such as Hepatitis C (HCV) and Dengue Virus 
(DENV) replicate their RNA genomes in replication complexes located on and within ER membranes, 
shielding the nascent RNA from recognition by many of the PRRs primed to detect dsRNA in the 
cytoplasm. While HCV also synthesises a protease which is able to cleave MAVS, preventing many PRR 
signals from stimulating an antiviral response (Li et al., 2005). Furthermore, HCV NS4B and NS3 
proteins prevent STING signalling and IRF3 activation by phosphorylation (Nitta et al., 2013). Evasion 
of detection by RNA viruses may be even more effective if conducted within intracellular organelles, 
such as Influenza whose replication takes place in the nucleus and incoming viral RNA is coated in 
nucleoprotein, once again shielding the viral RNA from detection in the cytoplasm by PRRs.  Viral RNAs 
may also be processed from 5’-triphosphates to prevent activation of RIG-I, such as the 5’ overhangs 
seen in Arenaviruses which are unable to activate RIG-I (Marq et al., 2011). If detection cannot be 
evaded PRRs or MAVS may be bound and modified, cleaved and degraded or even sequestered; one 
example is Hepatitis B virus (HBV) which encodes an X protein that interacts with MAVS and prevents 
signal transduction through stimulating its degradation (Wei et al., 2010).  
DNA sensors may be degraded also, both Herpex Simplex Virus 1 (HSV-1) and human cytomegalovirus 
(HCMV) have been shown to degrade IFI16 through the activity of the encoded infected cell protein 0 
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(ICP0) and pUL83 protein respectively (Orzalli et al., 2012, Li et al., 2013b).  Furthermore STING can be 
cleaved and inactivated, as is the case in DENV infection (Aguirre et al., 2012), while Kaposi Sarcoma 
Herpes Virus (KSHV) encodes a vIRF1 protein which can bind and inactivate STING (Ma et al., 2015).  
In addition to these mechanisms to evade activation of interferon transcription, viruses may also 
evade the interferon stimulated genes (ISGs) themselves for example HCMV can antagonise PKR 
through preventing phosphorylation of eIF2D (Ziehr et al., 2016). 
 
1.6.2 Polyomaviruses, BKPyV and Innate Antiviral Immunity 
Little is known about the interactions of innate immunity and polyomaviruses. SV40 TAg was shown 
to stimulate ATR kinase, leading to an induction of ISGs such as IFIT3, IFIT1 and OASL, which resulted 
in an antiviral state (Forero et al., 2014). However, the same has not been shown for BKPyV. MCPyV 
tAg was observed to bind the NF-κB adaptor protein NEMO, preventing NF-κB activation and 
downstream interferon induction (Griffiths et al., 2013), while MCPyV TAg downregulates TLR9 
(Shahzad et al., 2013); again these interactions appear to be specific for MCPyV and have not been 
shown for BKPyV.  
Interestingly, expression of the early protein TAg, late protein VP1, and total viral replication is 
reduced significantly with IFN-γ treatment of cells from 3-6 hours post infection (hpi) in both BKPyV 
and JCPyV infections (Abend et al., 2007, De-Simone et al., 2015), suggesting that both these 
polyomaviruses are susceptible to IFN. However, while JCPyV replication was shown to be inhibited 
by an IFN-type I response stimulated during infection in Renal Proximal Tubule Epithelial (RPTE) cells, 
BKPyV infection of the same cell type sees no such attenuation of replication. Indeed, while IFN-β is 
generated by RPTE cells in both JCPyV and BKPyV infections, those cells infected with JCPyV showed 
much greater expression of ISGs than those infected with BKPyV, suggesting innate immune responses 












Figure 1.8: dsDNA viruses trigger transcription of ISGs and IFN.  
Aberrant early uncoating of viral particles releases viral dsDNA into the cytoplasm, a compartment in which DNA is 
not usually located, triggering activation of DNA sensors of the STING and MAVS pathway. Pathway activation leads 
to translocation of phosphorylated IRF3 dimers or NF-κB (a p50/p65 dimer) that go on to transcribe an array of ISGs 
and IFN. Secreted IFN may then further activate surrounding cells by binding IFN receptors, a dimer of IFNAR-1 and 
IFNAR-2. The subsequent downstream signal leads to phosphorylation and dimerization of STAT1 and STAT2, which 
then binds to IRF9 and translocates to the nucleus and transcribes additional ISGs (Adapted from (Gale and Foy, 2005, 
Schneider et al., 2014)) 
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1.7 Adaptive Immunity 
1.7.1 General Overview of Adaptive Antiviral Immunity 
Adaptive antiviral immunity relies on the processing of non-self viral proteins into peptides by antigen 
presenting calls (APCs) which are loaded onto major histocompatibility complexes (MHCs), presented 
to T cells and can lead to cytotoxic cellular killing by CD8+ T cells or B cell activation by CD4+ T cells.  
Intracellular pathogens, such as viruses, are primarily tackled by MHC-I. Cytosolic viral peptides are 
cleaved by the proteasome and the resultant 8-10 amino acid peptides are transported to the ER 
where they are loaded into MHC-I binding groove by chaperones and transport associated with 
antigen processing (TAP) protein (Wieczorek et al., 2017). Once loaded the viral peptide and MHC-I is 
transported to the cell surface where it is presented to immature CD8+ T cells whose T cell receptors 
(TCRs) are rearranged and driven to become more specific for the antigen should the TCRs be 
repeatedly stimulated along with co-stimulation by CD80, CD86, or CD4+ T helper cells. Active CD8+ 
cells stimulated by IL-2 clonally expand to produce a population of CD8+ T cells which are able to 
recognise infected cells that are presenting MHC-I bound with the same stimulatory peptide. CD8+ T 
cells are cytotoxic and are able to effectively kill those infected cells by perforin and granzyme 
mediated lysis (Andersen et al., 2006).  
Extracellular viral proteins that are taken up by antigen presenting cells (APCs) via endocytosis, or viral 
proteins which are contained within early endosome and lysosomes of APCs, are tackled by MHC-II. 
These viral proteins are cleaved by endosomal and lysosomal proteases in a subcellular antigen-
processing compartment, generating 14-18 amino acid peptides that are then loaded into the binding 
groove of MHC-II found in the membranes of the same compartment (Wieczorek et al., 2017). MHC-
II loaded with viral peptides are then transferred to the plasma membrane, where they are presented 
to naive CD4+ T cells in secondary lymphoid organs, activating them. Activated CD4+ T cells go on to 
activate naïve B cells which, with the help of TFH cells, proliferate. Activated B cells are then able to 
produce antibodies as short-lived plasma cells, or undergo further affinity selection and clonal 
expansion, eventually generating highly specific antibody-secreting long-lived plasma cells and 
memory B cells (Damle et al., 1991). 
The antibodies generated are able to challenge infection in a number of ways. Antibodies generated 
against capsid or envelope proteins can bind extracellular virions and either neutralise infectivity, 
opsonisation and phagocytosis, or induce complement-mediated lysis of membraned viruses. 
Alternatively antibodies may recognise infected cells that are presenting MHC loaded with viral 
peptides, leading to killing of infected cells by antibody dependant cellular cytotoxicity (ADCC) or 
complement-mediated lysis and phagocytosis (Forthal, 2014).  
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1.7.2 Polyomaviruses, BKPyV and Adaptive Antiviral Immunity 
It is well established that polyomaviruses induce an adaptive immune response; indeed prior 
polyomavirus infection rates are measured by the presence of seroconverted antibody in patient 
serum (Shah et al., 1973, Kean et al., 2009, Viscidi et al., 2011). However, what remains unclear is why 
these responses often fail to clear polyomavirus infections entirely.  
Studies of adaptive immune responses to polyomaviruses are largely limited to MuPyV due to the 
availability of a mouse model. These studies have determined that both CD4+ and CD8+ T cell 
responses are generated in response to infection, with CD4+ T cells going on to aid the establishment 
of long-term antibody-secreting B cells that mount an effective neutralising antibody response in the 
face of persistent infection from 3-4 weeks post infection (Guay et al., 2007). CD8+ T cells show the 
greatest response at around one week post infection, killing infected cells with perforin and granzyme 
mediated lysis (Kemball et al., 2005). Those mice lacking perforin show a much-increased viral load, 
emphasizing the importance of early CD8+ T cell responses (Byers et al., 2007). CD8+ T cells are also 
long lasting, but exhibit a switch from acute CD8+ T cells to chronic during the persistent infection, 
with acute CD8+ T cells possessing a lower activation threshold, higher levels of lymph node homing 
due to greater proportions expressing CD62L-selectin and CCR7 receptors, and a higher IL-7 Receptor-
D expression, meaning greater response to cytokine expression (Kaech and Wherry, 2007). Even with 
these extensive adaptive immune responses MuPyV is rarely cleared but merely controlled, as MuPyV 
DNA is detected many weeks later in the presence of long-lived antibody-secreting B cells and chronic 
CD8+ T cells; without which increased critical levels of MuPyV replication is seen (Lee et al., 2006). In 
addition to the roles in viral clearance and management CD8+ T cells also play a role in the detection 
and prevention of MuPyV tumour development. E2m -/- mice that cannot express MHC-I exhibit a 
higher occurrence of MuPyV related tumours, however B cells alone are unable to prevent such 
tumour development (Drake and Lukacher, 1998).  
In relation to BKPyV similar observations have been made. BKPyV is rarely cleared but controlled by 
CD8+ T cells and antibody-secreting B cells, without which greatly increased levels of viral replication 
are seen, often leading to PVAN and renal failure (Binggeli et al., 2007, Comoli et al., 2008, Egli et al., 
2009). Analogous to MuPyV differences in acute and chronic CD8+ T cell responses have also been 
observed in humans in response to BKPyV (Mueller et al., 2010), lending some weight to the use of 
MuPyV mouse models to understand BKPyV pathogenesis (Lee et al., 2006).  
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1.8 Aim of this Thesis 
The broad aims of this thesis were to investigate BKPyV interactions with host proteins, pathways and 
processes throughout the viral lifecycle in order to better understand the ways in which such a simple 
virus is able to persist in the population. In investigating these interactions it was my specific intention 
to understand if BKPyV could be secreted from infected cells in a non-lytic manner, characterising any 
potential non-lytic secretory pathways discovered. Furthermore it was an objective to define changes 
to the host cell proteome during infection and study any pathways or processes which were 
dysregulated in infected cells compared with uninfected cells.  
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2. BKPyV can be released in an active and non-lytic manner 
2.1 Introduction 
The continued life cycle of BKPyV and other persistent polyomaviruses from primary infection in early 
childhood, through to lifelong persistence and propagation, is poorly understood. A predominantly 
lytic infection is observed in most BKPyV in vitro studies. However frequent rounds of lytic infection in 
vivo could lead to extensive cell lysis, tissue damage and inflammatory responses, such as those 
observed in patients suffering PVAN or HC (Rinaldo et al., 2013), which could induce a range of antiviral 
responses detrimental to virus persistence. A less destructive mechanism of virus spread that doesn’t 
involve extensive cell lysis could therefore be advantageous for polyomaviruses in vivo. A better 
understanding of viral release from cells would be invaluable due to the growing need for new 
therapeutics to treat BKPyV related diseases in the ever increasing number of patients under 
immunosuppressive therapies (Hirsch et al., 2005). 
While non-enveloped viruses are commonly thought to spread solely by cell lysis, either through 
expression of lytic viral proteins or passive cellular cytotoxic damage, it is now clear that a number of 
non-enveloped viruses can be released from cells in an active and non-lytic manner including the 
positive strand RNA viruses poliovirus and HAV. For poliovirus, evidence for non-lytic release was first 
identified when persistent poliovirus infection was observed in vitro, where release of virus into 
medium was detected without any appreciable cell death (Lloyd and Bovee, 1993). Moreover, in 
polarised Caco-2 cells poliovirus appeared to be trafficked along microtubules to the apical surface, 
where it was released from the vesicles in which it had aggregated (Tucker et al., 1993). These 
poliovirus secretory vesicles were observed to be autophagy induced, a method of viral release found 
to be common among a number of enteroviruses including Coxackievirus and rhinovirus (Mutsafi and 
Altan-Bonnet, 2018). Comparable observations about HAV have been made for some time. HAV is 
considered to be released primarily in a non-lytic manner from polarised cells, despite it being classed 
as a non-enveloped virus (Feng et al., 2013). During human infections with HAV it was noted that virus 
is excreted in stool, and livers are heavily infected before any immune-mediated responses or damage 
occur, indicating the virus spreads between cells without lysis (Cuthbert, 2001). Such release has been 
suggested to occur via the formation of exosomes within MVBs (Bird and Kirkegaard, 2015, Seggewiss 
et al., 2016).  
Two non-enveloped dsDNA viruses also show evidence of non-lytic release from cells. The parvovirus 
Minute Virus of Mice (MVM) makes use of cellular gelsolin to mediate viral egress via lysosomal and 
late endosomal vesicles, exploiting an active secretory pathway (Bar et al., 2008). Particularly relevant 
to the work in this thesis, the primate polyomavirus SV40 was shown to be released from cells in an 
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active non-lytic manner that is inhibited by monensin (Clayson et al., 1989). Taking these discoveries 
of non-lytic release via both conventional and unconventional secretory pathways in other non-
enveloped viruses, coupled with the lack of evidence for extensive cell lysis during in vivo BKPyV 
infections, investigations were begun into BKPyV secretion and the potential inhibition thereof. Some 
preliminary work had been commenced by Dr G Evans prior to my arrival in the lab (credited where 
























2.2.1 Infectious BKPyV release from RPTE cells is inhibited by the anion channel inhibitor DIDS 
The capacity for newly synthesised BKPyV virions to be trafficked and released from intact cells as a 
method of viral progeny release was investigated. Analysing the percentage of total infectious virions 
released into the supernatant of cells infected with BKPyV proved an efficient way to study the effect 
of a variety of trafficking inhibitors on BKPyV secretion. For these studies RPTE cells, a primary human 
cell type that is readily infected by BKPyV and in which the virus replicates efficiently, were used.  RPTE 
cells currently represent the in vitro culture system that best mimics the natural site of BKPyV infection 
(Low et al., 2004). Prior to my arrival to the lab a number of preliminary investigations had been 
conducted by Dr G Evans. These studies demonstrated that the percentage of infectious BKPyV virions 
released into the supernatant at 48 hours post infection (hpi) from infected yet uninhibited cells was 
approximately 1% of total infectious BKPyV content (Fig. S1). Investigation into the effects of a number 
of trafficking inhibitors on the BKPyV secretion had also been conducted (Table S1). Just one inhibitor, 
4,4’-diisothiocyano-2,2’-stilbenedisulfonic acid (DIDS), showed an appreciable reduction in 
percentage of BKPyV secretion while having little effect on total virus yields or cell viability, 
consequently this was chosen to be explored further and these subsequent studies form the basis of 
this chapter. 
DIDS is a broadly acting anion channel inhibitor that blocks chloride channels (ClCs) with an 
approximate IC50 = 40 µM (Schulz et al., 2010). RPTE cells were infected at one infectious unit per cell 
(IU/cell) and at 24 hpi DIDS was added in a range of concentrations up to 100 µM. Dimethyl sulfoxide 
(DMSO) was the diluent for DIDS and so cells were treated with the highest amount of DMSO as an 
infection control. At 48 hpi the cell-associated and supernatant samples were harvested separately. 
Infectious virions reach the ER by 8 hpi (Moriyama and Sorokin, 2008), soon after which they enter 
the nucleus (Bennett et al., 2013). Consequently, addition of DIDS at 24 hpi should avoid any effects 
on initial viral infection and entry, whilst remaining effective throughout new virion synthesis and 
secretion. Viral titres of each supernatant and cell-associated harvest were ascertained using a 
fluorescent focus unit (FFU) assay (Fig. 2.1a). To remove any potential effect of DIDS on viral entry or 
replication in supernatant FFU titres, all DIDS was removed from supernatant samples by 
ultracentrifugation of virus. Supernatant virus pellets were then resuspended in PBS at twenty times 
the original concentration, allowing for dilution of virus into culture media when infecting for FFU.  
A dose dependent reduction in supernatant virus titre was observed, reduced by three-and-a-half-fold 
at 25 µM to fifty-fold at 100 µM. Little effect was observed on cell-associated virus titre, reduced by 
no more than two-fold at the highest 100 µM DIDS concentration. The percentage of total infectious 
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virus that was released into the supernatant was calculated (Fig. 2.1b), demonstrating that DIDS 
caused a significant dose-dependent reduction in virus release by up to twenty-fold at the highest 
concentrations. Interestingly, more specific chloride channel inhibitors were tested in the initial 
inhibitor screens by Dr G Evans, but none showed an effect of BKPyV secretion (Table. S1).  
  






   
  
(b) 
Figure 2.1: Infectious BKPyV release from RPTE cells is inhibited by the anion channel inhibitor DIDS.  
RPTE cells were BKPyV infected at 1 IU/cell and treated with increasing concentration of DIDS, or DMSO as a control, at 
24 hpi. At 48 hpi supernatant media and cells were harvested independently. Cell associated virus was freeze-thawed 
three times in fresh media to release the cell-associated virus, supernatant virus was pelleted by ultracentrifugation and 
resuspended in PBS at 20x the original volume. To determine the virus concentration in each harvest an FFU assay was 
conducted (a). The percentage of release for each condition was calculated (b). Graphs show the mean of 4 independent 
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2.2.2 BKPyV capsid protein release from RPTE cells is inhibited by the anion channel inhibitor DIDS 
To ascertain whether the reduction of infectious virus release was due to reduced numbers of BKPyV 
virions in the culture media, or rather if the infectivity of released virions was affected by the presence 
of DIDS, an immunoblot was conducted to detect the viral structural proteins in the supernatant and 
cell-associated fractions for each condition. RPTE cells were infected at 1 IU/cell and at 24 hpi DIDS 
was added in a range of concentrations up to 100 µM, or DMSO was added as a control, and mock 
infected cells were treated with 50 µM DIDS or DMSO. At 48 hpi the cell-associated and supernatant 
samples were harvested separately. Virions in the supernatant samples were pelleted by ultra 
centrifugation to ensure sufficient concentration of viral proteins to be observed by immunoblot. 
Immunoblots were conducted for the viral structural proteins VP1, VP2, VP3 and the early protein TAg 
on cell-associated harvests, using tubulin as a loading control (Fig. 2.2a), while an immunoblot for VP1, 
VP2, VP3 and tubulin was conducted on the supernatant harvests (Fig. 2.2b). The low levels of VP2 
and VP3 in the supernatant harvest were at the limits of detection, this is due to the relatively low 
quantities of VP2 and VP3 incorporated into virions compared with an abundance of free VP2 and VP3 
in cell-associated samples. TAg is an early viral gene which is not packaged into virions, as such TAg 
was not blotted in the supernatant. As a cellular protein tubulin was not clearly detected in the 
supernatant samples, strongly suggesting little cell lysis had occurred. The level of VP1 present in each 
sample was quantified using Li-Cor Odyssey software (Fig. 2.2c), which demonstrated that levels of 
released supernatant VP1 reduced to approximately 30% of control at 25 and 50 µM, and 20% of 
control at 100 µM. There was a small reduction in cell-associated levels of VP1 at 25-50 µM DIDS, 
although a greater effect of 100 µM DIDS was observed reducing cell-associated VP1 levels by up to 
approximately 50% in this experiment, although such drastic reductions were not always observed. 
Despite the reduction in cell-associated capsid protein levels, the greater reduction in the level of VP1 
in supernatant fractions in the presence of DIDS further suggests that DIDS inhibits the release of 
BKPyV virions from RPTE cells in a dose dependant manner, rather than simply reducing the infectivity 
of released BKPyV virions. Independent experimental data produced by Dr G Evans showed these 
same observations and his further analysis by qPCR of BKPyV genomes released further validated the 
observed dose-dependent reduction of BKPyV release in the presence of DIDS (Fig. S2). 
  







Figure 2.2: BKPyV major capsid protein release from RPTE cells is inhibited by DIDS.  
RPTE cells were BKPyV infected at 1 IU/cell and treated with increasing concentration of DIDS, or DMSO as a control, 
at 24 phi. At 48 hpi supernatant media and cells were harvested independently. RPTE cellular control was mock 
infected and treated with DMSO, while DIDS control was mock infected and treated with 50 µM DIDS.  To determine 
relative levels of capsid proteins in the cell-associated (a) and supernatant (b) samples immunoblots were 
conducted for the structural BKPyV proteins and the early protein TAg. To enable detection supernatant proteins 
were concentrated by ultracentrifugation and as such represent relative protein levels. Tubulin was used as a 
cellular loading control. Li-Cor Odyssey software was used to determine the density of VP1 bands of the cell-
associated (corrected to tubulin) and the supernatant virus samples producing a graph showing relative VP1 levels 
in DIDS inhibited conditions, compared with control (arbitrarily set to 100%) (c). Data from one experiment shown. 
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2.2.3 DIDS does not affect RPTE cell viability or viral protein stability 
Given the reduction in VP1 expression levels that were observed in the DIDS treated cells (~50% at 
100 µM DIDS) there was some concern about whether DIDS was affecting cell viability or viral protein 
stability, which could impact the interpretation of the data described above. To address the concern 
that DIDS may be reducing viability of cells, a trypan blue exclusion assay was conducted on RPTE cells 
that had been incubated for 24 h in increasing concentrations of DIDS up to 100 µM, or DMSO as a 
control. Non-viable cells take up the trypan blue impermeable dye, whilst it is excluded from cells that 
are viable thus allowing quantitation of non-viable cells as a percentage of total cells. These data 
demonstrated that whilst the viability of RPTE cells was reduced slightly in the presence of DIDS, cell 
viability remained above 85% even at the highest concentration of DIDS (Fig. 2.3). This may partially 
explain the small decrease in cell-associated infectious virus shown in Fig 2.1a, but is unlikely to cause 
the large reduction in virus released into the supernatant observed throughout these experiments. 
For further experimental investigations a standard of 50 µM DIDS was adopted as more than 90% of 
cells remained viable at this concentration, yet virion secretion was reduced by almost eight-fold. 
The stability of proteins can be assessed using a cycloheximide (CHX) chase assay. CHX is an inhibitor 
of protein synthesis in eukaryotes, interfering with ribosomal translocation and preventing elongation 
of nascent proteins (Ennis and Lubin, 1964). Addition of CHX to cells therefore inhibits new protein 
synthesis, and subsequent analysis of protein content over time after CHX addition by immunoblot 
allows the turnover rate of proteins to be determined in a number of conditions, as there is no new 
protein synthesis. The stability of major viral capsid protein VP1 was investigated in this manner.  RPTE 
cells were infected with BKPyV at 1 IU/cell then treated at 24 hpi with either 50 µM DIDS, or DMSO as 
a control, with or without the inhibitor of protein synthesis CHX. Cells were harvested at 0, 12, 24 and 
36 h after addition of DIDS +/- CHX and immunoblots for VP1 were then conducted, using tubulin as a 
cellular loading control (Fig. 2.4a). The levels of VP1, normalised to tubulin, were determined using Li-
Cor Odyssey software and plotted (Fig. 2.4b). VP1 levels increased in the absence of CHX and 
decreased in the presence of CHX as expected, although VP1 levels decreased very little from 12-36 h 
after CHX addition suggesting that VP1 is a very stable protein with a long half-life. Importantly VP1 
levels were comparable in the presence of DIDS or DMSO control, either when protein synthesis was 
inhibited by CHX or not, demonstrating that VP1 synthesis or stability is not affected by the presence 
of DIDS even after 36 h incubation with this inhibitor. Taken together these results suggest that DIDS 
does indeed inhibit the secretion of BKPyV virions, and that the reduction in BKPyV release is not due 
to changes in cell viability, viral protein expression or stability, or reduced virion infectivity in the 
presence of DIDS. 










Figure 2.3: RPTE cell viability remains high in the presence of DIDS.  
The effect of DIDS on RPTE cell viability was determined with a trypan blue exclusion assay. 
RPTE cells were treated with increasing concentrations of DIDS, or DMSO as a control, for 
24 hours then harvested, incubated with trypan blue and cells scored as trypan blue positive 
or negative. Data represent mean percentage of cells that were trypan blue negative from 
three independent experiments. Error bars show standard deviation. 
 





















Figure 2.4: BKPyV capsid protein stability is not affected by the presence of DIDS.  
RPTE cells were BKPyV infected at 1 IU/cell and were then treated with 50 µM DIDS, or DMSO as a control, with or 
without cycloheximide (CHX) at 24 hpi. Cells were harvested at 0, 12, 24 and 36 hours after addition of DIDS +/- CHX 
and analysed by immunoblot (a). Li-Cor Odyssey software was used to determine the density of VP1 bands (normalised 
to tubulin) and plotted on a graph (b); data from one experiment shown. 
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2.2.4 DIDS alters the subcellular localisation of BKPyV virions 
Further consideration was then given to the intracellular location of BKPyV virions when virus 
secretion was inhibited by the addition of DIDS; namely whether virions remained nuclear or were 
cytoplasmic but restricted from reaching the supernatant though perturbation of trafficking. To 
address this question the subcellular localisation of BKPyV structural proteins in the presence or 
absence of DIDS was investigated by immunofluorescence microscopy. RPTE cells were infected with 
BKPyV at 1 IU/cell, or mock infected as a control, and treated with 50 µM DIDS or DMSO at 24 hpi. At 
48 hpi cells were fixed and stained for either VP1 (antibody PAb597) (Fig. 2.5a) or VP2 and VP3 using 
an antibody which recognises both proteins due to their common C-terminal sequence (Fig. 2.5b). 
DIDS auto-fluoresces in the 415 nm channel (DAPI) and localises to cytoplasmic vesicle/vacuole 
structures which presumably contain DIDS-sensitive anion channels in their membrane. VP1 staining 
showed strong nuclear signals and a diffuse cytoplasmic signal that showed no change in the presence 
of DIDS. Staining for the minor capsid proteins VP2 and VP3 showed a clear accumulation in DIDS 
positive cytoplasmic vesicles. This suggested that virus particles may become trapped in these DIDS-
containing vesicles. It was surprising that the major capsid protein VP1 wasn’t detected in these 
vesicles and the minor capsid proteins were, even though VP2 and VP3 would be expected to be 
relatively inaccessible to antibodies in intact virions. The VP1 antibody used in these assays (PAb597) 
was originally generated to SV40 VP1 and likely recognises a linear epitope as it detects denatured 
VP1 by immunoblot (Broekema and Imperiale, 2012) and so may not recognise VP1 when folded into 
its native virion conformation. To determine whether the VP2/VP3 antibody or the VP1 PAb597 
antibody can bind virions in their capsid conformation, immunofluorescence microscopy analysis of 
cells with surface attached BKPyV virus particles was conducted. RPTE cells were incubated with 1 
IU/cell BKPyV on ice for 1 h, after which time cells were fixed and stained with either VP1 PAb597 or 
VP2/VP3 antibodies (Fig. 2.6a). Clear VP2/VP3 antibody staining was observed on cells with bound 
virions, while no signal could be detected for VP1 PAb597, supporting the notion that this VP1 
antibody does not recognise intact virions but the VP2/3 antibody does. To further investigate VP1 
localisation in the presence or absence of DIDS, a conformational-dependent VP1 monoclonal 
antibody (L5) that neutralises BKPyV infectivity and thus should bind mature virions was obtained 
(Randhawa et al., 2008). RPTE cells were infected with BKPyV, treated with or without DIDS at 24 hpi, 
and fixed at 48 hpi as before. Staining with VP1 L5 antibody showed clear accumulation of VP1 to DIDS 
positive vesicles (Fig. 2.6b), suggesting that DIDS treatment causes BKPyV virions to become trapped 
in intracellular vesicles. 
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Figure 2.5: In BKPyV infected cells DIDS colocalises with VP2 and VP3.  
RPTE cells were mock infected (control) or BKPyV infected at 1 IU/cell and treated with 50 µM DIDS, or DMSO as a drug 
treatment control, at 24 hpi. At 48 hpi cells were fixed and stained for VP1 (PAb597) or VP2/3 antibody (both shown in 
green). DAPI staining along with DIDS auto-fluorescence is shown in blue. VP1 (PAb597 staining is diffuse and does not 
localise with DIDS puncta (a), while VP2/3 staining showed clear coloalisation with DIDS positive puncta, shown in 


























Figure 2.6: In BKPyV infected cells DIDS colocalises with VP2 and VP3, and conformational-dependent VP1 antibodies.  
(a) RPTE cells were incubated with 1 IU/cell BKPyV, or mock media as a control, on ice for 1 hour and then fixed and 
stained with VP1 (PAb597) or VP2/3 antibodies (both shown in green). DAPI stain is shown in blue. VP1 (PAb597) does 
not bind to surface virions indicating the antibody does not recognise VP1 in virion conformation, while the VP2/3 
antibody is able to bind surface epitopes available in virion conformation.  (b) RPTE cells were BKPyV infected at 1 IU/cell 
or mock infected (control) and treated with 50 µM DIDS, or DMSO as a control, at 24 hpi. At 48 hpi cells were fixed and 
stained for VP1 (L5) (shown in green). DAPI staining and DIDS auto-fluorescence is shown in blue. The conformational 
VP1 (B5) antibody shows colocalisation with DIDS positive puncta. All images produced from single z-slices from a Leica 
SP5 confocal microscope. 
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2.2.5 VP2 and VP3 containing DIDS positive vesicles are LysoTracker and LAMP1 positive 
The nature of the DIDS positive vesicles in which BKPyV particles appear to accumulate upon addition 
of DIDS was explored. Among other roles such as transport and membrane stabilisation ClCs can 
contribute to the acidification of intracellular vesicles. Acidic organelles such as endosomes and 
lysosomes contain a variety of import channels including ClC-3, ClC-5 and ClC-7 (Jentsch and Pusch, 
2018), and so the BKPyV and DIDS-positive vesicles observed could be endosomal or lysosomal in 
nature. Immunofluorescence was used to examine this hypothesis. RPTE cells were infected at 1 
IU/cell and 50 µM DIDS, or DMSO as a control, was added at 24 hpi. At 48 hpi cells were fixed and 
stained for VP2 and VP3, and either co-stained for lysosomal-membrane associated protein 1 (LAMP1) 
(Fig. 2.7b) or treated with LysoTracker 2 h before fixing (Fig. 2.7a). LysoTracker is a fluorescent marker 
of acidic cellular organelles, and will fluoresce in late endosomes and lysosomes, while LAMP1 is a 
lysosome associated membrane glycoprotein and is located primarily in lysosomal membranes. In 
infected cells treated with DIDS VP2/VP3, LysoTracker and DIDS were shown to colocalise in several 
large cytoplasmic vacuole-like structures (arrows Fig. 2.7a). This suggests that the compartments to 
which BKPyV particles are being relocalised in the presence of DIDS are acidic and thus may be late 
endosomal or lysosomal in nature. A number of vacuoles were positive for DIDS and LysoTracker which 
were not positive for VP2/3, this could be due to the varying types of acidic vesicles within the cell, for 
example lysosomal and endosomal vesicles may show differing levels of VP2/3 uptake or 
colocalisation. Similarly it must be noted that free VP2/3 within the cytoplasm of cells presents a 
somewhat diffuse background on which to observe these colocalisation puncta.  
 VP2/3, LAMP1 and DIDS also showed some colocalisation in a few vacuole-like structures in infected 
cells (Fig. 2.7b arrows), however LAMP1 staining was relatively weak and diffuse. This was particularly 
evident in uninfected RPTE cells, where LAMP1 showed little concentration in any obvious cytoplasmic 
structures. To confirm that the LAMP1 antibody was effective the commonly used HeLa cell line was 
fixed and stained with this antibody in parallel with RPTE cells (Fig. 2.7c). Staining of HeLa cells showed 
the expected distribution of LAMP1 with several bright puncta observed in the cytoplasm, whereas 
RPTE cells showed a relatively diffuse somewhat ER-like pattern. This suggests the LAMP1 antibody is 
effective but that either this represents the normal distribution for these RPTE cells and there is little 
concentration of LAMP1 in the expected endosome/lysosome type compartments, or the antibody 
epitope is masked in these cells. Nevertheless, the detection of LAMP1 signals in DIDS and VP2/3 
positive vacuoles, albeit relatively weak, further suggests that the compartments in which BKPyV 
particles becomes localised in the presence of DIDS are endo-lysosomal in nature. 
 




Figure 2.7: In BKPyV infected RPTE cells VP2 and VP3 colocalises 
with DIDS, LysoTracker and Lamp1 positive vesicles.  
RPTE cells were BKPyV infected at 1 IU/cell and treated with DIDS or 
DMSO as a control at 24 hpi. At 48 hpi cells were fixed and stained 
for VP2/3 (green), and LAMP1 (red) (b) or treated with LysoTracker 
2 hours before fixing (red) (a), DAPI and DIDS auto-fluorescence are 
shown in blue (a & b). Colocalisation of VP2/3 DIDS and LysoTracker 
(a) and LAMP1 (b) can be observed, although LAMP1 stain was 
unusually diffuse in RPTE cells. (c) To confirm LAMP1 antibody was 
staining the correct subcellular compartments RPTE and HeLa cells 
were fixed and stained with LAMP1 (green), clear puncta seen in 
HeLa cells represents usual distribution of LAMP1. All images 
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2.2.6 TAg localisation is unaffected by addition of DIDS 
Thus far the effect of DIDS on the expression and location of late structural BKPyV proteins had been 
investigated, while only the total expression of the early protein TAg had been studied (Fig. 2.2a). To 
understand whether DIDS also affected the subcellular location of early BKPyV gene products 
immunofluorescence was conducted for BKPyV TAg expression in both the presence or absence of 
DIDS. RPTE cells were infected with BKPyV at 1 IU/cell and at 24 hpi 50 µM DIDS, or DMSO as a control, 
was added. At 48 hpi cells were fixed and stained for TAg and with DAPI (Fig. 2.8). The localisation of 
TAg in BKPyV infected cells showed no change upon addition of DIDS, demonstrating that the VP1 and 
VP2/3 positive vacuole-like structures observed in the presence of DIDS are unlikely to be blebs or 
fragments of nucleus. 
  





Figure 2.8: In BKPyV infected cells TAg localisation is unaffected by the 
presence of DIDS.  
RPTE cells were BKPyV infected with 1 IU/cell and treated with 50 µM DIDS, 
or DMSO as a control, at 24 hpi. At 48 hpi cells were fixed and stained for TAg 
(red). DAPI and DIDS auto-fluorescence are shown in blue. Images produced 
from single z-slices from a Leica SP5 confocal microscope. 
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2.2.7 DIDS causes perturbation of chloride homeostasis and causes an increase in acidic vesicles.  
DIDS is a broad-range inhibitor of ClCs but is also thought to inhibit the function of a wide variety of 
additional anion channels. Given the proposed importance of chloride ion transport for maintaining 
the acid environment in intracellular compartments the increase of acidic vesicles observed by 
immunofluorescence analysis of LysoTracker stained cells in the presence of this inhibitor may seem 
counter-intuitive. To ascertain whether the increase of LysoTracker positive acidic vesicles was driven 
by addition of DIDS alone, or whether BKPyV infection was also necessary to observe this effect, 
uninfected RPTE cells were treated with 50 µM DIDS, or DMSO as a control. LysoTracker was added 2 
h prior to fixation, and after 24 h of treatment cells were fixed and stained with VP2/3 antibody, as a 
control for the absence of infection, and DAPI as a nuclear marker (Fig. 2.9a). A clear increase in 
LysoTracker positive vesicles was observed in the presence of DIDS treatment, suggesting that with 
the disruption of ClC activity, or other anion channels, does indeed increase the number of acidic 
vesicles within RPTE cells. DIDS blocks both chloride transporters and antiporters, although whether 
the observed the increase of vesicle acidification upon DIDS treatment is caused by inhibition of a 
specific channel or a combination of several is unclear. 
To control for the effect of DIDS on chloride homeostasis in RPTE cells, staining with N-
ethoxycarbonylmethyl-6-methoxyquinolinium bromide (MQAE) was used. MQAE is a fluorescent 
indicator that is quenched in the presence of intracellular Cl-. RPTE cells were treated with 50 µM DIDS, 
or DMSO as a control, for 24 h, and MQAE was added for the last hour of incubation (Fig. 2.9b) and 
MQAE fluorescence was monitored in live cells by fluorescence microscopy (imaging performed by Dr 
G Evans). It can be seen that in untreated cells there is a strong signal MQAE signal, while in those cells 
treated with DIDS the signal is largely quenched, suggesting DIDS is effectively disrupting chloride 










Figure 2.9: DIDS alone is sufficient to perturb 
chloride homeostasis and causes an increase 
in LysoTracker positive vesicles.  
Uninfected cells were treated with 50 µM DIDS 
for 24 h. 2 h prior to fixing cells were treated 
with LysoTracker (red). DAPI and DIDS auto-
fluorescence are shown in blue. Images 
produced from single z-slices from a Leica SP5 
confocal microscope (a). RPTE cells were 
treated with DIDS, or DMSO as a control, for 24 
h, and MQAE added for the last hour of 
incubation. Cells were washed with PBS and 
imaged using 10x lens of Olympus IX81 wide-
field fluorescence microscope (b). MQAE 
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2.2.8 DIDS inhibits BKPyV release in immortalised RPTEC/TERT1 cells 
To confirm that the observed effects of BKPyV can be replicated in an alternative cell line RPTEC/TERT1 
cells were used. These cells are a primary RPTE cell type that has been immortalised with the insertion 
of a human telomerase expression cassette (Wieser et al., 2008). RPTEC/TERT1 cells are not from the 
same patient that the RPTE cells used for these experiments were obtained from. They also display a 
different morphology yet can still be infected by BKPyV, representing a useful cell line in which to 
validate our results with DIDS, given that most other cell types do not support robust BKPyV 
replication. RPTEC/TERT1 and RPTE cells were infected with BKPyV at 1 IU/cell and treated with 50 µM 
DIDS, or DMSO as a control, at 24 hpi. At 48 hpi the cell-associated and supernatant samples were 
harvested separately. Viral titres of within supernatant and cell-associated fractions were determined 
using an FFU assay (Fig. 2.10). A greater than ten-fold reduction in supernatant virus titre was 
observed in DIDS treated cells compared with untreated, while the concentration of cell-associated 
virus titre remained relatively unaffected for both cell types. Both cell types showed equivalent 
reduction in BKPyV secretion in the presence of DIDS treatment demonstrating our data observations 
that DIDS inhibits BKPyV release reproducible in different renal epithelial cell lineages. 
  







Figure 2.10: DIDS inhibition of BKPyV release is replicated in immortalised RPTEC/TERT1 cells. 
RPTE or RPTEC/TERT1 cells were BKPyV infected at 1 IU/cell and treated with 50 µM of DIDS, 
or DMSO as a control, at 24 hpi. At 48 hpi supernatant media and cells were harvested 
independently. Cell associated virus was freeze-thawed three times in fresh media to release 
the cell-associated virus, supernatant virus was pelleted by ultracentrifugation and 
resuspended in PBS at 20x the original volume. To determine the virus concentration in each 
harvest an FFU assay was conducted; Data from one experiment shown. 
 




The observations made in this chapter provide compelling evidence that BKPyV secretes a proportion 
of progeny virions into the supernatant, and that this secretion is an active and non-lytic method of 
viral release, which can be inhibited by anion homeostasis disruption. Around 1% of total BKPyV is 
secreted into the supernatant in uninhibited conditions by 48 hpi, and the anion channel inhibitor 
DIDS inhibits this secretion of BKPyV by up to 20-fold, in a dose dependant manner. DIDS has a broad 
effect on a number ClCs, although ClC3-7 are potentially relevant targets of DIDS for this study. ClC3-
7 are Cl-/H+ antiporters that are commonly expressed in mammalian cells and localised to intracellular 
organelles (Stauber and Jentsch, 2010). However DIDS also inhibits the activity of a number of other 
Cl- channels including Golgi-pH regulator (GPHR) (Maeda et al., 2008). The use of more specific Cl- 
inhibitors, such as 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulphonic acid (SITS) (Table S1), did 
not cause any clear reduction in BKPyV secretion, and thus it is impossible to conclude which specific 
ClCs may be responsible for these observed effects, and it may be that inhibition of several ClCs by the 
broad action of DIDS is necessary. Alternatively, the inhibition of BKPyV release could be due to some 
unknown off-target effect of DIDS. 
These studies suggest that the reduction in secreted infectious BKPyV is not simply due to inhibition 
of secreted BKPyV particle infectivity. The fraction of the structural viral protein VP1 that was released 
into the supernatant was also reduced in the presence of DIDS in a dose dependant manner, and 
further work conducted by Dr G Evans showed that BKPyV genomes present in the supernatant were 
also reduced by DIDS in a dose dependant manner (Fig. S2). Taken together these data suggest DIDS 
is truly inhibiting the secretion of virions from infected cells and suggests BKPyV can be released by a 
non-lytic pathway as it seems highly unlikely that the effect of DIDS is to reduce cell lysis. 
RPTE cell viability in the presence of 75-100 µM DIDS was reduced to around 85%. While this is 
considered an acceptable level of viability, taken in conjunction with the reduction in cell-associated 
virus titre observed in Fig. 2.1a and reduced viral protein load observed in Fig. 2.2a, it was decided 
that further experiments should be limited to 50 µM DIDS. The aim was to reduce any confounding 
effects that reduced cell viability may have as at 50 µM DIDS cell viability remained above 90% in all 
three replicates of the viability test. It is possible DIDS could affect extracellular virion stability, leading 
disruption of particle integrity and reducing the yield of virions harvested by ultracentrifugation. While 
this is formally possible, no effect on protein stability in cells was detected. At 50 µM DIDS viral 
proteins were no less stable than in the presence of DMSO control. This possibility could be addressed 
however by pre-treating purified virus with DIDS, then spinning out the virus to remove DIDS and 
comparing the infectivity of virus remaining.  
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Investigations into the localisation of cytoplasmic BKPyV in DIDS treated cells reveals that virions 
appear to be relocalised to acidic late endosomal or lysosomal organelles that presumably contain 
DIDS sensitive ClCs because of the accumulation of DIDS in these compartments. ClC-6 and ClC-7 are 
both localised to late endosomal and lysosomal compartments and are highly sensitive to DIDS 
inhibition (Verkman and Galietta, 2009), suggesting that these antiporters may play a role in BKPyV 
relocalisation in the presence of DIDS. There is no evidence at this stage, however, that these 
compartments form part of the normal pathway by which BKPyV is secreted and could be indicative 
of a dead-end pathway in which virions become trapped. Indeed, treatment with DIDS alone on 
uninfected cells also leads to an increase in acidic (LysoTracker positive) organelles, thus their increase 
is not driven by BKPyV infection.  
The observed increase in acidic organelles in the presence of DIDS is somewhat surprising as ClCs have 
been shown to contribute to organelle acidification, and it therefore follows that their inhibition may 
lead to a reduction in acidic organelles (Hara-Chikuma et al., 2005, Gunther et al., 2003). The role of 
anion homeostasis and intracellular organelle pH, particularly lysosomal and late endosomal, is not 
well studied, and previous studies suggest lysosomal pH is not affected in ClC-6 or ClC-7 lacking mice 
(Kasper et al., 2005, Poet et al., 2006). Another rationalisation of this observed phenomena may be 
that the global effects on cellular anion homeostasis caused by DIDS may trigger a large number of 
secretory pathways to be disrupted. Such disruption would lead to an increase in autophagic vesicles 
taking up many cellular and viral products, including virions. Autophagic vesicles fuse with lysosomes 
and are of low pH, consistent with this hypothesis.  
The observation that around 1% of BKPyV progeny can be actively secreted and that this secretion can 
be inhibited by addition of DIDS was replicated successfully in another cell line RPTEC/TERT1 cells. It 
should be noted that the effect of DIDS on BKPyV release was also observed, albeit less dramatic, 
when conducted in African Green Monkey Kidney (VERO) cells (completed by Dr G Evans, Table S1). 
However a number of studies have shown that VERO cells may traffic BKPyV during their entry in a 
different manner than RPTE cells (Eash et al., 2004, Zhao et al., 2016), suggesting viral trafficking 
pathways between the two cells lines are not directly comparable. Also VERO cells only support 
relatively low levels of BKPyV replication with low infectious titres produced from these cells 
compared to RPTE cells, furthermore while VERO cells are somewhat permissive to BKPyV they are 
not representative of a natural infection site in vivo.  
In summary, the data in this chapter suggest BKPyV can be secreted via an active non-lytic pathway, 
which is sensitive to anion homeostasis. Much of the data in this chapter was included in a co-first 
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author paper published during the time of this thesis (Evans et al., 2015). Further work to investigate 
the pathway by which BKPyV is being non-lytically secreted is detailed in the following chapter. 
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3. Secretion of BKPyV virions is by an unconventional secretion pathway 
3.1 Introduction 
Having established that BKPyV can be released from cells by an active and non-lytic secretion 
mechanism, it was important to identify by which pathway secreted virions were being trafficked. Past 
studies have previously shown that non-enveloped viruses can be trafficked through conventional and 
unconventional secretory mechanisms. The well-studied primate polyomavirus SV40 was shown to 
secrete via a pathway that can be inhibited by monensin almost 30 years ago (Clayson et al., 1989), 
although no further characterisation of SV40 secretion was published. Monensin is a sodium 
ionophore which disrupts trafficking via the Golgi, part of the conventional secretion pathway.  
Non-lytic spread of the non-enveloped picornavirus, poliovirus, has been observed after persistent 
infections in stable cell lines were described (Lloyd and Bovee, 1993). It is thought that poliovirus 
acquires LC3 positive autophagic double membranes, and subsequent trafficking via the 
unconventional autophagy induced secretory pathway leads to fusion of the outer vesicle membrane 
with the cell plasma membrane. This releases the inner single membraned vesicle, whose contents 
include viral progeny, into the extracellular space (Jackson et al., 2005, Bird and Kirkegaard, 2015). 
HAV is thought to release predominantly in an unconventional secretory manner, where it is 
incorporated into exosomes within MVBs which are released into the extracellular space upon MVB 
fusion with the plasma membrane (Feng et al., 2013). Further observations of norovirus and rotavirus, 
both non-enveloped enteric viruses, observed that virions were released from cells in a non-lytic 
manner contained within large extracellular vesicles and that these vesicles, when shed in stool, were 
more infectious than free virus found within the same stool. This pathway was found not to occur via 
LC3-positive autophagic membranes, but may be exosomal or derived directly from plasma membrane 
budding (Santiana et al., 2018).  
Given the diverse range of pathways different non-enveloped viruses have been proposed to use to 
undergo non-lytic release, it was important to investigate a range of potential pathways of secretion 








3.2.1 Observation of BKPyV virion size and morphology by electron microscopy 
Polyomaviruses are relatively small (~45nm) viruses and various cytoplasmic structures such as 
polysomes and glycogen granules can appear similar in size which can make it difficult to detect 
virions within infected cells. Therefore, the size and morphology of newly synthesized virions in the 
nucleus was observed in order to facilitate identification of cytoplasmic virions throughout future 
experiments. RPTE cells were infected at 3 IU/cell and cells were fixed for TEM sample processing 
and imaging at 72 hpi. At this late time point of infection large numbers of BKPyV progeny are 
expected to have been assembled in the nuclei of infected cells, becoming densely packed as their 
number increases. Indeed, upon imaging an infected nucleus (N) vast arrays of icosahedral 40-45 nm 
virions were clearly visible (Fig. 3.1a & b). Furthermore, in areas of nuclei where virions are 
particularly dense their icosahedral shape, combined with limited nuclear volume, cause virions to 
be arranged into a distinctive lattice-style structure (Fig. 3.1c & d). 
These images allow clear identification of virions, and serve as a reference point for virion shape, 
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Figure 3.1: BKPyV virions are densely packed in the nuclei of infected cells. 
RPTE cells were infected with BKPyV (3 IU/cell) and fixed for TEM at 72 hpi. Nuclear (N) and cytoplasmic (C) 
spaces are labelled. Virions are found in large numbers in the nucleus (a & b). In dense areas a distinctive 
lattice-style conformation of virions is observed (c & d). Images collected by M Hollinshead; Dept. of 
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3.2.2 BKPyV virions are in single membraned vesicles and ER-like membranes 
To investigate the cellular location of virions at late time points of infection, which may be in the 
process of exiting the cell, RPTE cells were infected with BKPyV at 3 IU/cell. After one hour of 
inoculation the virus was removed and cells thoroughly washed 3 times with PBS to remove as much 
residual unattached virus as possible, before replacing with fresh media. At 72 hpi cells were fixed for 
TEM processing and images taken. 40-45 nM BKPyV virions were visible, not only tightly packed within 
the nucleus as seen previously (Fig. 3.3a, N) but also inside single membrane vesicles at the cell 
periphery (Fig. 3.2a & b) and in lumen of smooth convoluted membranes near the nucleus (Fig. 3.3a, 
b, c & d).  
TEM images only allow observation of cellular ultrastructure at a fixed point in time and provides no 
information regarding directionality of, for example, transport vesicles. As such it is impossible to be 
certain about whether these observed virions within the lumen of cytoplasmic vesicles and membrane 
compartments are entering or exiting the cell, but some observations can be made in an attempt to 
address this question. During primary infection virions are thought to reach the ER by 8-12 hpi and 
BKPyV is known to enter cells in single membraned vesicles in a clathrin and caveolin independent 
manner (Eash et al., 2004, Zhao et al., 2016). Should endocytosed virions account for the single 
membraned virions we observe here in Fig. 3.2 they would be newly synthesised virions re-entering 
infected cells before 72 hpi. The observed titre of newly synthesised BKPyV virions that are secreted 
into the culture media by 72 hpi is approximately 5x105 IU in in the same experimental set up as the 
TEM sample preparation (Data taken from Fig. 3.5a). The number RPTE cells at full confluence after 
72 h growth in this experimental set up is at least 6x105 cells, suggesting that there would be fewer 
than 1 newly synthesised infectious BKPyV virion for each cell to be re-infected with. Given that several 
single membraned virions were observed in the cytoplasm of cells (See Fig. 3.2a & b), only high 
particle:infectivity ratios could account for such numbers. Data on BKPyV particle:infectivity ratio is 
not known, however for SV40 ratios appear to be between 100-200 non-infectious virions for every 
one infectious virion (Black et al., 1964).  
Similar interpretations can be made regarding the virions observed within smooth convoluted 
membranes (Fig. 3.3). These membranes have a morphology resembling smooth ER, and BKPyV is 
known to traffic via the ER during entry infectious entry into cells. During initial infection virions are 
thought to leave the ER and reach the nucleus by 12-18 hpi. The large number of virions observed in 
the smooth ER-like membranes at 72 hpi also suggests that they are unlikely to be virions re-infecting 
the cell, as the number of newly synthesized infectious virions released from cells at 72 hpi is fewer 
than 1 IU/cell (calculated above).   
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Figure 3.2: BKPyV virions are found within single membraned vesicles. 
RPTE cells were infected with BKPyV (3 IU/cell) and fixed for TEM at 72 hpi. (a) Cytoplasmic (C) and extracellular (E) 
spaces are labelled, virions are found tightly wrapped within single membraned vesicles towards the cellular 
periphery. (b) Image of the same section in at higher magnification shows single membrane vesicles; highlighted 
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Figure 3.3: BKPyV virions are also located in convoluted membranes at the perinuclear space. 
RPTE cells were infected with BKPyV (3 IU/cell) and fixed for TEM at 72 hpi. (a & c) Cytoplasmic (C) and nuclear (N) 
spaces are labelled, virions are found within smooth convoluted membranes at the perinuclear space. (b & d) At higher 
magnification of the same section virions can be clearly seen in smooth convoluted membranes, which resemble 
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3.2.3 Convoluted membranes containing virions can be labelled with an ER marker 
To identify the nature of the smooth ER-like membranes that were found to be laden with virions at 
72 hpi, a unique property of ER sorting mechanisms was exploited. KDEL is an ER targeting sequence 
found at the C-terminus of proteins that need to be maintained within the lumen of the ER. KDEL-
motif containing proteins that exit the ER are bound by the KDEL-receptor in subsequent 
compartments such as the cis-Golgi, which causes their recycling back to the ER by retrograde vesicle 
transport, and only upon cleavage of this sequence or saturation of the KDEL-receptor retrieval 
mechanism are such proteins able to leave the ER and continue along the secretory pathway (Pelham, 
1990). Attaching a KDEL motif to a marker protein is therefore a useful method to label the ER. To this 
end a KDEL motif tagged to Horseradish Peroxidase (KDEL-HRP) containing plasmid was transfected 
into BKPyV infected cells at 48 hpi and the cells were fixed for TEM processing and imaging at 72 hpi. 
This transfection time point allowed ample time for expression of the KDEL-HRP but not to saturating 
levels, while being at a late time point post infection to avoid any potential effects on viral entry. The 
location of the HRP-KDEL marker was revealed by catalysis of a biotinylated tyramide solution to 
produce a diaminobenzidine (DAB) reaction product that could be detected as a darker stain by TEM.  
The dark stain was seen exclusively in convoluted ER membranes (Fig. 3.4a & c), which once again 
contained numerous virions throughout (Fig. 3.4b & d; highlighted with black arrows). These data 
confirm that these observed virion containing organelles were indeed of ER origin, and likely smooth-
ER given the lack of obvious ribosomes that decorate rough-ER. DAB can render such organelles less 
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Figure 3.4: Convoluted membranes that contain virions are endoplasmic reticulum. 
RPTE cells were infected with BKPyV (3 IU/cell), at 24 hpi cells were transfected with a KDEL-HRP plasmid. At 72 hpi 
cells were fixed for TEM and HRP developed for 5 minutes. The HRP, retained in the ER due to the KDEL motif, 
renders the ER darker than surrounding organelles. This darkened structure looks morphologically similar to the 
smooth convoluted membranes seen in Fig. 3.3 (a & c). Higher magnification reveals virions highly concentrated 
within this ER membrane (b & d), a number of which have been highlighted with black arrows. Images collected by 
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3.2.4 Neutralising antibodies did not reduce the presence of virions within single membraned 
vesicles or smooth ER 
In order to address whether virions observed with smooth-ER compartment and single membrane 
vesicles could be due to virions undergoing entry as opposed those that were egressing the cell, 
experiments were conducted in the presence of a neutralising antibody against BKPyV to neutralise 
the infectivity of virions that were secreted into the supernatant. Neutralised virions should then be 
prevented from re-infecting cells.  
A conformation-dependent antibody to BKPyV VP1 (C1), previously shown to neutralise infection, was 
obtained (Randhawa et al., 2009). While published data provides evidence that pre-incubation with 
VP1 (C1) antibody can reduce BKPyV infectivity it was important to confirm this in our assay systems. 
RPTE cells were infected at 3 IU/cell and 40 µl VP1 (C1) antibody (kindly provided by Dr. Christensen) 
was added to the supernatant of cells at 24 hpi, at 48 hpi media was removed and retained for testing, 
cells were washed once gently with PBS and fresh media supplemented with 40 µl VP1 (C1) antibody 
was added. A mouse monoclonal antibody specific to HSV-1 glycoprotein D (LP2), which should have 
no effect on BKPyV, was used as an isotype control. Cells and supernatant virus were harvested at 72 
hpi. Virus titres of supernatants and cells were then assessed by FFU, confirming that the neutralising 
antibody VP1 (C1) was able to reduce the infectivity of secreted BKPyV by 84%, compared to control 
(Fig. 3.5).  
While these data demonstrate that the anti-VP1 (C1) antibody effectively neutralises released virus 
infectivity, it is possible that this could be through either inhibiting receptor binding and thus prevent 
virus internalisation, or by inhibiting a post-internalisation stage such genome release which is thought 
to require capsid conformational changes in the ER. In order to investigate this BKPyV (3 IU/cell), or 
mock media, were incubated in the presence or absence of anti-VP1 (C1) neutralising antibody or the 
anti-HSV-1 (LP2) isotype control for 1 h and then used to infect RPTE cells. Cells were fixed at 6 hpi to 
allow sufficient time for BKPyV binding and internalisation, and processed for immunofluorescence.  
All fixed samples were then first incubated with the IgG2a anti-VP1 (C1) antibody, which had been 
used to neutralise the virions, and then anti-VP1 (B5, IgM). This was conducted to ensure that any 
potential failure to observe colocalisation or intracellular VP1 (B5) was not simply due to anti-VP1 (C1) 
obscuring the anti-VP1 (B5, IgM) epitope when bound to virions.  
In samples that were not pre-treated with neutralising antibodies no specific signal was observed in 
mock infected cells, while in BKPyV infected samples numerous C1-positive puncta were observed in 
cells, many of which colocalised with the B5 antibody staining highlighted with white arrows (Fig. 
3.6a). Overall, fewer B5-positive puncta were observed than C1-positive puncta, which could reflect 
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either more restricted epitope accessibility for the larger pentavalent IgM compared to the IgG, a 
better signal-to-noise ratio for the C1 antibody, and/or competition for binding between the two 
antibodies. Nevertheless, the detection of costained puncta within cells is indicative of virion 
internalisation. In samples pre-treated with anti-VP1 (C1) neutralising antibody relatively large blobs 
of signal were observed in mock infected cells, presumably due to aggregates of the C1 antibody 
binding to cells (Fig. 3.6b). While similar large aggregate-like anti-VP1 (C1) antibody stain was observed 
in BKPyV infected samples, the number of small C1-positive puncta observed in cells was greatly 
reduced and very few puncta showing C1 and B5 colocalisation could be seen. Samples pre-treated 
with the non-neutralising HSV-1 LP2 showed numerous small C1 positive puncta with many also 
positive for B5 staining, very similar to no antibody pre-treatment (Fig. 3.6c).  
This data taken together suggests that the anti-VP1 (C1) antibody not only neutralises BKPyV 


































Figure 3.5: VP1 (C1) antibody can neutralise infection. 
RPTE cells were infected (BKPyV 3 IU/cell), at 1 hpi cells were washed with PBS and fresh media added. At 24 
hpi VP1 (C1) neutralising antibodies or non-neutralising HSV-1 LP2 antibodies were added to media to 
neutralise any virions released into the supernatant. At 48 hpi supernatant was removed and retained, cells 
washed with PBS and media supplemented with fresh antibody was added to cells. Cell-associated and 
supernatant virus was harvested at 72 hpi. Cell-associated samples were freeze/thawed three times to 
release virus, while the two supernatant virus harvests were combined, pelleted by ultracentrifugation and 
resuspended in 20x original volume. An FFU conducted was conducted to assess viral titres of each sample. 
Percentage of total infectious virus in the supernatant specified. Data from one experiment shown. 
 
 



























































Figure 3.6: VP1 (C1) antibody reduces 
BKPyV entry into cells. 
BKPyV (3 IU/cell) infectious media or mock 
media were incubated for 1 h with no 
antibodies (a), neutralising VP1 (C1) 
antibody (b), or non-neutralising HSV-1 
LP2 antibody (c). RPTE cells were then 
infected with each incubation. At 48 hpi 
cells were fixed for immunofluorescence 
and stained. VP1 (C1) stain shown in red, 
VP1 (B5) shown in green, DAPI shown in 
blue.  
White arrows are used to show points of 
colocalisation between VP1 (C1) and VP1 
(B5) antibodies. Images taken on Olympus 
IX81 immunofluorescence microscope. 
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Given that VP1 (C1) can neutralise the infectivity and inhibit the entry of BKPyV, the TEM were 
repeated on RPTE cells that had been infected at 3 IU/cell followed by the addition of neutralising anti-
VP1 (C1) antibody at 24 and 48 hpi to investigate whether this affected the observed BKPyV particles 
in the lumen of cytoplasmic vesicles or the ER lumen. Cells were fixed at 72 hpi and processed for TEM. 
In the presence of neutralising antibodies the same single membraned vesicles were observed as 
previously (Fig. 3.7a & b, arrowed), and were as numerous as observed previously. Similarly smooth-
ER membranes were once again found to contain large quantities of virions (Fig. 3.7c & d).  
These data, suggest that these observations are not due to the internalisation of virions into cells and 
support the hypothesis that BKPyV particles can undergo egress from cells via transport involving the 
smooth-ER and single membraned vesicles.  
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Figure 3.7: Single membraned vesicles and convoluted membranes containing BKPyV virions are seen in the presence 
of neutralising antibodies. 
RPTE cells were infected (BKPyV 3 IU/cell), 1 hpi cells were washed with PBS and fresh media added along with VP1 (C1) 
neutralising antibodies. Neutralising antibodies were further replenished at 48 hpi. 
(a & b) BKPyV virions were once again observed in the cytoplasm of cells towards the cellular periphery, highlighted with 
white arrows at higher magnification. (d & e) BKPyV virions were once again observed in convoluted smooth membranes 
in the cytoplasm of cells, highlighted with black arrows are higher magnification. Images collected by M Hollinshead; 
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3.2.5 Disruption of Golgi transport does not affect BKPyV secretion  
Conventional secretion involves transport from ER to cis-Golgi, through the Golgi stack and then trans-
Golgi (outlined in Fig. 1.5). Golgi-dependent transport of proteins can be disrupted by monensin 
(Dinter and Berger, 1998), an ionophore that has previously been shown to inhibit secretion of SV40 
from Vero cells (Clayson et al., 1989). To assess whether BKPyV virions are being secreted via Golgi 
mediated conventional secretion RPTE cells were subjected to monensin inhibition assays. RPTE cells 
were infected with BKPyV (1 IU/cell) and at 24 hpi were treated with monensin at ranges from 5nM 
to 5PM, or ethanol (the diluent) as a control. These concentrations were chosen based on 
concentrations used by Clayson et al. to inhibit SV40 without affecting viral protein synthesis (100 nM-
10 µM), however concentrations 10 µM and above have been shown to have adverse effects in at 
least one cell type and as such concentrations were limited to 5 µM (Takemura et al., 1992).  
Cells and supernatant were harvested separately at 48 hpi and infectious virus levels were titred by 
FFU (Fig. 3.8a). The proportion of virus secreted into the supernatant was unaffected by the addition 
of monensin, even at the highest concentrations, suggesting that BKPyV does not traffic via Golgi 
mediated conventional secretion. As a control for these assays it was important to ensure that 
monensin is active in RPTE cells. It is known that monensin treatment leads to an increase in early 
endosome antigen 1 (EEA1)-positive vesicles due to the disruption of endocytic pathway trafficking 
(Hellevik et al., 1998). RPTE cells were treated with 5PM monensin, or ethanol as a control, for 24h 
and fixed for immunostaining. EEA1 staining is much more abundant in those cells treated with 
monensin than in control conditions (Fig. 3.8b). In addition, Golgi transport is required for HSV-1 
assembly, for the appropriate maturation and transport of HSV-1 envelope glycoproteins, as well as 
HSV-1 secretion after intracellular envelopment. To further validate the activity of the monensin stock 
replication and secretion of HSV-1 was assessed in the presence or absence of this inhibitor. Vero cells 
were infected with HSV-1 (3 PFU/cell) and treated with 5PM monensin from 6 hpi, or ethanol as a 
control. Cells and supernatant were harvested separately at 22 hpi and virus titres were assessed by 
plaque assay (Fig. 3.8c). Monensin treatment caused a reduction in the total production of infectious 
HSV-1 by approximately 90% and showed a greater reduction of virus release (approximately 60% 
reduction in proportion of total infectious virus that was released) demonstrating the expected 
inhibition of HSV-1 assembly and secretion by monensin. Taken together, these data suggest that 








































Figure 3.8: The inhibitor of Golgi transport, monensin, does not affect the release of BKPyV from cells. 
(a) RPTE cells were BKPyV infected at 1 IU/cell and 24 hpi treated with increasing concentrations of monensin, or ethanol 
as a control. At 48 hpi cells and supernatant virus were harvested separately. Cell-associated samples were freeze/thawed 
three times to release virus, while supernatant virus was pelleted by ultracentrifugation and resuspended in 20x original 
volume. An FFU assay was then conducted. Mean data from two independent experiments, error bars show standard 
error. (b) Uninfected RPTE cells were treated for 24 h with 5PM monensin or ethanol as a control. Cells were then fixed 
for immunofluorescence and stained for EEA1 (green). DAPI is shown in blue. The abundance of EEA1 increases when Golgi 
transport is disrupted. Images taken on Olympus IX81 immunofluorescence microscope. (c) Vero cells were infected with 
HSV-1 at 3 IU/cell. At 6 hpi cells were treated with 5PM monensin or ethanol as a control. At 22 hpi cells and supernatant 
were harvested. Cell-associated samples were freeze/thawed three times to release virus. HSV-1 titres were determined 
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3.2.6 Autophagic vesicles are not involved in BKPyV secretion for RPTE cells 
Various unconventional secretion pathways that do not follow classical ER to Golgi routes have been 
described (Fig. 1.6). To date four distinct pathways have been described, while more may continue to 
be identified. As BKPyV does not appear to secrete via the Golgi, it was important to investigate which 
of the unconventional secretion pathways may be involved. The first pathway is one by which small 
proteins are able to translocate across the plasma membrane by pore formation (Nickel and Rabouille, 
2009), a pathway which would seem highly unlikely for BKPyV due to its size (~45nm). MVBs serve as 
a conduit for the second type of unconventional secretion where cargo is incorporated into 
intraluminal vesicles of MVBs, which can be released as exosomes by fusion of the MVB with the 
plasma membrane (Qu et al., 2007, Andrei et al., 2004). If BKPyV were to use this pathway, this would 
result in the virus particles being inside intraluminal vesicles within MVBs and furthermore retaining 
a host derived lipid bilayer (the exosome) after they are released, as observed for HAV virus (Feng et 
al., 2013). No evidence of BKPyV particles within MVBs or being coated with a membrane in the 
extracellular matrix has been observed by TEM analysis of BKPyV infected cells, suggesting this 
MVB/exosome-based unconventional secretory pathway is unlikely to be exploited as a means of 
BKPyV release. 
A third unconventional secretory pathway that has been described involves autophagy-derived 
membranes, which serve to envelop cytoplasmic components (Duran et al., 2010). This results in a 
double membrane autophagosome containing cytoplasmic contents, which has been shown to be a 
route of non-lytic egress for certain enteroviruses (Mutsafi and Altan-Bonnet, 2018). While the 
structures seen in TEM that contain BKPyV virions close to the cell periphery are single membraned 
vesicles thus unlikely to be autophagic in origin, it was nevertheless hypothesised that autophagy may 
regulate BKPyV secretion. To investigate this autophagy was induced or inhibited during the final 
stages of BKPyV infection to observe whether this increased or reduce levels of BKPyV secretion. RPTE 
cells were BKPyV infected (1 IU/cell) and treated with 3Pg/ml Brefeldin A in serum-free OptiMEM to 
induce autophagy (Ding et al., 2007), 100nM wortmannin to inhibit autophagy, or DMSO as a control 
at 3, 6 and 12 h before harvesting at 48 hpi (Fig. 3.9a). Titres of cell-associated and supernatant virus 
showed that inducing autophagy lead to a small reduction in secreted virus, and by 12 h treatment 
intracellular viral loads were also vastly reduced. In addition to this, autophagy inhibition lead to a 
slight increase in BKPyV secretion. These data suggest that an autophagy-related pathway is not 
required for BKPyV secretion.  
To confirm induction of autophagy by serum-starvation (OptiMEM) and Brefeldin A treatment an 
immunoblot was conducted on cell pellets taken from the same experiments and blotted for both LC3 
and lipidated LC3 (Fig. 3.9b). When autophagy is induced LC3 becomes lipidated, as observed in the 
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Brefeldin A and OptiMEM treated cells. Low basal levels of lipidated LC3 in uninduced (control) RPTE 
cells meant validation of the autophagy inhibition activity of wortmannin was better validated by 
observing changes to the subcellular localisation of LC3 in RPTE cells, treated with or without 
wortmannin by immunofluorescence microscopy (Fig. 3.9c). Several LC3-positive puncta were 
observed in untreated RPTE cells indicating steady-state levels of autophagy, while in wortmannin 
treated cells no such puncta are present and LC3-staining displayed a diffuse signal indicating effected 
inhibition of autophagy by this inhibitor in RPTE cells. These data, in conjunction with the morphology 
of virion-containing ER-like compartments and single membrane vesicles strongly suggest that BKPyV 


















































Figure 3.9: Autophagy modulation is not involved in BKPyV secretion. 
(a) RPTE cells were infected with BKPyV (1 IU/cell). At 3, 6 and 12 hours prior to 48 hpi harvest cells were either treated 
to inhibit autophagy (10mM wortmannin), induce autophagy (3Pg/ml Brefeldin A, in OptiMEM), or DMSO as a control. 
At 48 hpi cells were harvested for immunoblot analysis, and cellular and supernatant virus was harvested separately. 
Cell-associated samples were freeze/thawed three times to release virus, while supernatant virus was pelleted by 
ultracentrifugation and resuspended in 20x original volume. FFU titration was then conducted. Mean data from three 
independent experiments, error bars show standard deviation. (b) To validate the effectiveness of Brefeldin A plus 
starvation in inducing autophagy an immunoblot of lipidated and unlipidated LC3 in untreated (control) RPTE cells or 
in the presence of autophagy inducer Brefeldin A + optiMEM for 12h was conducted, LC3 becomes lipidated during 
autophagy. (c) To validate the effectiveness of wortmannin in inhibiting autophagy RPTE cells were untreated (control) 
or treated with the wortmannin and stained for LC3 and imaged by immunofluorescence, shown in green, DAPI is 
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3.2.7 VP1 conformational antibodies colocalise with GORASP1, GORASP2 and Calnexin, but not 
EEA1, TGN46, GM130 or LysoTracker 
A fourth unconventional secretion pathway that has been described is termed ‘Golgi bypass’, and 
involves the trafficking of single membraned vesicles, pinched from the ER, directly to the cell surface 
(Rabouille et al., 2012). The Golgi-bypass associated single membraned vesicles have been shown to 
contain the Golgi Reassembly and Stacking Protein 1 (GORASP1) and Golgi Reassembly and Stacking 
Protein 2 (GORASP2), however this pathway has thus far only been described in mammals for 
transmembrane cellular proteins such as mis-folded CFTR (Gee et al., 2011). While we have seen clear 
localisation of virions to the ER by TEM, to further characterise the secretion pathway used by BKPyV 
it was important to investigate the localisation of BKPyV particles in subcellular organelles by 
immunofluorescence microscopy, particularly secretory and endocytic pathway compartments. 
Having obtained a panel of conformation-dependent BKPyV VP1 antibodies (Randhawa et al., 2009), 
testing of these antibodies in immunofluorescence demonstrated that those of IgM subtype 
preferentially stained particles in the cytoplasm, while those of IgG subtypes stained both nuclear and 
cytoplasmic conformational VP1. This is presumably due to reduced accessibility for binding epitopes 
of the large IgM molecules within the densely packed nucleoplasm. As the majority of viral particles 
are contained within the nucleus, the ability to exclude this signal in colocalisation imaging is beneficial 
for the detection of viral particles in the cytoplasm; the relatively weak signals for virions in the 
cytoplasm can easily be obscured by the very bright signals in the nucleus when using IgG subtype 
anti-VP1. To confirm that cytoplasmic signals when using conformation-dependent anti-VP1 IgM 
antibody (B5) are virus particles RPTE cells were infected BKPyV (1 IU/cell) or mock infected, fixed at 
48 hpi and then co-stained with an IgM subtype anti-VP1 (B5) and an IgG2a subtype anti-VP1 (D11), 
both of which are conformation-dependent VP1-specific antibodies that neutralise BKPyV infectivity 
(Fig. 3.10). Clear colocalisation was observed in the cytoplasm between both subtypes of 
conformational VP1 antibody in infected cells, while nuclear signal was lacking in VP1 (B5) staining. No 
signal was detected for either antibody in uninfected cells. All subsequent colocalisation studies with 
cellular compartment markers were conducted with the IgM anti-VP1 (B5) antibody. 
To investigate localisation of BKPyV particles to sub-cellular compartments RPTE cells were infected 
with BKPyV (1 IU/cell), or mock infected, and fixed at 48 hpi and stained with anti-VP1 IgM (B5) 
together with a range of cellular markers. LysoTracker, a marker of acidic vesicles (Fig. 3.11a), GM130, 
a marker of the cis-Golgi (Fig. 3.11b), TGN46, a marker of the trans-Golgi network (Fig. 3.11c) or EEA1, 
an early endosomal marker (Fig. 3.11d) failed to show colocalisation with VP1 (B5), suggesting that 
BKPyV does not localise to these compartments during intracellular trafficking at late stages of 
infection. Interestingly, colocalisation between VP1 (B5) and GORASP1 (Fig. 3.11e), GORASP2 (Fig. 
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3.11f) and calnexin (Fig. 3.11g) was observed (highlighted with white arrows). Calnexin is an ER 
marker, and while staining is rather widespread in these cells, colocalisation can be seen, providing 
further evidence that virions are present in the ER at late times post infection. GORASP1 and GORASP2 
are known to tether Golgi stacks together, but in times of cellular and ER stress a proportion can be 
relocalised to vesicles involved in ‘Golgi-bypass’ unconventional secretion, which involves direct 
vesicle transport from the ER to the cell surface. The observed colocalisation between GORASP1 or 











































Figure 3.10: VP1 IgM conformational antibodies bind VP1 in the cytoplasm but not the nucleus. 
RPTE cells were infected with BKPyV (1 IU/cell) or mock infected and fixed for immunofluorescence at 48 hpi. Cells 
were immunostained with VP1 (D11, IgG2a) (each shown in red), VP1 (B5, IgM) (green) and DAPI (blue). Images were 
acquired on Olympus IX81 (x60 magnification).  
 





































Figure 3.11: VP1 IgM conformational antibodies colocalise with GORASP1, GORASP2 and calnexin, but not EEA1, 
TGN46, GM130 or LysoTracker.  
RPTE cells were infected with BKPyV (1 IU/cell) or mock infected and fixed for immunofluorescence at 48 hpi. Cells 
were immunostained with either LysoTracker (a), GM130 (b), TGN46 (c), EEA1 (d), GORASP1 (e), GORASP2 (f) or 
calnexin (g) (each shown in red), VP1 (B5) (green) and DAPI (blue). Colocalisation with VP1 (B5) seen with GORASP1 
(f), GORASP2 (g) and calnexin is indicated with white arrows. Images a, b and c, were acquired on Olympus IX81 (x60 
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3.2.8 Optimisation of GORASP1 and GORASP2 siRNA knockdown 
Further investigation into the role of GORASP1 and 2 during the egress of BKPyV was conducted by 
siRNA knock down of the expression of GORASPs 1 and 2. siRNA was chosen as the method of 
knockdown as primary RPTE cells are limited to approximately seven passages, which prohibits the 
possibility of creating CRISPR-Cas9 stable knockouts. GORASP1 and GORASP2 show >60% similarity 
and may be able to functionally compensate for one another (Bekier et al., 2017). Therefore, 
knockdown of both GORASP1 and 2 in combination may be necessary to understand their roles in the 
trafficking of BKPyV. 
GORASP1 and 2 siRNA 4-plex pools were obtained from ThermoFisher. Each pool was reverse 
transfected into RPTE cells upon plating. Cells were fixed at 24, 48, 72 and 96 h after the first 
transfection and stained for GORASP1 or 2 and GM130 (Fig. 3.12a & b). The greatest level of depletion 
for either GORASP1 or GORASP2 was observed at 96 h, suggesting these proteins have relatively long 
half-lives and low levels of protein turnover in RPTE cells. 
The activity of each individual siRNA construct for the 4-plex pools was then tested. The individual 
constructs of each pool were reverse transfected into RPTE cells when plating, followed by a further 
transfection at 52 h, cells were then fixed at 96 h and stained for either GORASP1 or GORASP2 (Fig. 
3.12c & d). GORASP1 siRNA #2 and GORASP2 siRNA #3 yielded the greatest levels of depletion. These 









































Figure 3.12: siRNA knockdown of GORASP1 and GORASP2 optimisation. 
RPTE cells were reverse transfected with either siRNA pools (a & b) or individual constructs (c & d) when cells were plated. 
(a & b) Cells were fixed at 24, 48, 72 or 96 h and stained for GORASP1 (a) or GORASP2 (b) (red), GM130 (green) and DAPI 
(blue). (c & d) Cells were fixed at 96 h and stained for either GORASP1 (c) or GORASP2 (d) (green) and DAPI (blue). Construct 
2 shows greatest depletion of GORASP1, while construct 3 shows greatest depletion of GORASP2. All images taken on 
Olympus IX81 immunofluorescence microscope. 
 
(d) 
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3.2.9 Effects of siRNA knockdown of GORASP 1 and GORASP2 on BKPyV secretion 
Knockdown of GORASP1 or GORASP2 individually, or combined knockdown of GORASP 1 and 2 from 
RPTE cells was then attempted using this protocol. Knocked down cells were also infected with BKPyV 
and the percentage of virus released into the supernatant after 48 h was determined by FFU.  
RPTE cells were reverse transfected with GORASP1, GORASP2, GORASP1 and 2, or scrambled siRNA 
ConX as a control. 48 h after the first siRNA transfection cells were infected with BKPyV (1 IU/cell) for 
1 h and then were washed with PBS and incubated in fresh media. At 6 hpi cells were transfected for 
a second time with the same siRNAs. At 48 hpi cells and supernatant were harvested separately and 
infectious titres determined for both by FFU assay and protein expression levels in cell samples 
determined by immunoblot. Knockdown was attempted in three separate experiments, with variable 
levels of depletion attained (Fig. 3.13c). Densitometry analysis of immunoblots, each normalised to 
tubulin control, were conducted. Knockdown of either GORASP1 or GORASP2 proved somewhat 
successful. When transfected alone GORASP2 siRNA caused GORASP2 protein depletion in all three 
experiments, showing a 61%, 55% and 36% reduction in experiments 1, 2 and 3 respectively. GORASP1 
alone proved more difficult to deplete, showing a 13%, 49% and 24% reduction in experiments 1, 2 
and 3 respectively. For both GORASP1 and GORASP2 knockdown, an increase in the expression levels 
of the other GORASP was observed. While this has not been previously noted during knockout 
experiments in mice in vivo (Veenendaal et al., 2014), it was observed for GORASP2 knockdown in the 
human cell line HEK293 and for GORASP1 knockdown in HeLa cells (Bekier et al., 2017). Combined 
knockdown of both GORASP1 and GORASP2 together was more inefficient. Whilst largely unsuccessful 
in experiments 1 and 2, appreciable levels of knockdown of both GORASP1 and 2 were obtained in 
experiment 3 (70% knockdown of GORASP1, 71% knockdown of GORASP2), however cells appeared 
unhealthy when examined by microscopy before harvest, as evidenced by reduced levels of tubulin 
(31% reduction in abundance compared to scrambled ConX siRNA control). Knockdown of both 
GORASP1 and GORASP2 has previously been shown to result in severe Golgi fragmentation (Bekier et 
al., 2017). 
The effects GORASP1 and 2 depletions on the secretion of BKPyV at 48 hpi was determined by FFU 
assay (Fig. 3.13a). While these data must be treated with caution due to variable levels of knockdown 
by siRNA, a clear trend is evident. Scrambled control siRNA treated cells secreted 0.97% of total BKPyV 
into the supernatant, GORASP1 depletion alone reduced secretion to 0.54% of total BKPyV. GORASP2 
depletion caused BKPyV secretion to be reduced to 0.72% of total BKPyV, although the low cell-
associated titre in experiment 2 must be taken into account (Fig. S3). Interestingly, even though 
knockdown efficiencies were generally poorer in the combined GORASP1 and 2 siRNA transfected cells 
a greater reduction if the secretion of BKPyV was observed, to 0.37% (Fig. 3.13b).   
Chapter 3. Secretion of BKPyV is by an unconventional secretion pathway 
97 
 
Figure 3.13: siRNA knockdown of GORASP1 and GORASP2 proteins suggests depletion may have an effect on BKPyV 
secretion. 
RPTE cells were treated with double 100mM siRNA knockdowns of GORASP1, GORASP2, a combination of both GORASP1 
and GORASP2, or ConX as a control. 48 h after siRNA treatment cells were infected with BKPyV (1 IU/cell). At 48 hpi cells 
and supernatant were harvested separately. Half of cell-associated samples were freeze/thawed three times to release 
virus and half kept for immunoblot, while supernatant virus was pelleted by ultracentrifugation and resuspended in 20x 
original volume. (a) Mean FFU titre of cell-associated and supernatant virus from three independent experiments. Error 
bars show standard error of mean. (b) Mean percentage level of secreted BKPyV taken from Fig. 3.12a; three independent 










TEM of infected RPTE cell nuclei allowed the morphology of BKPyV virions to be identified and 
described, which were then be used as reference when identifying virions in the cytoplasm of infected 
cells. While this proved useful it was not without limitations; identifying virions within ER-like 
convoluted membranes and single membraned vesicles relied exclusively on visual identification, and 
it is possible that individual virions could be mistaken for similar sized cellular structures, e.g. glycogen 
granules. Likewise, it is possible that virions in other cytoplasmic compartments could have been 
missed, particularly if they were sparse and individual particles. In order to limit errors of this nature 
the samples were extensively analysed by Dr M. Hollinshead, an extremely experienced electron 
microscopist, which provided confidence that we were indeed detecting BKPyV virions within these 
specific membrane compartments, although it is impossible to rule out rare examples of BKPyV 
particles in other compartments. The convoluted membranes in which virions were contained were 
confirmed to be ER through the retention of an ER retained HRP-KDEL marker. Furthermore, the 
accumulation of virions with the lumen of the ER and in single membrane vesicles near the cell 
periphery were observed even in the presence of neutralising antibodies, suggesting these particles 
are undergoing egress rather than entry. However, some caution must be given to the specific activity 
of neutralising antibodies. While the ability of the conformation-dependent VP1 (C1) antibody used in 
these studies to neutralise BKPyV infectivity has been well documented (Randhawa et al., 2009), it 
was not known whether the antibody completely blocks entry to cells. Some neutralising antibodies 
may inactivate virus not by preventing virion binding or endocytosis but may inhibit a post entry step 
such as ER-exit or genome uncoating. The data in this chapter suggests this antibody does reduce virus 
internalisation, providing more confidence that the virions detected in the ER and single membrane 
vesicles. It is worth noting that whilst BKPyV entry was reduced in the presence of neutralising VP1 
(C1), it was not completely inhibited, so we cannot rule out a contribution of virion entry to the 
observed virus particles with cytoplasmic membrane compartments. However, in TEM experiments 
we conducted for a recent paper investigating the role of Agno demonstrated that in cells infected 
with an Agno deletion BKPyV virions are unable exit the nucleus and no virions were observed in the 
lumen of the ER or single membrane vesicles (Panou et al., 2018). These data demonstrate that the 
virus particles we detect in cytoplasmic ER compartments and vesicles are highly unlikely to be due to 
input virus from the initial infection of cells, although do not rule the possibility that they could be due 
to re-internalisation of newly synthesised virions that have been released from cells. 
Active and non-lytic BKPyV secretion, which was perturbed by addition of DIDS, was not affected by 
the disruption of Golgi transport by monensin treatment, suggesting that an unconventional secretory 
pathway was responsible. Of those unconventional secretory pathways thus far described only 
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autophagy-derived membranes and exosome-related pathways have been shown to be used by other 
non-enveloped viruses as a means of virion secretion (Feng et al., 2013, Jackson et al., 2005). Both of 
these pathways would result in a double membrane structure around cytoplasmic virions and 
potentially host-derived membrane coating extracellular virions, neither of which were observed in 
extensive TEM analysis. The lack of observed viruses within double membraned vesicles along with 
data from this chapter showing that autophagy induction failed to increase secretion, while autophagy 
inhibition failed to reduce secretion, indicates that BKPyV does not secrete via such unconventional 
secretory pathways. The unconventional secretory pathway that best describes secretion which 
involves trafficking via the ER and single membraned vesicles, but not the Golgi, is the so-called ‘Golgi-
bypass’ pathway. In times of ER stress Golgi-bypass enables vesicles to be pinched off from the ER and 
trafficking of membrane bound contents directly to the plasma membrane, upon which vesicle fusion 
occurs and contents are released into the extracellular space (Gee et al., 2011). Such Golgi-bypass 
transport vesicles have been described to contain GORASP proteins, which are usually responsible for 
holding Golgi ribbons together. Data in this chapter shows that while colocalisation of virions was not 
observed with any Golgi marker, clear colocalisation was seen between BKPyV particles and both 
GORASP1 and GORASP2. While only relatively few cytoplasmic VP1-positive puncta colocalised with 
GORASPs, this can be explained by only transient recruitment of GORASPs to virion-containing 
transport vesicles, or if many of the observed ‘cytoplasmic’ virus particles had actually already been 
released but were still attached to the extracellular surface of the cell. GORASPs have not been 
described to be involved in any internalisation of endocytic pathway, lending further weight to the 
argument that these BKPyV particles are undergoing egress rather than entry. 
Attempts to define a functional role for GORASPs in BKPyV release were somewhat inconclusive, 
primarily because knockdown of GORASP1 and GORASP2 by siRNA proved difficult. While optimisation 
of individual siRNA constructs and protocol appeared successful, it was challenging to get knockdown 
results which could be replicated, particularly when attempting combined knockdown of both 
GORASP1 and 2. Indeed, in single knockdowns the alternative GORASP showed a slight increase in 
expression, possibly compensating for siRNA knockdown. It is also possible that depletion of both 
GORASPs simultaneously in deleterious to cells, published studies have shown that in cells where both 
GORASP1 and 2 have been deleted using CRISPR/Cas9 techniques Golgi stacking was impaired, the 
Golgi was fragmented and while protein secretion is increased, those secreted proteins were more 
likely to be incorrectly glycosylated (Bekier et al., 2017).  
Even with these experimental limitations a trend was observed where GORASP knockdown resulted 
in a moderate reduction of BKPyV secretion, more so for the double knockdown and single GORASP1 
knockdown than GORASP2 knockdown. To further investigate the role of GORASPs in BKPyV secretion, 
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gene knockout using CRISPR/Cas9 for one GORASP followed by transient siRNA depletion of the other, 
or gene knockout of both GORASP1 and 2 may be required.
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4. Quantitative proteomics analysis of BKPyV infection 
4.1 Introduction 
Polyomaviruses such as BKPyV have small genomes with relatively little coding potential and express 
only a handful of proteins. As such these viruses are very reliant on host cell activities for their 
replication. In order to study virus-induced alteration of secretory pathways, which could facilitate 
non-lytic egress, in addition the more global effects on other cellular pathway modulations during 
BKPyV infection, a whole cell proteomic analysis approach was implemented.  
While a number of studies have been conducted to investigate how BKPyV infection modulates the 
host cell environment during replicative infection, these have been primarily at the transcriptome 
level. Microarray studies of BKPyV infected primary RPTE and Human Umbilical Vein Endothelial (HUV-
EC) cells demonstrated significant abundance increases of cell division, apoptotic, DNA damage/repair 
and DNA replication pathway associated RNA levels at 40 and 72 hours post infection (hpi) (Abend et 
al., 2010, Grinde et al., 2007). In HUV-EC cells signal transduction pathway RNA levels were down 
regulated from as early as 20 hpi. In RPTE cells the innate immunity-related transcripts PTX3 and MICB 
were up regulated at 72 hpi although few other immune response-related genes were induced in 
either cell type. While these studies have proved useful in understanding the effects of BKPyV 
infection on cellular mRNA levels, they do not provide information regarding virus-induced changes 
to cellular protein levels, as changes in mRNA levels do not necessarily correlate with protein 
abundance.  
Similarly, an RNAseq study that included analysis of the effects of BKPyV infection on RPTE cells from 
3 to 9 days post infection (dpi) has shown that infection can induce IFN-β production by RPTE cells by 
3 dpi, but just four ISGs were found to be up regulated at 6 dpi (IFI6, IRF7, OAS3 and HERC5), and by 9 
dpi just one ISG was up regulated at the transcript level (HERC5), suggesting BKPyV may actively block 
induction of ISG transcription. Similar to microarray studies, RNAseq only provides transcriptomic data 
and in this study failed to detect any changes to the host transcriptome during the first round of BKPyV 
infection and replication, which takes place before 3 dpi, likely because the experimental setup of this 
study used a low multiplicity of infection (Assetta et al., 2016). 
To date there has only been one broad-scale analysis of the host cell proteome in BKPyV infection, 
where stable isotope labelling with amino acids in cell culture (SILAC) methods were used to 
determine protein abundance changes in nuclei isolated from primary RPTE cells at 3 days post 
infection. This study identified and quantified >2000 host proteins, of which 50 were shown to 
increase and 13 decrease in abundance to a significant level, including proteins involved in DNA 
damage response and apoptosis as well increased abundance of proteins which had not previously 
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been identified by RNA based analyses, such as p53. However, this study was restricted to a single 
time point of the viral replication cycle due to the limitations of using SILAC-techniques with passage-
limited primary cells, and provided little information regarding host proteins not present in the 
nucleus. Indeed, in this study it is unclear whether the identified changes in protein abundance may 
truly reflect changes in the total amount of protein with the entire cell or is more due to effects on 
the nuclear import/export of proteins. 
To gain a greater insight into host cell modification during BKPyV infect, a whole cell quantitative 
temporal viromic study of BKPyV infection comparing two independent BKPyV-permissive primary 
human cell types, RPTE and human urothelial (HU) cells, was conducted. This technique allows post-
experimental tagging of up to 11 independent samples with isobaric labels (Tandem-Mass-Tagging, 
TMT) followed by MS3 mass spectrometry, enabling the relative abundance of host proteins to be 
quantified throughout the time course of an infection in a highly multiplexed fashion (Weekes et al., 
2014). The development of such high throughput techniques have enabled the extensive 
characterisation of whole cell proteomes, or indeed localised proteomes, and provided the 
opportunity to directly compare infected and mock infected cells at multiple time points, and/or 
multiple virus strains, in parallel. Analysing quantitative changes in host cell protein expression in 
infected cells facilitates the identification of those proteins which may be important for the viral 
lifecycle. 
Once host proteins abundance changes during viral infection have been identified, these data can then 
be analysed using bioinformatic tools. In this way it has been possible to identify entire pathways or 
metabolic processes affected by viral infection to the point of being significant.  Indeed, when used to 
study HCMV infection, TMT-based proteomics revealed the detailed temporal expression of cell 
surface signalling pathway proteins used to subvert cellular immune responses, and furthermore 
identified potential therapeutic targets for this virus (Weekes et al., 2014).  These findings highlight 
the potential benefits of using TMT-based proteomics to elucidate the effects a BKPyV infection on 
the host cell proteome over the time course of an infection. 
  




4.2.1 Growth curves of two permissive cell types advises experimental design 
Two human primary BKPyV-permissive cell types, RPTE and HU cells, were both chosen to be analysed 
by whole cell proteomic analysis. HU cells are one of the very few other cell types available that 
support BKPyV infection and are representative of a natural site of infection (Li et al., 2013a). Analysis 
of two independent cell types allows comparisons to be drawn between them, enabling identification 
of host pathways particularly important for the virus, and not simply cell type specific responses to 
infection. In order to determine the most appropriate time points of infection at which to perform 
proteomic analysis BKPyV growth curves were first conducted. RPTE and HU cells grow at different 
rates and may support replication of BKPyV to different levels, thus it was important to identify time 
points which were suitable for analysis in both lines. RPTE cells are known to support a full round of 
BKPyV replication by approximately 72 hpi, while HU cells are less well described. RPTE and HU cells 
were infected with BKPyV (3 IU/cell) and cells were harvested directly into media to collect total 
infectious virus every 12 hours from 12 hpi to 96 hpi. Once harvested the virus was released from cells 
by several freeze/thaw cycles, after which the virus titre of each sample was determined by FFU assay 
(Fig. 4.1a). BKPyV replicated efficiently in RPTE cells and infectious titres continued to increase until 
84 hpi up to a maximum of 1.2x107 IU/mL, after which time virus levels began to plateau. HU cells 
supported BKPyV replication to a reduced extent to a maximum of 1.5x105 IU/mL by 48 hpi, after 
which infectious titres did not increase further. As such, the three time points chosen for infected cell 
analysis were 24 hpi, an early point of infection where early viral protein expression alone is expected 
to occur; 48 hpi, a middle point of infection for RPTE cells and a time at which HU cells should still be 
replicating virus; and 72 hpi, a late point in infection for RPTE cells, and a time at which BKPyV 
replication in HU cells has plateaued.  
At the time of this experiment TMT-based proteomics were limited to a maximum of 10 isobaric tags, 
therefore whilst three infected time points were chosen for each cell type, just two mock-infected 
time points could be included for each cell type (Fig. 4.1b). The mock infected time points, against 
which the infected samples could be compared for levels of fold change, were chosen as 24 and 72 
hpi. For data analysis these can be averaged allowing each infected time point to be compared against 
the average of the two mock time points for their cell type.  
These TMT-based proteomics studies were conducted in collaboration with Dr Michael Weekes’ 
laboratory. All infections, experimental conditions and harvesting were conducted in house, while 
tagging and mass-spectrometry analysis was conducted by members of the Weekes lab (credited 
where applicable).  
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Figure 4.1: TMT experimental design. 
(a) RPTE and HU cells were infected with BKPyV (3 IU/cell) and cell-associated and supernatant virus was harvested 
together every 12 h until 96 hpi. Infectious virus was released from cells by three rounds of freeze/thawing, then titred 
by FFU assay, producing a single-step growth curve for both cell types. (b) Three time points were the chosen to cover 
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4.2.2 Low numbers of cellular proteins were significantly changed in abundance throughout BKPyV 
infection. 
RPTE and HU cells were infected with BKPyV and 10-plex TMT used to identify whole cell protein 
changes by LC-MS3. Cells were infected with BKPyV (5 IU/cell) or mock infected. BKPyV infected cells 
were harvested at 24, 48 and 72 hpi and mock infections were harvested at 24 and 72 hpi. When 
harvesting, cells were washed thoroughly with ice-cold proteomic grade PBS and 75 µl of TMT lysis 
buffer added, into which cells were scraped. Samples were transferred to an Eppendorf tube and then 
vortexed extensively. After 10 minutes at room temperature samples were sonicated and centrifuged 
to pellet DNA. Supernatants were transferred to a fresh tube, the centrifuge step was repeated and 
supernatants were then snap frozen in liquid nitrogen and passed to Dr Weekes’ lab for processing. 
Digestion of samples in LysC protease in 200 mM HEPES (pH 8.5) and 1.5 M guanidine was conducted 
after cysteines were alkylated, a further digestion by trypsin in 200 mM HEPES (pH 8.5) and 0.5 M 
guanidine. After reactions were quenched digested peptides were subjected to solid phase extraction 
and vacuum-centrifuged. Samples were then labelled with TMT reagents and subjected to 
fractionation, vacuum centrifuge dried and resuspended in mass spectrometry solvent, ready for 
processing on the Orbitrap Lumos mass spectrometer. Parallel infections conducted at the same time 
as the initial infection in order to confirm cells were adequately infected. For this RPTE and HU cells 
were set up at the same confluency as TMT samples, infected with the same inoculum and fixed for 
immunofluorescence at 48 hpi. Cells were stained for TAg as a marker of infection and DAPI was used 
as a cellular marker. By calculating the number of cells expressing TAg it was confirmed 91.15% of 
RPTE cells and 91.3% of HU cells were infected. 
In total 8992 cellular proteins and 6 viral proteins were identified, including a novel peptide from a 
previously undescribed variant of the TAg open reading frame (Table S2). Each protein detected was 
identified by at least a single unique peptide and the log2 fold change of individual proteins from each 
time point were established as a ratio of the averaged mocks for that cell type. The signal:noise ratio 
was determined (Du et al., 2008), in addition the p value was estimated using significance B (Cox and 
Mann, 2008). This allowed scatterplots to be compiled for either cell type at each time point, showing 
every protein identified either up regulated (to the right of scatterplots), or down regulated (to the 
left of scatter plots) (Fig. 4.2 and 4.3), with those proteins defined as highly significant (p < 0.0005) 
shown in red.  
These scatterplots highlighted that very few cellular proteins are significantly changed in abundance 
in response to BKPyV infection. In RPTE cells at 24 hpi just 17 proteins are most significantly changed 
(p < 0.0005), 0.08% of all cellular proteins identified, at 48 hpi this number increases to 106 proteins 
although this remains just 1.2% of all proteins. At 72 hpi this number reduces to 85 proteins 
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significantly changed in abundance (0.9% of all cellular proteins). In HU cells similarly low numbers of 
proteins are most significantly modulated (p < 0.0005) in their expression. At 24 hpi 29 proteins are 
significantly changed in abundance (0.3% of total), and at 48 and 72 hpi this number remains low at 
90 and 56 respectively (1% and 0.6% of total) (Tables S3-8). It was interesting to note that, in both 
RPTE and HU cells, at 72 hpi fewer proteins were most significantly changed in abundance than at 48 
hpi. This might be attributable to the switch from early gene expression to late gene expression which 
occurs from 36-48h. The early proteins TAg and tAg are both multifunctional proteins which have large 
effects on cellular processes and cell cycle progression (Table 1.2), after early gene synthesis TAg is 
employed as a viral helicase and no further TAg is transcribed as late genes are then transcribed and 
translated. Such a switch might alter the effects of those early proteins on cellular processes, by 72 
hpi seeing cell cycle processes less affected. However further investigation into this hypothesis would 
be necessary.  
Also interesting to note were the numbers of most significantly down regulated proteins (p < 0.0005), 
which showed more changes in HU cells than RPTE cells at both 24 and 48 hpi. Whilst still a very small 
percentage to the total proteins identified, this suggests that there may be differences in how these 
two cell type respond to early infection, and may require further investigation. 
Expression of BKPyV early viral proteins, TAg and tAg, were observed in both cell type from 24 hpi, 
along with a potential novel TAg variant predicted to expressed an alternatively spliced early gene 
transcript (NOVEL_ORF), based on the detection of a single unique peptide that was predicted from a 
6 frame-translation of the entire BKPyV genome sequence. TruncTAg could not be identified due to 
its sequence being identical to the N-terminus of TAg, and the alternative C-terminus of TruncTAg 
would only result in the presence of only one very short (3 amino acid) peptide that is different to TAg 
being released after trypsin cleavage. VP1, VP2 and Agno were observed in both cell types from 48 
hpi. VP3 was not be identified due to its 100% homology with the C terminus of VP2, and the peptide 
corresponding to the extreme N-terminus that would be unique to VP3 was not quantified.  
Further analysis of proteins which were identified as significantly altered in abundance was 
undertaken, in order to identify specific host pathways that are modulated in response to BKPyV 
infection.  
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Increased protein expression in BK InfectedDecreased protein expression in BK Infected 
Figure 4.2: RPTE cell scatter plots of protein abundance change. 
The abundance of proteins identified at each BKPyV-infected time point, 24 hpi (a), 48 hpi (b) and 72 hpi (c), was divided 
by the average of the mock-infected samples (24 and 72 hpi). Scatter plots show all proteins identified with unique 
peptides. Fold change (RPTE cell BKPyV-infected/RPTE cell mock-infected average) is shown as the log2 ratio on the x-axis, 
to the right increasing in abundance, and to the left decreasing in abundance. The signal:noise is shown on the y-axis as 
log10. Significance B was used to estimate p values (Cox and Mann, 2008). All scatter plots kindly produced by Dr C Davies.  
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Figure 4.3: HU cell scatter plots of protein abundance change. 
The abundance of proteins identified at each BKPyV-infected time point, 24 hpi (a), 48 hpi (b) and 72 hpi (c), was divided 
by the average of the mock-infected samples (24 and 72 hpi). Scatter plots show all proteins identified with unique 
peptides. Fold change (HU cell BKPyV-infected/HU cell mock-infected average) is shown as the log2 ratio on the x-axis, 
to the right increasing in abundance, and to the left decreasing in abundance. The signal:noise is shown on the y-axis as 
log10. Significance B was used to estimate p values (Cox and Mann, 2008). All scatter plots kindly produced by Dr C Davies.  
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4.2.3 Cluster analysis of proteins significantly altered in abundance throughout infection 
Those cellular proteins that were significantly altered in abundance (p < 0.0005) in each cell type and 
at each time point were assessed for correlation between cell types by venn diagram (Fig. 4.4). There 
was no overlap between cell types for down regulated proteins at any time point (Fig. 4.4a). When 
RPTE and HU cells down regulated proteins from any time point were analysed by the Search Tool for 
the Retrieval of Interacting Genes/Proteins (STRING) cluster analysis, an online bioinformatic tool 
which uses previously identified or predicted protein-protein interactions to link proteins, no 
clustering was found (Fig. S4). Further analysis using the functional Database for Annotation, 
Visualisation and Intergrated Discovery (DAVID) to predict enrichment of particular biological themes 
which link proteins and provides enrichment scores and p values that allow conclusions to be drawn 
on potential false discovery rates, shows no pathway enrichment for these down regulated groups of 
proteins (Fig. S5). For the purpose of this study a stringent cut off of p < 0.0005 was implemented, to 
further analyse these down regulated proteins it may be possible to amend this cut off to p < 0.005 
and reanalyse, although there would be a concern that the possibility of identifying false positive hits 
in pathway analysis is then increased. It is not suggested that all the identified significantly down 
regulated proteins (p < 0.0005) are experimental noise, but some care must be taken when drawing 
conclusions of pathway analysis on such small protein numbers.    
Significantly up regulated proteins showed somewhat more overlap between cell types (Fig. 4.4b). At 
24 hpi 3 proteins were significantly up regulated in both RPTE and HU cells, while at 48 hpi 35 proteins 
were significantly up regulated in both RPTE and HU cells, and at 72 hpi 22 proteins were up regulated 
in both cell types (Table S9-11).  The groups of proteins up regulated in both cell types were also 
analysed by STRING and DAVID bioinformatic tools (Fig. 4.5).  
At 24 hpi two of the three proteins up regulated in both RPTE and HU cells are STRING linked (Fig. 
4.5a), and the DAVID enrichment scores of the same three proteins suggest they are involved in 
acetylation and DNA damage responses and these pathways are up regulated at this time point. While 
these enriched pathways have p values of relatively low significance for DAVID analysis (>0.0005), 
these pathways have been shown to be up regulated in BKPyV infection in previous BKPyV studies 
(Verhalen et al., 2015, Justice et al., 2015). At 48 hpi the 35 proteins up regulated in both RPTE and 
HU cells are all linked in one large STRING cluster, with the exception of just 3 proteins (Fig. 4.5c). 
Furthermore, DAVID analysis of these same 35 proteins shows the top eight enriched processes are 
related to cell division (cell cycle, cell division, mitosis, cytoskeleton, microtubule) or protein 
modification (phosphoprotein, ubiquitin conjugation). Surprisingly we do not see enrichment of any 
intracellular trafficking or secretory pathways, which were expected to be altered due to non-lytic 
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unconventional secretion of virions, nor was any modulation of innate immune responses identified 
(Fig 4.5d).  
Similar to 48 hpi, the analysis of the 22 proteins significantly up regulated in both cell types at 72 hpi 
shows STRING analysis is one large cluster, the same top eight enriched processes are identified by 
DAVID as was seen in 48 hpi (Fig. 4.5f). The three proteins which failed to cluster in up regulated 48 
and 72 hpi conditions appear to have roles in either cell cycle regulation or DNA damage response, 
but have yet to be annotated in STRING due to limited understanding of their pathways or roles. 
WDR76, WD repeat-containing 76, is a DNA binding protein which rapidly responds to DNA damage 
signals  (Gilmore et al., 2016). FAM111B, Homo sapiens family with sequence similarity 111 member 
B, is a cancer associated nucleoprotein whose mutation can lead to increased prostate cancer rates 
(Akamatsu et al., 2012), while PROSAPIP1, proSAP interacting protein 1 (identified in our screen by its 
alternative name LZTS3), is a tumour suppressor suggested to play a role in the regulation of non-small 
cell lung cancer cell proliferation and metastasis (He et al., 2018). This evidence suggests that these 
three STRING ‘non-clustering’ proteins may indeed be associated with the cell cycle pathways 
identified by DAVID once more evidence comes to light. Further scrutiny by STRING and DAVID 
pathway analysis of the most significantly (p < 0.0005) up and down regulated proteins at each time 
point for each cell type separately, rather than simply those which overlap between both cell types, 
revealed no clustering or pathways which were not previously identified in this described analysis (Fig. 
S4 & S5). 
To observe no up regulation of specific secretory pathways was disappointing yet not entirely 
surprising as activity of secretory pathways may be altered by more subtle means, such as changes in 
protein phosphorylation or subcellular localisation, which would not be picked up by this screen. While 
we identified a large number of trafficking associated proteins including 45 Rabs, multiple Rab 
interacting proteins such as Rab GAPs and GEFs, and 12 vesicle trafficking Sec proteins, none were 
changed significantly in abundance (Table S11). GORASP2 was detected with 12 unique peptides, 
however it was not altered in abundance throughout the course of infection, suggesting it is not 
actively up regulated. GORASP1 was not detected in this experiment. 
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  (a) 
(b) 
Figure 4.4: Correlation of significantly down regulated proteins between cells lines is low, while there is 
greater correlation between up regulated proteins of both cell types. 
Those proteins identified as significantly changed in abundance at either 24, 48 or 72 hpi (p < 0.0005 taken from 
Fig. 4.3 scatterplots) for either RPTE or HU cells were analysed for overlap between the two cell types. Down 
regulated in abundance at any time point (a), or up regulated in abundance at each time point (b).  
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                     (a) (b) 
(c) 
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Figure 4.5: Cluster analysis of proteins significantly up regulated in both HU and RPTE cells. 
Those proteins that were observed to be increased in abundance in both HU and RPTE cells at each time point (as shown 
in Fig. 4.4) were analysed using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) (a, c, & d) and the 
functional Database for Annotation, Visualisation and Integrate Discovery (DAVID) bioinformatic software (b, e, & f). 
STRING analysis shows each protein represented as a spot, with connections made between proteins representing 
known and predicted protein-protein interactions, the heavier the connecting line, the more confidence in the 
interaction based on experimental, co-expression, co-occurrence, gene fusion, textmining or neighbourhood evidence.  
DAVID analysis identifies functional pathways within groups of proteins, showing the fold enrichment of each pathway 
detected along with the significance of that pathway (compared to the background of the list of proteins submitted). 
The most significant eight pathways shown only for convenience.  
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4.2.4 Temporal profiles of BKPyV proteins throughout the course of infection 
BKPyV proteins are known to be expressed in a clearly described order. Early genes are expressed 18-
24 hpi, while late genes are expressed 36-48 hpi. The temporal expression of each protein found in 
the proteome can be plotted, showing time on the x-axis, while the fold change is shown on the y-
axis, as can be seen with the viral proteins plotted (Fig. 4.6). 
When plotting the temporal expression profiles of each detected viral protein a greater than two-fold 
increase in expression of TAg and tAg was observed by 24 hpi in both cell types, and while expression 
plateaus for TAg in both RPTE and HU cells at 48 hpi (11-fold and 7.7-fold increase respectively), tAg 
continues to increase in expression until 72 hpi, up to 10.9 and 10.5-fold in RPTE and HU cells 
respectively. TruncTAg was not identified due to its homology with the C-terminus of TAg, although a 
potential novel open reading frame predicted to be generated a splice variant of TAg, which has not 
yet been described, was observed to be expressed from 24 hpi in both RPTE and HU cells. This novel 
TAg variant was identified due to the detection of a single unique peptide that should not be generated 
by trypsin cleavage of canonical TAg due to the lack of an upstream arginine or lysine. The most likely 
explanation is the presence of a novel splice event that results in a lysine becoming immediately 
upstream of the detected peptide sequence. Such a potential splice site has been identified at base 
4953 (Fig. 4.7). 
The temporal profiles of the late viral proteins VP1, VP2 and Agno indicate that, as anticipated, these 
proteins are not widely expressed until after 36 hpi, in fact expression greater than two-fold was only 
recorded from 48 hpi, and the slight signal detected at 24 hpi for VP1 and VP2 could be due to input 
virions. VP1 and VP2 continue to increase in expression until 72 hpi, while Agno expression plateaus 
from 48 hpi. 
These observed results are in agreement with previously published data on viral gene expression and 
BKPyV life cycle, giving confidence in these data. 




Figure 4.6: Temporal expression profiles of viral proteins identified. 
Plots of relative peptide abundance changes over time for infected and uninfected RPTE and HU cells show 
expression of each viral protein as infection progresses. Time (hpi) is shown on the x-axis, fold change in expression 
shown on the y-axis. VP3 and TruncTAg could not be identified due to their homology with VP2 and TAg respectively. 
A potential novel open reading frame of the early viral protein TAg (NOVEL ORF) was identified in both HU and RPTE 
cells infected with BKPyV. 
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4.2.5 Temporal profiles and validation of key cellular proteins changed in abundance in BKPyV 
infection 
A number of proteins were chosen for validation by immunoblot or immunofluorescence. Cyclin A2, 
cyclin B1 and cellular Fos (cFos) were chosen due to their significant up regulation in both RPTE and 
HU cells at either 48 or 72 hpi (Fig. 4.4b). Cyclin dependant kinase 1 (CDK1), p53, geminin, mouse 
double minute 2 homolog (Mdm2) and cyclin D2 were chosen due to their roles within the enriched 
functional pathways detected through DAVID analysis of the significantly up regulated proteins. 
Despite the fact that cyclin D2 and Mdm2 were observed to decrease in abundance during infection, 
they are both closely linked with the cell cycle. In choosing verify the expression of these eight, both 
up and down regulated proteins could be validated. The temporal profiles for each of these cellular 
proteins is shown in Fig. 4.8. 
To validate changes in proteins abundance that were shown by TMT-based mass spectrometry, RPTE 
and HU whole cell lysates were harvested from BKPyV or mock infected cells at 24, 48 and 72 hpi and 
immunoblotted for cyclin A2, cyclin B1, cyclin D2, CDK1, p53, geminin, VP1 (infection marker) and 
tubulin (cellular loading control) (Fig.4.9). A substantial increase in the expression of cyclin A2, cyclin 
B1, CDK1, p53 and geminin was observed at 48 and 72 hpi, correlating with the observations made in 
the TMT data. Interestingly, by immunoblot CDK1 appeared to show a greater change in abundance 
at 48 and 72 hpi in RPTE cells than was observed in the TMT data. This could be due to failure to 
quantify some CDK1 peptides due to their being non-unique, or due to normalisation techniques used.  
In mock infected cells the abundance of cyclin A2, cyclin B1, CDK1, p53 and geminin was observed to 
decrease, this is likely due to mock infected cells reaching confluence at 72 hpi as both RPTE and HU 
cells are contact inhibited, exiting the cell cycle once they come into contact with one another 
(Aschauer et al., 2015, Ng et al., 2005). Cyclin D2 decreased in abundance by immunoblot in close 
correlation with TMT expression profile data. Geminin is a cellular regulator of DNA replication that 
inhibits the replication factor chromatin licensing and DNA replication factor 1 (CDT1), thus restricting 
assembly of the pre-replication complex (Ballabeni et al., 2013). In previous microarray studies 
geminin mRNA was observed to increase in expression in BKPyV infected cells (Abend et al., 2010), 
however this is the first time this increase in expression has been confirmed at the protein level, 
quantified by peptide abundance and validated by immunoblot.  
To further validate these abundance changes and test additional proteins, immunofluorescence 
microscopy analysis was conducted on BKPyV or mock infected RPTE cells that were fixed at 72 hpi. 
Cells were immunostained for cyclin B1, cyclin D2, CDK1, p53, Mdm2, cFos, and VP1 (infection marker); 
Mdm2 and cFos could not be analysed as above because the available antibodies did not detect any 
protein in immunoblots. Signal levels for cyclin B1, CDK1, p53 and cFos were observed to increase in 
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infected cells, whereas Mdm2 and cyclin D2 levels decreased in infected cells, correlating with the 
TMT data. In addition to validating the increased abundance of these proteins, immunofluorescence 
microscopy enabled the relocalisation of proteins in response to BKPyV infection to be observed in 
tandem with expression level changes (Fig. 4.10). In BKPyV infected cells cyclin B1, although increased 
greatly in abundance, remains predominantly cytoplasmic unlike in control cells where low levels of 
total cyclin B1 expression is observed to be equally cytoplasmic and nuclear. Cyclin B1 is known to 
become nuclear as cells enter M phase (Pines and Hunter, 1991), suggesting that M phase has not 
been achieved in these BKPyV infected cells. CDK1 appears also to be distributed differently, observed 
in greater abundance in the cytoplasm of BKPyV infected cells compared to control. In contrast, in 
BKPyV infected and control cells p53 is observed as expressed in the cytoplasm at the same intensities, 
however in BKPyV infected cells nuclear stain in greatly increased, a subcellular location where p53 is 
usually active as a transcription factor (Milner and Cook, 1986). Cyclin D2 is an early cell cycle 
associated protein and decreases in abundance as BKPyV infection progresses, suggesting cells are 
accumulating in a later stage of the cell cycle. Mdm2 is an E3 ubiquitin ligase with the ability to bind 
and ubiquitinate p53 tagging it for degradation by the proteasome, thus Mdm2 is a negative regulator 
of p53. Mdm2 is also able to ubiquitinate itself, leading to its own degradation, while p53 acting as a 
transcription factor is able to drive expression of both Mdm2 and additional p53, dependent on signals 
received. In this way there exists both a positive and negative feedback loop controlling p53 activity 
in healthy uninfected cells (Barak et al., 1993). Mdm2 is reduced in infected cells compared to control, 
however expression remains largely nuclear, as observed in control cells. This data suggests that 
BKPyV infection may play a role in modulating the p53:Mdm2 functional interaction.  
Taken together, the validation of abundance changes for all tested hits from the proteomics data, in 
HU and RPTE cells by immunoblot and in RPTE cells by immunofluorescence, suggests that our TMT 
proteomic analysis has yielded an extensive and robust data set. 
  




Figure 4.8: Temporal expression profiles of key cellular proteins whose abundances change. 
Plots of relative protein abundance changes over time for infected and uninfected RPTE and HU cells show changes in 
expression of the host proteins chosen for validation by immunoblot and immunofluorescence. hpi is shown on the x-axis, 
fold change in expression shown on the y-axis. Fold change was calculated by normalising to an average of the mock 
samples, arbitrarily set to 1. A number of cell cycle associated proteins were chosen for validation, including not only those 
which were significantly changed in abundance, but also a number which showed less dramatic effects on expression. 
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(a) RPTE Cells 
(b) HU Cells 
Figure 4.9: Validation by immunoblot of key cellular proteins whose abundances changed. 
RPTE (a) and HU cells (b) were infected with BKPyV (5 IU/cell) or mock infected, then harvested at 24, 48 and 72 hpi. 
Immunoblots were then conducted blotting for the presence of cyclin A2, cyclin B1, cyclin D2, CDK1, p53 and geminin. 
VP1 was used as an infection control; tubulin was used for a cellular and loading control. 
 








Figure 4.10: Validation by immunofluorescence of key cellular proteins whose abundances changed. 
RPTE cells were infected with BKPyV (5 IU/cell) or mock infected, then fixed at 72 hpi. Immunofluorescence staining for 
cyclin B1 (a), cyclin D2 (b), CDK1 (c), p53 (d), Mdm2 (e) and cFos (f) (shown in green), VP1 (shown in red; an infection 
control) and DAPI (shown in blue; a nuclear marker) was then conducted. All images taken on Olympus IX81 wide-field 
immunofluorescence microscope.  
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4.2.6  Mdm2 and p53 levels are modulated by TAg and cell cycle arrest during BKPyV infection 
To investigate the interplay between BKPyV infection, Mdm2 and p53, further investigations were 
made into their expression levels under different cellular conditions. 
Mdm2 is an E3 ubiquitin ligase which regulates p53 activity through ubiquitination, tagging p53 for 
degradation by the proteasome (Brooks and Gu, 2006). Mdm2 also self-ubiquitinates regulating its 
own expression in the same way (Fang et al., 2000). Furthermore p53 is a transcription factor for both 
p53 and Mdm2 (Wei et al., 2006), this transcriptional activity is governed by the strength of p53 
activity and signals which trigger initial p53 expression, such as cell cycle checkpoints, leading to the 
establishment of both positive and negative feedback loops (Boehme and Blattner, 2009). It has been 
established that TAg is able to bind, stabilise but also inhibit the activity of p53 (Sheppard et al., 1999), 
leading to increased p53 levels in infected cells. Our TMT data has shown for the first time that this is 
accompanied by a decrease in Mdm2 levels. It is hypothesised that this observed reduction in Mdm2 
is due to its self-ubiquitinating activity, which does not appear to be affected by BKPyV infection or 
TAg expression. To study this the Mdm2 inhibitor Nutlin-3 was used on mock and BKPyV infected cells. 
Nutlin-3 is an Mdm2 inhibitor which obstructs the interaction between p53 and Mdm2 by occupying 
the p53 binding pocket on Mdm2. When the ubiquitination activity of Mdm2 on p53 is inhibited by 
Nutlin-3 total Mdm2 levels in cells are known to increase. This is attributed to the inability of Mdm2 
to regulate p53 by ubiquitination, leading to increased p53 activity and increased transcription of 
Mdm2 in attempt to initiate the negative feedback loop (Vassilev et al., 2004).   
Mock or BKPyV infected RPTE cells, were treated with 5µM Nutlin-3 (or DMSO as a control) at 2 hpi 
and at 48 hpi cells were fixed for immunofluorescence. Cells were immunostained for expression of 
Mdm2, p53, TAg (an infection marker) and DAPI (a nuclear marker) (Fig. 4.11a). 
Endogenous levels of both Mdm2 and p53 were observed in the nuclei of untreated mock infected 
cells. Upon BKPyV infection Mdm2 levels were observed to reduce, while p53 levels were substantially 
increased, correlating with the changes observed in the TMT quantification. In mock infected cells 
treated with Nutlin-3 the level of Mdm2 increased, accompanied by a slight increase in p53 levels, in 
accordance with published effects of Nutlin-3 (Vassilev et al., 2004). Interestingly, in BKPyV infected 
cells treated with Nutlin-3 levels of Mdm2 did not increase, in fact Mdm2 levels were seen to reduce, 
whilst p53 levels once again substantially increased. This suggests that during BKPyV infection Mdm2 
may be able to self-ubiquitinate and be degraded by the proteasome in the presence of Nutlin-3, 
however transcription of Mdm2 by p53 is apparently inhibited, likely due to the published interaction 
of TAg and p53 (Sheppard et al., 1999). 
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To investigate whether TAg expression alone was sufficient to effect the observed Mdm2 decrease 
and p53 increase upon BKPyV infection, or if further stimuli such as G2/M phase cell cycle arrest was 
required, RPTE cells were transfected with TAg. At 2 h cells were treated with 5 µM Nutlin-3 (or DMSO 
as a control), in addition at 6 h cells were treated with 5 µM RO-3306 (or DMSO as a control). RO3306 
is a CDK1 inhibitor which is used to arrest cells in G2/M phase. At 24 h cells were fixed for 
immunofluorescence and stained for Mdm2, p53, TAg and DAPI (a nuclear marker) (Fig. 4.11b).    
Transfection of TAg alone was sufficient to induce a reduction in Mdm2 levels and slight increase in 
p53. However the increase in p53 levels observed was not comparable to p53 levels observed in BKPyV 
infected cells. This suggests there may be additional effects of BKPyV infection, other than TAg 
expression, on regulation of p53 and Mdm2 levels. Treatment of TAg transfected cells with Nutlin-
3 did not lead to increased expression of Mdm2, but instead those cells expressing TAg had reduced 
Mdm2 levels and a slight increase in p53 levels, much like the results seen with BKPyV infected cells 
(Fig. 4.10a). Once again p53 levels were not equivalent to those seen in BKPyV infected cells. 
Treatment of TAg transfected cells with the CDK1 inhibitor RO-3306 at 6 h shows a marked increase 
in p53 levels, akin to those seen in BKPyV infected cells, suggesting that CDK1 inhibition leading to 
G2/M arrest induces p53 transcription. Mdm2 levels are decreased in those same TAg expressing cells, 
further suggesting that induced levels of p53 are not active or able to transcribe Mdm2. Nutlin-3 
treatment on these RO-3306 inhibited TAg transfected cells further increased these observed 
changes.  
The expression of TAg alone is sufficient to cause a reduction in Mdm2 levels, it is suggested that this 
is due to TAg activity on p53, binding and inactivating it, while Mdm2 remains able to self-ubiquitinate 
and be degraded. Further Mdm2 expression cannot be driven by inactive TAg bound p53, thus Mdm2 
levels decrease. p53 levels increase only slightly as p53 is stabilised and not ubiquitinated by Mdm2, 
however the effects of BKPyV infection, in this instance G2/M arrest, appears to drive expression of 
p53. Both the cell cycle and mitosis were identified as enriched pathways in the significantly (p < 
0.0005) up regulated proteins (Fig. 4.5d & f). While it has been known for some time that p53 
expression can drive cell cycle arrest (Kastan et al., 1991), it is more unusual to note that cell cycle 
arrest drives p53 expression itself. It has however been noted that RO-3306 can induce p53 in cell lines 
positive for acute myeloid leukaemia (AML) (Kojima et al., 2009). 
This provides a potential mechanism by which p53 might be induced in BKPyV infected cells (Fig. 
4.12).  
  







Figure 4.11: BKPyV infection, TAg expression, CDK1 inhibition and Nutlin-3 treatment modulate p53 and Mdm2 
expression. 
(a) RPTE cells were mock or BKPyV-infected (1 IU/cell) and either treated with 5µM Nutlin at 2 hpi or DMSO as a control. 
At 48 hpi cells were fixed for immunofluorescence and stained for Mdm2 (red), p53 (Blue), TAg (Green) and DAPI (used as 
a nuclear marker). (b) RPTE cells were transfected with TAg and at 2 h were treated with 5µM Nutlin (or DMSO as a 
control), and further treated at 6 h with 5µM RO3306 (or DMSO as a control). After 24 h cells were fixed for 
immunofluorescence and stained for Mdm2 (red), p53 (blue), TAg (Green) and DAPI as a nuclear marker.  




Figure 4.12: Proposed interaction mechanism of Mdm2, p53, TAg and Nutlin-3. 
(A) Untreated cells undergo ubiquitination and proteasomal degradation of both p53 and Mdm2. (B) Nutlin-3 inbibits 
the interaction of MDM2 with p53, preventing p53 degradation. Mdm2 contibues to be ubiquitinated and degraded, 
causing p53 driven transcription of Mdm2 resulting in increased expression of Mdm2. (C) Cells expressing TAg in the 
absence of infection exhibit reduced Mdm2 expression as Mdm2 continues to be ubiquitinate and be proteasomally 
degraded, while TAg causes p53 to be inactive and unable to drive transcription of additional Mdm2. p53 levels 
remain stable, increased only slightly by prevention of degradation. (D) Cells which are BKPyV infected, or cells 
expressing TAg combined with cell cycle arrest/damage show reduced Mdm2 expression as seen in panel (C), 
however additional stimulation linked to infection, cell cycle arrest or DNA damage drive increased expression of 
p53. 
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4.2.7 Validation of innate immune response protein expression during BKPyV infection 
One of the surprising findings from these whole cell proteomics, as highlighted in the DAVID analysis, 
was a lack of detectable induction of any anti-viral pathways such as an interferon response, despite 
the fact these are primary cells that should be competent to detect and respond to viral infection. 
Indeed, many components of PRR pathways and ISGs known to be involved in antiviral responses were 
identified in this screen. This was intriguing as it suggested that these cells are unable to detect or 
respond to BKPyV infection. To validate these findings RPTE cells were used, due to the difficulty in 
culturing HU cells. 
To investigate the ability of these cells to mount an interferon response, RPTE cells were mock or 
BKPyV infected (5 IU/cell), or treated with IFNα2A (104 U/ml) as a positive control. Cells were then 
harvested at 24, 48 and 72 hpi. Immunoblots reveal that the expression of the well characterised ISGs 
MX1, ISG15, IFIT1, IFIT2, IFIT3, IRF3, IFI16, and BST2 do not appear to be changed greater than 2-fold 
in abundance upon BKPyV infection, throughout the time course (Fig. 4.13). This correlates somewhat 
to the temporal expression profiles of each protein throughout the course of infection (Fig. 4.14), with 
a few notable observations. By immunoblot MX1 appears to be extremely low in abundance in mock 
infected RPTE cells (Fig. 4.13), while the temporal expression profile shows a small decrease in 
abundance of MX1 when RPTE cells are infected with BKPyV (Fig. 4.14). It may not be possible to 
validate such changes by immunoblot due to the small nature of abundance changes (< two-fold) and 
the initial low abundance of the protein. Furthermore, there are small (< two-fold) increases in the 
abundance of IFIT1, IFIT2 and IFIT3 in HU cells and BST2 in both RPTE and HU cells which were not 
seen in the immunoblot validation in RPTE cells alone, suggesting it might be interesting to investigate 
HU cells further in future studies. 
Stimulation with IFNα2A up regulated the expression of MX1, ISG15, IFIT1, IFIT2, IFIT3, IFI16, and BST2 
upon stimulation, while IRF3 is not up regulated in response to stimulation. This was unsurprising as 
IRF3 may be phosphorylated in response to stimulation (Lin et al., 1998) but has not been shown to 
be induced in response to IFN. Further inspection of all ‘innate immunity’ or ‘antiviral defence’ related 
proteins (by UniProt key descriptors) that were identified in proteomics data shows there is little-to-
no change in any of these proteins in response to BKPyV infection (Table S12), suggesting that RPTE 
cells do not appear to generate an innate immune response to BKPyV infection. 




Figure  4.13:  Validation  by  immunoblot  of  key  innate  immune  proteins  identified  whose  abundances  did  not  
change  in  BKPyV  infection.   
RPTE  cells  were  infected  with  BKPyV  (5  IU/cell),  stimulated  with  IFNα2A (104 U/mL)  or  mock  infected,  then  
harvested  at  24,  48  and  72  hpi  or  stimulation.  Immunoblots  were  then  conducted  blotting  for  the  presence  of  
BST2,  IFI16,  IFIT1,  IFIT2,  IFIT3,  ISG15,  MX1  and  IRF3.  VP1  was  used  as  an  infection  control;  tubulin  was  used  
for  a  cellular  and  loading  control.  IFNα2A  was  used  as  a  positive  control  to  stimulate  expression  of  interferon-
induced  genes.    
 




Figure 4.14: Temporal profiles of selected innate immune proteins. 
Plots of relative protein abundance changes over time for infected and uninfected RPTE and HU cells showing minimal 
changes in expression a number of those innate immune host proteins that were quantified. hpi is shown on the x-axis, fold 
change in expression shown on the y-axis. A number of innate immune related host proteins were chosen for validation, 
particularly those that highly sensitive to IFN induction and are expected to change in abundance in response to viral 
infection. 
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4.2.8 RPTE cells are able to respond to stimulation by nucleic acids, but do not respond to BKPyV 
infection 
The lack of ISG induction in BKPyV infected RPTE cells suggests that either the virus is not detected by 
these cells, or has potent mechanisms to block either interferon production or signalling. To 
investigate whether RPTE cells have active RNA and DNA sensing pathways, and whether these can be 
activated in response to BKPyV infection, the localisation of IRF3, a key transcription factor in antiviral 
responses, was analysed by immunofluorescence. Upon activation of RNA and DNA sensing pathways 
IRF3 is phosphorylated, allowing it to dimerise and translocate to the nucleus, leading to the 
transcription and expression of Type I and III interferons. As positive controls uninfected RPTE cells 
were stimulated with either poly(I:C), a double stranded RNA mimic which stimulates RIG-I and other 
RNA sensors, or a short mostly double stranded DNA molecule shown to be a potent inducer of cGAS 
then fixed after 6 hours (Herzner et al., 2015) (Fig. 4.15a). Translocation of IRF3 can be clearly seen in 
poly(I:C) stimulated cells, while in DNA stimulated cells IRF3 translocation can be seen in a number of 
cells, although to a lesser extent than in poly(I:C) stimulated cells. This confirms that RPTE cells are 
able to translocate IRF3 into the nucleus in response to either RNA or DNA stimulation. However, no 
nuclear translocation was observed in BKPyV infected RPTE cells at 48 hpi, and IRF3 remained wholly 
cytoplasmic, with infected cells being indistinguishable from mock infected cells.  
This observation suggests that BKPyV infection does not activate IRF3 translocation, although whether 
this was by inhibition of translocation or prevention of phosphorylation was unclear. To address this 
question RPTE cells were mock or BKPyV infected (3 IU/cell) and harvested at 0, 6, 24, 48 and 72 hpi, 
while positive control samples treated with poly(I:C) or DNA were harvested at 6 hpi. An immunoblot 
was conducted to ascertain overall levels of IRF3 and of IRF3 phosphorylation (specific for 
phosphorylation at residue S386), with tubulin used as a loading control and VP1 as a marker of BKPyV 
infection (Fig. 4.15b). IRF3 remained unphosphorylated throughout the time course in both mock and 
BKPyV infected cells, while in poly(I:C) and DNA stimulated cells IRF3 was clearly phosphorylated, 
albeit differing in band size and density. This difference between IRF3 phosphorylation in poly(I:C) and 
DNA stimulated cells in intriguing, while it was initially hypothesised that the upper band could be 
dimerization of IRF3, often seen in DNA stimulated cells (Wu et al., 2013) it does not appear to be as 
large as an IRF3 dimer (94 kDa), being less than 75 kDa. It therefore suggested that the upper band is 
as a result of IRF3 hyperphosphorylation, a feature of highly stimulated IRF3 (Clement et al., 2008). 
This suggests that rather than preventing the translocation of phosphorylated IRF3, IRF3 remains 
unphosphorylated in the presence of BKPyV infection.  
  






Figure 4.15: IRF3 is phosphorylated and translocated to the nuclei of cells when stimulated with synthetic RNA or 
DNA, but not in response to infection. 
(a) RPTE cells were mock or BKPyV-infected (3 IU/cell) and fixed at 48 hpi, or stimulated with poly(I:C) (2 µg/ml) or 
annealed DNA oligonucleotides (2 µg/ml) and fixed at 6hpi. Cells were stained for IRF3, VP1 (infection control), DAPI 
(nuclear marker). Images were taken on Olympus IX81 wide-field immunofluorescence microscope. (b) To further 
validate RPTE cells were mock or BKPyV-infected (3 IU/cell) and harvested at 0, 6, 24, 48 and 72hpi, while poly(I:C) 
or annealed DNA oligonucleotides stimulated RPTE cells (2 µg/ml) were harvested at 6h. Samples were 
immunoblotted for IRF3 and phosphorylated IRF3 (S386), tubulin was used as a loading control, VP1 was used an 
infection control. 
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4.2.9 BKPyV infection does not inhibit synthetic RNA or DNA-induced IRF3 activation 
The lack of observed IRF3 activation during BKPyV infection could be due to an active process of viral-
mediated inhibition of RNA and DNA sensing pathways, such as through binding and inhibition of IRF3 
as observed with HPV-16 E6 protein (Ronco et al., 1998), or by a more passive process of evading 
activation of these pathways. To address these questions, RPTE cells were mock or BKPyV infected (3 
IU/cell) and subsequently stimulated with poly(I:C) or DNA at 42 hpi, followed by harvesting cells for 
immunoblot at 48 hpi. Immunoblots were stained for IRF3, phosphorylated IRF3 (S386), VP1 (as a 
marker of infection) and tubulin (as a loading control) (Fig. 4.16a). Phosphorylation of IRF3 occurred 
in poly(I:C) or DNA stimulated cells, whether infected with BKPyV or mock infected, and no differences 
were observed in the levels of IRF3 phosphorylation between infected and uninfected cells.  
To confirm whether RNA/DNA-stimulated IRF3 translocation to the nucleus was affected by the 
presence of BKPyV , RPTE cells were infected with BKPyV (0.5 IU/cell) and at 42 hpi stimulated with 
poly(I:C) or DNA. Cells were subsequently fixed at 48 hpi for immunofluorescence and stained for IRF3 
and TAg (Fig. 4.16b). IRF3 translocation to the nucleus was observed in response to both poly(I:C) or 
DNA stimulation irrespective of whether wells were infected (TAg positive) or not. As before, poly(I:C) 
gave a more robust stimulation of IRF3 nuclear translocation. These data confirm that BKPyV infection 
does not prevent the activation of IRF3 in response to synthetic RNA or DNA stimuli. These data taken 
together suggest that BKPyV does not actively down regulate the activation of IRF3, and so infected 
cells are fully competent to detect foreign nucleic acids and stimulate the transcription of type I and 
III interferons, and thus should be capable of mounting an effective antiviral innate immune response. 
This suggests BKPyV can efficiently evade detection by any PRRs in these kidney epithelial cells. 
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Figure 4.16: BKPyV and mock-infected RPTE cells do not differ in their responses to synthetic RNA and DNA 
stimulation.  
(a) RPTE cells were mock or BKPyV-infected (3 IU/cell), stimulated at 42 hpi with poly(I:C) (2 µg/ml) or annealed DNA 
oligonucleotides (2 µg/ml), or unstimulated. Cells were then harvested for immunoblot at 48 hpi, tubulin was used 
as a loading control, VP1 was used as an infection control. (b) RPTE cells were mock or BKPyV-infected (0.5 IU/cell) 
and at 42 hpi stimulated with poly(I:C) (2 µg/ml) or annealed DNA oligonucleotides (2 µg/ml) and fixed at 48 hpi. 
Cells were stained for IRF3, TAg (infection control), DAPI (nuclear marker). Images were taken on Olympus IX81 wide-
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4.2.10 Repeat TMT-based experiment reveals close correlations between data sets and no cellular 
effects of virion binding 
The surprising lack of change in the host cell proteome at the earliest time point of 24 hpi suggested 
little or no effect of virus binding and penetration. To investigate this further a second TMT-based 
whole cell proteomics experiment was conducted at early time points, starting at just 12 hpi when 
little-to-no viral proteins are expressed. 
As in the first TMT-based experiment RPTE cells were mock infected or infected with BKPyV (3 IU/cell), 
additionally RPTE cells were also infected with BKPyV (3 IU/cell) that had been inactivated with 
ultraviolet light. UV inactivation causes pyrimidine dimers which prevent DNA replication, effectively 
rendering the virus inert, while the capsid remains intact (Tseng and Li, 2007). As such any changes to 
the cellular proteome upon infection with UV inactivated BKPyV will be attributable to virion binding 
and viral entry.  
Samples for mock, BKPyV and UV inactivated BKPyV were harvested at 12, 24 and 48 hpi for TMT 
processing and labelling as previously described (section 4.2.1), then subjected to MS3 mass 
spectrometry. In this repeat 7703 cellular and 5 viral proteins were identified, 96% of which were 
identified in the first TMT-based data set.   
Very few changes in protein abundance were observed at 12 or 24 hpi during BKPyV infection, while 
a similar set of cellular proteins observed in the first data set were upregulated at 48 hpi (Fig. 4.15a). 
UV-irradiated virus induced virtually no changes at any time point, suggesting that replicating virus 
was required to account for the effects observed (Fig. 4.17a). Correlation between the first experiment 
and the second showed a strong positive linear relationship (Fig. 4.17b), providing evidence that our 
dataset is strong and reproducible. Further analysis on this data has been limited due to the very small 
changes induced at this early additional time points. 
 
  




Figure 4.17: Correlation between repeat TMT-based analysis and first TMT-based analysis  
(a) The abundance of proteins identified at each BKPyV-infected time point, 12, 24 and 48 hpi, was divided by the 
average of the mock-infected samples from each time point. Scatter plots show all proteins identified with unique 
peptides. Fold change (RPTE cell BKPyV-infected/RPTE cell mock-infected average) is shown as the log2 ratio on the x-
axis, to the right increasing in abundance, and to the left decreasing in abundance. The signal:noise is shown on the y-
axis as log10. Significance B was used to estimate p values (Cox and Mann, 2008). (b) Scatter plot showing the Pearson 
correlation between experiments 1 (first) and 2 (repeat) in RPTE cells, for proteins quantified by ≥2-peptides. All scatter 












The TMT-based proteomic analysis detailed in this chapter has established a comprehensive proteome 
resource for two primary human epithelial cell types from the reno-urinary system, RPTE and HU cells, 
and provided details of temporal changes in viral and host proteomes throughout the course of a 
productive BKPyV infection. Of the 8992 cellular proteins that were identified, surprisingly few 
changed significantly in abundance in response to BKPyV infection, taking into account fold-change 
and signal-to-noise corrections. In previous studies using the same proteome analysis technique to 
study a large dsDNA virus, HCMV, 56% of cellular proteins demonstrated abundance changes of more 
than two-fold in infected cells (Weekes et al., 2012). Here, with BKPyV infection, we see fewer than 
5% of cellular proteins altered in abundance greater than two-fold.  
Confidence that this data set is robust and reproducible was demonstrated by successful validation of 
a wide variety of cellular proteins that were up regulated, down regulated or unchanged during 
infection by immunoblot and/or immunofluorescence, in addition to a repeated TMT-based analysis 
at early time points. While experiments in HU cells were limited after initial validation due to these 
cells being more technically difficult to culture, there was considerable correlation in protein changes 
between RPTE and HU cells, providing confidence that data generated using RPTE cells reflects virus-
host interactions in both cell types. The replication of BKPyV was overall less efficient in HU cells than 
RPTE cells, suggesting RPTE cells are a better model for BKPyV replication. All observed changes are 
unlikely to be as a result of virion binding and entry due to the limited observed effects of infection 
with UV inactivated BKPyV, thus the changes in cellular proteomes can be attributed to viral gene 
expression.  
The viral protein data indicates that in RPTE cells the early proteins TAg and tAg were the first to be 
synthesized at 24 hpi, and relative abundance levels of the late proteins identified, VP1, VP2 and Agno, 
were much lower at this point. In HU cells the difference between early and late gene synthesis 
initiation is less marked, this may be due to the differences in cellular metabolisms and viral replication 
rates between these cell types (Li et al., 2013a). It was also observed that viral protein expression 
continued to increase throughout 72 h of infection, as the highest abundance of each is at the final 72 
hpi in both RPTE and HU cells. Most interesting was the identification of a novel previously 
undescribed TAg variant, identified through a single unique peptide that could not be generated by 
trypsin cleavage due to the lack of arginine or lysine in the canonical TAg to cause such a peptide. An 
alternative splice donor site has been identified upstream of the canonical splice donor site which 
would place a lysine directly upstream of the splice site, such splicing could therefore explain the 
existence of the identified peptide after cleavage. Further investigations into this potential TAg variant 
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could include the generation of TAg splice donor site mutants in both virus and TAg expressing 
plasmids. This will allow study of phenotype, subcellular localisation of TAg variants and detect any 
changes in the number of TAg species by immunoblot.  
Analysis of the virus-induced changes to the cellular proteomes of the two cell types demonstrated 
that BKPyV infection affects virtually no cellular processes other than those involved in cell cycle and 
DNA replication. These data support and expand upon evidence from previously published data 
indicating G2/M phase arrest is driven by polyomavirus infection (Harris et al., 1996, Lilyestrom et al., 
2006, Stubdal et al., 1997, Rundell and Parakati, 2001). It is likely that infected cells are restricted from 
progressing through the G2/M check point, as indicated by cyclin B1 remaining primarily cytoplasmic 
in infected cells; nuclear translocation of cyclin B is a marker for M phase progression (Pines and 
Hunter, 1991). This M phase progression does not appear to occur in BKPyV infected cells, and G2-
arrest has been previously observed in JC polyomavirus JCPyV TAg transfected cells (Orba et al., 2010).  
Limitations of analysing these particular cell types have included the necessity to compare all 
proteome changes to an average of the mock samples (taken at 24 and 72 hpi). Whilst this is often 
done in immortalised cell lines that proliferate unimpeded, both HU and RPTE cells are contact 
inhibited (Aschauer et al., 2015, Ng et al., 2005). They exit the cell cycle as they come into contact with 
one another and form tight junctions. Such phenomena can mean that at 72 hpi mock infected cells 
have an altered protein expression profile (less proliferative, more senescent) than 24 hpi mock 
infected cells. The effect of averaging these samples to produce a ‘base’ against which to judge 
changes upon BKPyV infection might obscure more subtle changes. If given the opportunity to repeat 
this experiment I would suggest including a mock infected control for each time point being studied 
in order to directly compare against the appropriate mock time point.  
An interesting observation from the proteomics data was the lack of any detectable changes that could 
be associated with an immune response upon infection. While we were able to identify a large number 
of well-established antiviral response-associated proteins, such as IFI16, TMEM173 (STING), NFκB, 
IRF3, and numerous ISGs, they showed very little change in abundance in response to BKPyV infection. 
Such a study was not, however, able to highlight any changes in subcellular locations of immunological 
proteins. For example, while MHC-I and NK receptors did not appear to change in abundance 
throughout infection, an altered expression at the plasma membrane might stimulate killing by NK 
cells in vitro. To address this question one could conduct plasma membrane profiling of BKPyV and 
mock infected cells.  
What is true, however, is that BKPyV infection does not induce an IRF3-mediated immune response 
or expression of interferon stimulated genes. Furthermore, infection with BKPyV does not inhibit the 
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IRF3 response. This might be attributed to the stability of the BKPyV virion, maintaining very low levels 
of aberrant uncoating in the cytoplasm. In addition the BKPyV dsDNA genome is circular, thus not 
exhibiting any overhangs which are immunostimulatory (Herzner et al., 2015), and when condensed 
with host-derived histones, this might reduce sensing to negligible levels. It was interesting to note 
that stimulation of RPTE cells by DNA oligomer was much less pronounced than stimulation with 
poly(I:C), suggesting that recognition of DNA in the cytoplasm is sub-optimal, even when using a 
validated immunostimulatory DNA oligomer (Herzner et al., 2015). 
The effect of BKPyV infection, compared with the roles individual viral proteins play, in the up and 
down regulation of cellular proteins is important to consider. While expression of TAg alone was 
sufficient to reduce overall levels of Mdm2 and increase levels of p53 slightly, likely through TAg 
binding and stabilising p53, the vastly increased levels of p53 observed in BKPyV infected cells was 
only replicated in TAg expressing cells when cell cycle was inhibited, specifically in G2/M phase. It 
seems likely that the DNA damage response (DDR), known to be activated in BKPyV infection (Verhalen 
et al., 2015), also contributes to induction of p53 levels. 
Given the specific and extensive cell cycle deregulation and an apparent pseudo-G2 phase arrest 
caused by BKPyV infection, this may suggest that stalling cells in a G2-like state provides several 
advantages to the virus in addition to promoting viral DNA replication via stimulation of cells into S 
phase. Therefore further investigation into the role of BKPyV-regulated cell cycle status during viral 
replication was conducted. 
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5. Cell cycle status is important for productive BKPyV infection 
5.1 Introduction 
The predominance of cell cycle and cell cycle related pathways being induced throughout the 
observed TMT-based proteomic analysis of infected cells highlights the importance of cell cycle during 
BKPyV replication. Increased levels of G2 and M phase proteins during BKPyV infection, such as CDK1, 
cyclin B1, cyclin A2, geminin and p53, in conjunction with reduced early cell cycle proteins such as 
cyclin D2, suggests strongly that BKPyV induces a G2/M-like cell cycle arrest. Furthermore cyclin B1 
was observed to remain cytoplasmic during BKPyV infection, signifying that these cells do not pass the 
G2/M checkpoint, at which time cyclin B1 would become nuclear. These observations suggest that 
BKPyV infection induces a pseudo-G2 arrest in both RPTE and HU cells, similar to that proposed for 
the closely related papillomavirus HPV-16 (Davy et al., 2002). 
Cell cycle progression has been shown to be essential for a number of polyomaviruses including SV40 
and JCPyV. Proliferating cell nuclear antigen (PCNA), only present in replicating cells, was revealed to 
be essential for SV40 replication in vitro (Prelich et al., 1987), while SV40 replication rates can be 
slowed by reducing cellular proliferation (Bettuzzi et al., 2002). Furthermore, inhibition of JCPyV with 
the CDK1/2 inhibitor Roscovitine, for in excess of 3 days, was able to drastically reduce infectivity, 
although this effect was largely attributed to Roscovitines inhibition of CDK1 and its activity on CDK2 
was not considered (Orba et al., 2008). The phosphorylation of TAg is required for its viral helicase 
activity that is essential in viral replication (Moarefi et al., 1993). It has been proposed that 
phosphorylation of a number of TAg residues is effected by various protein kinases; primarily cyclin 
A:CDK2 and, to a lesser extent, cyclin B:CDK1 complexes (Li et al., 1997). However, just a single 
threonine residue is implicated in the formation of the TAg viral helicase, in SV40 this phosphorylation 
site has been shown to be T124, while in JCPyV it is T125 (McVey et al., 1996, Swenson and Frisque, 
1995). Mutation of these threonine residues prevents viral replication (Swenson et al., 1996, McVey 
et al., 1996). For SV40 TAg, phosphorylation of T124 was shown to be primarily mediated by CDK1 
(cdc2) (McVey et al., 1989). In BKPyV a threonine residue is present at TAg position 126, suggesting 
there may be a similar phosphorylation event required to form the viral helicase, although to date this 
has not been investigated. 
The MAPK/ERK pathway, by stimulating cell cycle progression, has also been shown to be essential for 
BKPyV replication (Seamone et al., 2010). Moreover the activity of ATM/ATR kinases that are involved 
in DNA damage response pathways, which are key mediators of the G2 checkpoint, have been shown 
to be important for effective BKPyV replication (Verhalen et al., 2015, Jiang et al., 2012). While cell 
cycle progression during BKPyV infection is largely driven by the activity of both TAg and tAg on Rb 
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family proteins, PP2A and p53 among others (Harris et al., 1996, Pallas et al., 1990), the extent to 
which different stages of cell cycle inhibition can be overcome by BKPyV infection or effects on the 
replication of BKPyV is not well understood. To address this the effect of number of different cell cycle 
inhibitors on BKPyV replication was investigated.  
 




5.2.1 Cell cycle inhibition exhibits variable effects on BKPyV-induced cell cycle progression and 
pseudo-G2 arrest  
In the first instance CDK inhibitors commonly used to inhibit the cell cycle were tested for toxicity in 
RPTE cells in a range of concentrations for 24 and 48 h (Fig. 5.1) with a trypan blue assay, allowing 
quantitation of cell death after inhibitor treatment. RPTE cells were treated with 250 nM, 500 nM and 
1 PM concentrations of PD0332991, a CDK4/6 inhibitor that prevents cells from exiting G1 and 
entering S phase (Fig. 5.1a). More than 90% of RPTE cells remained viable even at the highest 
PD0332991 concentration for 48 h. Cells were also treated with 20 PM, 40 PM and 60 PM 
concentrations of Roscovitine, an inhibitor of both CDK1 and CDK2 that prevents cells from 
progressing through the G1/S checkpoint, S phase, G2 and M phase, thus it has a broad effect on 
general cell cycle progression (Fig. 5.1b). 60 PM Roscovitine treatment lead to a substantial reduction 
of cell viability after 24 h treatment (~70% of cells viable), while more than 95% of cells treated with 
40 PM Roscovitine remained viable after 24 h of treatment, although viability was reduced to <85% 
by 48 h at this concentration. 20 PM Roscovitine treatment showed much less effect on cell viability, 
with ~92% of cells remaining viable after 48 h treatment. Finally cells were treated with 1 PM, 5 PM 
and 10 PM RO-3306, a CDK1 inhibitor that blocks cells in G2 and M phase (Fig. 5.1c). Treatment with 
RO-3306 reduced cell viability to below 90% by 48 h at any concentration, and at 10 µM RO-3306 by 
24 h. However, little effect of treatment with 1 or 5 µM RO-3306 on cell viability was observed by 24 
h. Conditions that resulted in >90% cell viability were deemed acceptable and so it was concluded that 
inhibitors should be used for no longer than 24 h, and at 1 µM for PD0332991, 20 µM for Roscovitine, 
and RO-3306 should be used at 5 PM.  
  




Figure 5.1: Cell cycle inhibitors effects 
on cell viability. 
RPTE cells were subjected to CDK4/6 
inhibition (PD0332991) (a), CDK1/2 
inhibition (Roscovitine) (b) or CDK1 
inhibition (RO-3306) (c) at a variety of 
concentrations for 24 and 48 h, then 
harvested and a trypan blue cell viability 
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These inhibitors were then tested in RPTE cells for their ability to perturb the cell cycle and induce 
various states of cell cycle arrest in both infected and uninfected cells.  Cells were stained with 
propidium iodide (PI), a fluorescent DNA intercalator that is stoichiometric, binding DNA 
proportionally to the amount of DNA within each cell. Using this method those cells in G0 or G1, cells 
containing a single compliment of chromosomes (2n), will emit a base fluorescent signal, while double 
signal intensity indicates cells which have undergone genome synthesis but not yet undergone mitosis 
(4n). Any signal intensity between these two set values indicates a cell undergoing genome synthesis. 
In this way the cell cycle status of each cell can be determined by flow cytometry, using FlowJo cell 
cycle analysis software (v10.5). Thus, RPTE cells were mock or BKPyV infected (3 IU/cell), and at 24 hpi 
were either untreated, subjected to CDK4/6 inhibition (1 PM PD0332991), CDK1/2 inhibition (20 PM 
Roscovitine) or CDK1 inhibition (5 PM RO-3306) for a further 24 h, after which time cells were 
harvested and their DNA content stained with PI. Cells were then analysed by flow cytometry, and cell 
cycle status determined. Three independent experiments were conducted and the average proportion 
of cells in each cell cycle phase was calculated from the three independent datasets were calculated 
(Fig. 5.2a), flow cytometry histograms from a single experiment shown (Fig. 5.2b).  
Mock infected cells responded as expected to inhibitor treatments. In mock infected untreated cells 
~72% were in G1 or G0 phase, ~10% were in S phase and ~18% were in G2/M phase. RPTE cells are 
slow to replicate, taking up to 40 h to double in number (Lonza specifications), thus this relatively low 
number of cells in S, G2 or M phase was unsurprising. In mock infected cells the number of cells in G1 
or G0 phase were increased to ~84% when inhibited with CDK4/6 inhibitor PD0332991, while those in 
S phase and G2/M phase reduced accordingly (~4.5% and ~11.5% respectively), indicating an increased 
number of cells in G0/G1 arrest. When inhibited with CDK1/2 inhibitor Roscovitine there was little 
difference to untreated cells with ~75% of mock infected cells were observed to be in G1 or G0 phase, 
~9.5% were in S phase and ~14.5% were in G2/M phase. This was also expected because CDK1 and 2 
activities are important not only throughout S, G2 and M phase, but also during late G1 where, in 
complex with cyclin E CDK2 orchestrates G1/S checkpoint progression, thus CDK1/2 inhibition should 
lock cells in the state in which they are in when the inhibitor is applied. Treatment of mock infected 
cells with CDK1 inhibitor RO-3306 resulted in an increased percentage of cells in G2/M (~23%), a 
similar percentage of cells in S phase as untreated cells (~12%) and a reduced percentage of cells in 
G1 or G0 (~65%). This was also as expected because suggests that the CDK1 inhibition should cause 
G2/M arrest and cells to accumulate in this phase. These results suggest the inhibitors are effective at 
the selected concentrations in RPTE cells.  
In contrast to mock infected untreated samples, untreated BKPyV infected samples were observed to 
have just ~57% of cells in G1 or G0, ~12% were in S phase and ~31% were in G2/M phase. This agrees 
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with published data showing that TAg and tAg are able to promote cell cycle progression through the 
G1/S checkpoint in BKPyV infected cells, enhancing viral replication (Bollag et al., 2010, Hesbacher et 
al., 2016, Sheng et al., 1997). Furthermore, these data support the observations made in chapter 4 of 
this thesis that cell cycle arrest in a G2/M-like state is caused by BKPyV infection. BKPyV infected RPTE 
cells that were inhibited with CDK4/6 inhibitor PD0332991 showed little difference in their cell cycle 
status compared to untreated BKPyV infected cells, with a very small increase in the proportion of 
cells in G1 and S phases indicating a slight delayed in progression. The little-to-no effect of CDK4/6 
inhibition on BKPyV infected cells can be explained by the ability of TAg to bind Rb-family members 
and release E2F, which can drive cells through the G1/S checkpoint independently of cyclin D:CDK4/6, 
and thus CDK4/6 inhibition is ineffective at preventing cell cycle progression in the face of BKPyV 
infection. CDK1 and 2 inhibition by Roscovitine had a much more dramatic effect on virus-induced cell 
cycle modulation leading to a profile more akin to uninfected untreated cells with ~73% of cells in G1 
or G0 phase, 8% in S phase and ~19% in G2/M phase. This is best explained by an inhibition of virus-
induced S phase progression because of CDK2 inhibition, which would prevent infected cells reaching 
and becoming stalled in G2. Finally, BKPyV infected cells which were inhibited with CDK1 inhibitor RO-
3306 showed a similar proportion of cells in G2/M to untreated infected cells at ~30%, with more cells 
in S phase (~21%) and consequently fewer in G1 or G0 (~49%). This suggests that CDK1 inhibition does 
not prevent virus induced G2/M arrest, unsurprisingly as RO-3306 also causes G2/M arrest, but CDK1 
inhibition either delays transition from S to G2 phase or increases G1 to S phase transition in infected 
cells. The increase in cells in S phase in infected cells caused by RO-3306 may have consequences for 
viral DNA synthesis. Overall, infection by BKPyV or inhibition of CDK1 by RO-3306 have very similar 
effects on cell cycle status, namely inducing cells to accumulate in G2/M. This might be explained by 
BKPyV inhibiting CDK1 activity, although it is likely to be more complicated as inhibition of CDK1 in 
infected cells appears to cause an additional increase in the proportion of cells in S phase in addition 
to G2 arrest. This leads to the question of whether CDK1 activity is required for BKPyV replication. 
  




Figure 5.2: Cell cycle inhibitors modulate 
the RPTE cell cycle status of uninfected 
cells. 
The cell cycle status of RPTE cells was 
determined for a number of different 
experimental conditions. RPTE cells were 
infected with BKPyV (3 IU/cell) or mock 
infected. At 24 hpi infected and mock 
infected cells were subjected to CDK4/6 
inhibition (PD0332991 1 µM), CDK1/2 
inhibition (Roscovitine 20 µM) or CDK1 
inhibition (RO-3306 5 µM). At 48 hpi cells 
were harvested by trypsinisation. (a) 
Collected cells were stained with 
propidium iodide (PI) and analysed by 
flow cytometry. Data from three 
independent experiments show, error 
bars show standard deviation. (b) 
Histograms of PI stain intensity for each 
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5.2.2 Effects of cell cycle inhibition on BKPyV DNA synthesis gene expression and replication 
To investigate the effects of cell cycle inhibitors on viral DNA replication RPTE cells were infected with 
BKPyV (3 IU/cell) and treated with PD0332991 (1 PM), Roscovitine (20 PM) or RO-3306 (5 PM) at 24 
hpi. At 48 hpi cells were harvested and DNA extracted for analysis by qPCR for virus and host genome 
copy numbers. The number of BKPyV genome copies per sample were normalised to host DNA copy 
numbers (using primers to the TNFD gene) for each sample, to control for variations in samples such 
as DNA extraction efficiency. Data were normalised to uninhibited control samples (set arbitrarily to 
1) for each experiment, and six independent experiments were conducted (Fig. 5.3a). Inhibition of 
CDK4/6 demonstrated no significant effect on BKPyV genome replication compared to control, which 
was anticipated because TAg can effectively bypass CDK4/6 regulated G1/S checkpoint and 
PD0332991 had virtually no effect on BKPyV-induced cell cycle progression. Inhibition of CDK1/2 
exhibited a significant 86% reduction in BKPyV genome synthesis most likely due to inhibition of CDK2-
dependent S phase progression which is important for viral DNA replication. Intriguingly, CDK1 
inhibition caused a significant reduction in BKPyV genome replication by 56%, despite the fact RO-
3306 had little effect on cell cycle progression in inhibited cells. This suggests that CDK1 activity is 
important for efficient viral DNA replication, which may be related to phosphorylation of TAg. 
To examine viral genome synthesis occurs in the presence of Roscovitine, or whether the detected 
viral DNA is simply due to input virions, RPTE cells were infected with BKPyV (3 IU/cell) and at 2 h 
harvested, or at 24 hpi treated with Roscovitine (20 µM), the known inhibitor of viral DNA synthesis 
cidofovir (40 µg/mL), or untreated, then at 48 hpi harvested for DNA extraction and analysis by qPCR 
(Fig. 5.3b). Cidofovir is an effective antiviral against BKPyV through inhibiting incorporation of 
deoxycytidine triphosphate into nascent DNA, being incorporated into DNA in its place, leading to 
chain termination and prevention of genome replication (Bernhoff et al., 2008). BKPyV genome levels 
in the samples harvested at 2 hpi, a time point at which genomes will not have been replicated, were 
greater than ten-fold lower than those observed in cidofovir or Roscovitine treated samples, 
suggesting a limited amount of viral DNA synthesis occurs in the presence of these inhibitors, possibly 
during the first 24 h of infection before inhibitor addition, and the detected DNA is not simply from 
input virus. Roscovitine was almost as effective as cidofovir in inhibiting viral replication, and both 
caused a greater than ten-fold reduction in viral DNA levels.  
   




Figure 5.3: CDK1/2 and CDK1 inhibitors 
significantly affect viral genome synthesis, while 
CDK4/6 inhibitor does not. 
(a) RPTE cells infected with BKPyV (3 IU/cell) were 
subjected to CDK4/6 inhibition (PD0332991 1 µM), 
CDK1/2 inhibition (Roscovitine 20 µM) or CDK1 
inhibition (RO-3306 5 µM) from 24 hpi, and 
harvested for analysis at 48 hpi. The effect of 
inhibition on BKPyV genome copy number, was 
determined by qPCR of DNA extracted from each 
harvested condition. BKPyV genome copy number 
was normalised to the cellular gene TNFα, and 
normalised to control. Data from six independent 
experiments. ***p < 0.001; ****p < 0.0001; ns = 
not significant; students t-test of experimental 
conditions versus control. Error bars show standard 
deviation. (b) RPTE cells infected with BKPyV (3 
IU/cell) were either untreated then harvested at 
2hpi and 48hpi, treated with cidofovir (40 µg/mL) 
at 4hpi then harvested at 48 hpi, or treated with 
Roscovitine (20 µM) at 24 hpi then harvested at 48 
hpi. Data from two independent experiments. Error 
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The effects of cell cycle inhibition on viral protein expression levels were also examined. As before 
RPTE cells were infected, inhibitors added at 24 hpi and cells were harvested for immunoblot at 48 hpi 
(Fig. 5.4a), and protein expression levels quantified by densitometry (corrected to uninhibited control) 
(Fig. 5.4b). Blots were probed for the cellular loading control tubulin, VP1, VP2, VP3, Agno and TAg. 
CDK4/6 inhibition had no effect on viral protein levels whereas inhibition of CDK1 and 2 by Roscovitine 
caused a dramatic reduction in the amount of all viral protein. CDK1 inhibition by RO-3306 
demonstrated little effect on the levels of viral capsid proteins (VP1, 2 and 3) although did cause a 
modest reduction in the levels of non-structural proteins TAg and Agno, although it is unknown 
whether this is due to effects on protein synthesis or turnover.  
These effects of these cell cycle inhibitors on the production of infectious BKPyV was then determined. 
As before RPTE cells were infected, inhibitors added at 24 hpi and cells harvested at 48 hpi. Viral titres 
were then determined by FFU assay and the data was normalised to uninhibited control samples 
(arbitrarily set at 1) (Fig. 5.5). While CDK4/6 inhibition by PD0332991 had minimal effects on virus 
synthesis, Roscovitine caused a significant and dramatic reduction in infectious virus titres by ~99%. 
Interestingly CDK1 inhibition by RO-3306 also reduced infectious virus production by ~68%. This level 
of inhibition is similar to that observed for viral DNA synthesis, although there is presumably a large 
excess of viral DNA in cells compared to assembled virions. These data suggest that that the activity 
CDK1 is important for efficient production of infectious viruses. 




Figure 5.4: CDK1/2 inhibitor greatly affects viral protein synthesis, while CDK1 and CDK4/6 inhibitors do not. 
RPTE cells mock infected or infected with BKPyV (3 IU/cell) were subjected to CDK4/6 inhibition (PD0332991 1 µM), 
CDK1/2 inhibition (Roscovitine 20 µM) or CDK1 inhibition (RO-3306 5 µM) from 24 hpi, and harvested for 
immunoblot analysis at 48 hpi. (a) Immunoblot showing the effect of inhibition on viral protein expression is shown, 
tubulin used as a loading control. (b) Band densities were determined using Li-Cor software, density blots show 










Figure 5.5: CDK1/2 and CDK1 inhibitors inhibit infectious virus production, while CDK4/6 inhibitor does not. 
RPTE cells infected with BKPyV (3 IU/cell) were subjected to CDK4/6 inhibition (PD0332991 1 µM), CDK1/2 
inhibition (Roscovitine 20 µM) or CDK1 inhibition (RO-3306 5 µM) from 24hpi, and harvested for analysis at 48hpi. 
Virus was released from cells by three rounds of freeze/thawing and infectious titres determined by fluorescent 
focus unit (FFU) assay, normalised to control. Data from seven independent experiments, error bars show standard 
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5.2.3 CDK1 inhibition impedes effective BKPyV secretion  
After determining the effect of CDK1 inhibition on efficient BKPyV replication, consideration was then 
given to the effect CDK1 may have on non-lytic BKPyV secretion from cells. There is evidence that 
during mitosis GORASPs are phosphorylated, leading to fragmentation of the TGN and inhibition of 
conventional secretion (Preisinger et al., 2005, Colanzi and Sutterlin, 2013). RPTE cells were infected 
with BKPyV (1 IU/cell) and at 24 hpi inhibited with RO-3306 (5PM), or untreated, and at 48 hpi cell and 
supernatant virus samples were harvested separately for FFU (Fig. 5.6). For this experiment it was 
decided not to include inhibition with the CDK1/2 inhibitor Roscovitine as this inhibitor reduced 
infectious virus production so drastically (~99%) that assessing any secreted virus would be beyond 
the limits of detection in this instance. 
After three replicates a ~70% reduction in the percentage of secreted virus was observed in RO-3306 
inhibited samples in comparison to the uninhibited samples. This suggests that CDK1 activity may play 








Figure 5.6: CDK1 inhibited cells show reduced levels of BKPyV secretion. 
(a) RPTE cells infected with BKPyV (1 IU/cell) were either subjected CDK1 inhibition (RO-3306 5 µM) or 
uninhibited from 24hpi. At 48 hpi cell and supernatant virus was harvested separately, supernatant virus was 
pelleted by ultracentrifugation and resuspended in PBS in 1/20th of the original volume, and cell-associated 
virus was released from cells by three rounds of freeze/thawing. Infectious titres were determined by FFU 
assay. (b) The percentage of total virus released in each condition was then calculated. Data from three 
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5.2.4 RPTE cells of higher confluency are less able to be productively infected with BKPyV  
Primary RPTE cells are contact inhibited, whereby upon approaching confluency their division rate 
decreases until they reach full confluence at which time they exit the cell cycle and enter G0, a state 
in which CDKs 4, 6, 2 and 1 are inactive. This property of primary cells can thus be exploited as another 
method by which to investigate the importance of cell cycle status for BKPyV infection.  To investigate 
the effect cell confluency on the initiation of virus infection the expression of the early viral protein 
TAg in cells seeded at increasing densities, from subconfluent (1.25x104 cells per well in a 24 well 
plate), up to fully confluent (2x105 cells per well in a 24 well plate). Cells were infected the following 
day with 600,000 IU, equivalent of 3 IU/cell of the highest density condition and a maximum of 480 
IU/cell at the lowest cell density. This should lead to 95-100% cells infected at the highest cell density. 
At 48 hpi cells were fixed and stained for TAg expression, along with DAPI to stain the nuclei. The 
percentage of cells which were expressing TAg was then calculated as a proportion of total DAPI 
positive cells (Fig.5.9).  
These data clearly demonstrated that TAg was less readily expressed in cells which were of greater 
confluency, in a cell density-dependent manner. At the lowest cell density TAg was expressed in near 
100% of cells, while at the highest density less than 10% were positive for TAg, far lower than the 
expected 95% for a multiplicity of infection of 3. This suggests cells which are contacted inhibited are 
less permissive to BKPyV infection, although whether TAg was unable to be expressed due to defects 
in BKPyV bind or entry into cells that are at high density, or whether cells had received genome but 
were less able to express TAg, was then investigated. 
  




Figure 5.7: Cells at higher confluency are less permissive to BKPyV infection than expected. 
RPTE cells were seeded on coverslips in 24 well plates at increasing densities, up to 2x105 cells per well. 24 h 
later cells were BKPyV infected with 600,000 IU/well (3 IU/cell of highest density of seeding). At 48 hpi cells 
were fixed and stained with an antibody specific for the early gene TAg and DAPI, a nuclear marker. The 
number of TAg positive cells compared to DAPI-positive cells per well were then counted using images taken 
on an Olympus IX81 wide-field fluorescence microscope. Ten fields of view were counted per condition. 
Red lines representative of expected infection level determined by Poisson distribution for multiplicity of 
infection used in each condition. 
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5.2.5 BKPyV gene expression is affected by cell confluency, while genome delivery is not 
To address the question as to whether BKPyV is less able to deliver viral genome to cells as they 
become confluent and contact inhibited, due to some physical restriction to virus binding for example, 
or whether BKPyV genomes are delivered to cells but viral gene expression is impaired due to changes 
in the intracellular environment caused by contact inhibition and exiting the cell cycle, a novel 
application of a classical scratch assay experiment was implemented. Scratch assays, where a section 
of a cell monolayer is damaged (‘scratched’), are commonly used to investigate and measure cell 
migration. For investigating BKPyV infection, a scratch assay was employed to effectively generate two 
different zones within the same monolayer, one where cells are more actively replicating (the 
scratched zone) and one where cells are more contact inhibited (the unscratched zone), allowing 
direct comparison between the two zones in cells that have previously been treated equivalently (e.g 
infected with BKPyV). Cells were set up on coverslips at subconfluent (1.25x104 cells per well in a 24 
well plate) or confluent (2x105 cells per well in a 24 well plate) densities, and the following day infected 
with BKPyV at 1 IU/cell, which would be expected to lead to ~63% of cells being infected. The 
coverslips were then either scratched immediately after infection or at 24 hpi, and then fixed for 
immunofluorescence at 48 hpi (Fig. 5.11a). Cells were stained with a TAg specific antibody and DAPI, 
while approximate boundary lines between the scratched and unscratched zones were drawn by eye 
due to obvious cell density differences. When drawing the boundary lines at scratch zones, the areas 
of each scratch were deliberately underestimated avoid include cells which may be at the scratch 
periphery, and so still potentially contact inhibited Example images of defined scratch zones are shown 
in Fig. 5.11b. All DAPI-positive and TAg positive cells were counted in ten fields of view per condition 
and the percentage of cells positive for TAg expression were calculated for four independent 
experiments (Fig.5.11c). Approximately 64% of subconfluent cells expressed TAg whether they were 
in unscratched or scratched zones at 0 hpi or at 24 hpi. This closely matched the expected proportion 
of infected cells at 1 IU/cell. However, in confluent cells it was only in the scratch zones that TAg was 
expressed at levels exceeding 60%, and it did not matter whether they were scratched immediately 
after infection or at 24 hpi. In the unscratched zones of confluent cells just 35% of cells were observed 
to express TAg, a significant reduction compared to the proportion of TAg positive cells in unscratched 
zones for subconfluent cells and the expected infection rate at 1 IU/cell. 
These data suggest that BKPyV can enter and deliver its genome to a similar percentage of cells in 
confluent and subconfluent cells, but that expression of viral genes is substantially enhanced when 
cells are not contact inhibited and are actively cycling. The fact that the same effect was observed for 
scratch zones that were generated immediately after BKPyV infection (0 hpi) and at 24 hpi further 
suggests that intact BKPyV genomes can remain within cells and are not degraded for at least 24 hours 
Chapter 5. Cell cycle status is important for productive BKPyV infection 
156 
 
after delivery into contact inhibited cells. These data have interesting connotations for the 
mechanisms of BKPyV persistence in tissue, where the majority of cells would be expected to be in 
G0. 
  











Figure 5.8: Scratch assays reveal BKPyV genome delivery appears to be unaffected by confluency, but gene 
expression is delayed in confluent cells. 
Experimental design of the scratch assay (a). RPTE cells were seeded in 24 well plates at confluent (2x105 cells/well) 
or subconfluent (1.25x104 cells/well) densities. 24 h later cells were BKPyV infected at 1 IU/cell for each density. 
Coverslips were then either scratched at 0 hpi or 24 hpi. At 1 hpi cells were washed thoroughly with PBS and fresh 
media added. Cells were then fixed for immunostaining at 48 hpi. Cells were stained for TAg expression (red), and 
DAPI (blue) stained as a cellular marker, examples of scratch zones shown using images taken on an Olympus IX81 
wide-field fluorescence microscope (b). Coverslips were counted for TAg expression, as a percentage total of cells 
in either the unscratched cell monolayer (U), the zone in the 0 hpi scratched monolayer (0), and the zone in the 24 
hpi scratched monolayer (24), in both confluent and subconfluent conditions. Data from four independent 
experiments, error bars show standard deviation. ***p < 0.001; ns = not significant; t-test confluent cell conditions 









The CDK inhibitors used in this chapter caused the expected cell cycle arrest effects in uninfected RPTE 
cells, although the magnitude of each cell cycle arrest was relatively small, presumably due to the slow 
cycling rate of RPTE cells (up to 40 hours to divide). This relatively slow rate of cell division likely 
prevents many cells reaching the stage of the cell cycle in which a particular CDK inhibitor is effective 
(G2/M for example with CDK1 inhibition) within the 24 h treatment timeframe. Unfortunately, 
inhibitor treatment could not be easily extended for longer than the 24 h to cause greater levels of 
cell cycle arrest because of cell toxicity issues, potential due to apoptosis that is induced by extended 
periods of cell cycle arrest. Another option to investigate cell cycle dependency of BKPyV replication 
would be to synchronise RPTE cell prior to these CDK inhibition experiments. However, serum 
starvation has little effect on RPTE cells, as the serum levels are already low in the media that is used 
to propagate these cells (0.5% FCS), while effective chemical synchronisation often uses CDK inhibitors 
such as RO-3306 and PD0332991, and using these inhibitors to synchronise cells prior to infection 
would confound investigation into the role of these inhibitors for virus replication. 
The cell cycle status, and ability of BKPyV infection to overcome cell cycle arrest caused by chemical 
inhibitors, is important for BKPyV to replicate its genome, synthesise proteins, and ultimately produce 
infectious virions. BKPyV infection is not affected by CDK4/6 inhibition as TAg can bypass the G1/S 
checkpoint even in the absence of upstream cues that normally rely on CDK4/6 activity. Conversely, 
CDK1/2 inhibition showed a dramatic reduction in the ability of BKPyV to induce cell cycle progression 
through S phases and into a pseudo-G2 phase, and the synthesis of viral genomes, viral proteins and 
infectious virus were all significantly affected by CDK1/2 inhibition. This is likely to be due to inhibition 
of CDK2 primarily, as this kinase is necessary for S phase entry and progression. It must also be 
considered however, that Roscovitine appears to have off-target effects on CDK7 and CDK9. CDK7 and 
9 are important for the initiation and completion of transcription by phosphorylating the C-terminal 
domain of RNA polymerase II, thus the widespread inhibition of BKPyV replication may also be 
somewhat attributed to an inhibition of protein synthesis (Holcakova et al., 2014). Without early viral 
protein synthesis there would be insufficient TAg to form a viral helicase, thus greatly reducing viral 
genome replication and eventually inhibiting infectious virus production. The effects of the CDK1 
inhibitor RO-3306, on the other hand, are more likely to be due to reduced CDK1 activity as RO-3306 
is more specific and is thought not to inhibit CDK7 or CDK9 (Kojima et al., 2009). RO-3306 had little 
effect on BKPyV-induced modulation of the cell cycle, and in fact RO-3306 and BKPyV infection 
independently lead to a similar amount of cells arrested in G2/M phase. Somewhat surprisingly CDK1 
RO-3306 caused a decrease in the amount of viral genome and infectious virus production. These 
observations suggest that activity of CDK1, and not just cell cycle status, is important for effective 
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BKPyV replication, and conversely BKPyV-induced G2/M arrest cannot simply be due to virus inhibition 
of CDK1 activity. CDK1 activity also appeared to be important for effective BKPyV secretion, and it is 
tempting to speculate that BKPyV may promote CDK1 activity in the cytoplasm to enhance virus 
release, perhaps by phosphorylating mediators of Golgi-bypass type unconventional secretion such as 
GORASPs, but exclude active CDK1 from the nucleus where it would normally cause cell cycle 
progression into M phase and ultimately cell division. However, some caution must be exercised when 
interpreting the decreased proportion of virus secreted in RO-3306 treated cells because the total 
amount of infectious virus was also reduced by RO-3306 and it is currently unknown what effect 
reduced virus concentration within a cell may have on the release pathways used by the virus. Further 
experiments to specifically increase or inhibit cytoplasmic CDK1 activity or to analyse the effect of RO-
3306 or other CDK1 inhibitors on cellular secretory pathways may shed more light on this. 
The results in this chapter also demonstrate that the status of cells prior to infection is important to 
determine the outcome of virus genome entry. Cells which are contact inhibited, and so more likely 
to be in G0 and thus more refractory to virus induced cell cycle entry/progression, are less able to be 
infected, with a clear inverse correlation of the proportion of cells showing TAg expression with cell 
density. While this could be attributed to RPTE cells exiting the cell cycle once they become contact 
inhibited, this may equally be due to another intracellular metabolic change between subconfluent 
and confluent cells. However scratch tests of confluent and subconfluent cells suggests that genome 
is delivered to the same percentage of cells, whether subconfluent or confluent, however confluent 
cells are less able to initiate or support TAg expression.  
In summary the data in this chapter suggests that BKPyV specifically alters the cell cycle to drive cells 
into S phase to enable efficient viral genome synthesis, but then to stall cells in a G2-type phase, which 
promotes the assembly and release of infectious virions. Furthermore, BKPyV can enter contact 
inhibited and actively cycling cells equivalently, but the initiation of viral gene expression only occurs 
when cells exit senescence and re-enter the cell cycle. 
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6: Concluding Remarks 
6.1 Non-lytic BKPyV release from cells 
The results in this thesis suggest there is an active pathway that secretes BKPyV from infected cells in 
a non-lytic manner. Around 1% of BKPyV progeny is released into the supernatant of cultured cells by 
48 hpi without any appreciable cell death. Importantly, BKPyV secretion is specifically inhibited by the 
anion channel inhibitor DIDS, which perturbs anion homeostasis and leads to the formation of large 
intracellular vacuoles that are acidic and positive to BKPyV structural proteins. However, it is unclear 
why DIDS causes a specific inhibition of virus release, and whether anion homeostasis or acidic 
organelles are involved in the normal route of BKPyV non-lytic egress. It seems more likely that a 
widescale disruption of anion homeostasis by DIDS, which is active against many anion channels, may 
interfer with cellular secretion in a more general manner, rather than the drug specifically targeting 
the secretory pathway exploited by BKPyV. It is worth noting that other more specific anion channel 
inhibitors that were tested did not affect BKPyV secretion, and treatment with 50 µM DIDS, while not 
lethal to RPTE cells, is known to have off-target effects other than specific anion channels that could 
disrupt trafficking in a more general manner. One off target effect is the inhibition of GPHR by DIDS, 
as a regulator of Golgi pH it is plays an important role in acidification of the Golgi, mutations of which 
result in delayed proteins transport and incorrectly glycosylated proteins (Maeda et al., 2008). 
Furthermore DIDS appears to inhibit aquaporins at concentrations of just 10 µM (Endeward et al., 
2006).  
One possible explanation for the appearance of BKPyV structural proteins in large acidic vacuoles in 
response to DIDS could be autophagy of virion containing compartments (e.g. virus-containing ER-like 
membranes). Disruption of trafficking and ER stress has been shown to increase cellular autophagy 
(Ogata et al., 2006), and an inhibitor that disrupts trafficking of virus and causes its retention in the ER 
could increase such stress. These processes may account for the observed colocalisation between 
large DIDS positive vesicles, LysoTracker and VP2/3. Such structures were not detected with later TEM 
imaging of BKPyV infected cells that were not DIDS treated, suggesting they are induced by DIDS and 
may not be part of the BKPyV trafficking pathway. Moreover the acidic nature of these vesicles, 
determined by LysoTracker positive staining, suggests that they could be lysosomal. Virions 
autophagosytosed due to disrupted trafficking and cytoplasmic retention would then be exposed to 
lysosomal proteases, which could explain the exposure of VP2/3 epitopes enabling antibody binding 
and apparent colocalisation. LAMP1, a lysosomal and endosomal marker, was also found to colocalise 
with these vesicles, albeit against a more diffuse background. Caution must be exercised when 
interpreting intracellular VP2/3 staining as it is unclear whether this antibody would normally bind 
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fully intact virions, because VP2/3 is expected to be completely buried within the internal capsid 
structure and may be inaccessible to antibody binding. While it was demonstrated that the VP2/3 
antibody binds surface virions, and non-conformational VP1 antibody (PAb597) does not, this may due 
to the presence of partially damaged virions causing VP2/3 exposure, and the binding epitope where 
the VP2/3 antibody binds remains undetermined. However, conformation-dependent VP1 antibodies 
also demonstrated colocalisation to these large acidic vacuoles suggesting intact virions are present 
in these structures. Taking these data together, the most logical explanation, is that BKPyV virions 
undergoing egress are mistakenly incorporated into acidic/degradative compartments, possibly via an 
autophagic process, leading to damage to a proportion of particles. Therefore, the presence of BKPyV 
virions within such acidic organelles after DIDS treatment may not actually reflect the secretion 
pathway normally used by this virus and acidic organelles may not be part of the route used by the 
virus to exit cells. However the striking conclusion remains; BKPyV is secreted from cells in a non-lytic 
manner which is inhibited by perturbation of anion homeostasis. This is the first time in almost 30 
years that evidence for non-lytic release of polyomavirus has been established (Clayson et al., 1989, 
Evans et al., 2015). Such evidence is important for our understanding of the viral life cycle, in particular 
how BKPyV disseminates in healthy patients who appear not to experience inflammatory responses 
that would be expected from extensive lytic infections, but remain able to periodically shed virus 
(Urbano et al., 2016). 
 
6.2 The pathway to non-lytic secretion 
The observed path which newly synthesised BKPyV virions take on their route to exiting the cell 
appears to begin at the ER. Virions were easily observed in the lumen of smooth ER-like structures by 
TEM and the colocalisation of virions with the HRP-KDEL ER marker confirmed these observations. 
However, the mechanism by which virions can exit the nucleus and cross a membrane to gain access 
to the ER lumen without causing membrane damage is unclear It has been recently established that 
agnoprotein is important for nuclear egress of virions (Panou et al., 2018), furthermore agnoprotein 
is proposed to be a viroporin for some polyomaviruses (Suzuki et al., 2013). The ER is contiguous with 
the nuclear membrane (Hetzer, 2010), suggesting viral access to the ER could be achieved through 
breaching just the inner nuclear membrane, a process which could be facilitated by small pore 
formation. Many questions continue to remain regarding the physical process of membrane 
penetration of ~45nm diameter virions while keeping nuclear/ER integrity intact. 
Immunofluorescence data showing of BKPyV with calnexin, an ER marker, supported the EM 
observations but calnexin staining was rather diffuse and made further interpretation difficult. It was 
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clear, however, that virions are not trafficked via the Golgi: no colocalisation by immunofluorescence 
was observed and disruption of Golgi trafficking by monensin did not alter the secretion of BKPyV. As 
such, BKPyV is appears to be secreted by an unconventional secretion pathway, potentially in a similar 
pathway to ‘Golgi-bypass’ secretion (Gee et al., 2011, Jung et al., 2016). Individual BKPyV virions were 
observed in small single-membraned vesicles, and canonical autophagy pathways do not appear to be 
involved in BKPyV secretion. The nature of these vesicles remains intriguing, they could be derived 
from ER but did not contain detectable HRP marker when imaged by TEM in KDEL-HRP expressing 
cells. This could be due to the efficiency of ER retention of the HRP-KDEL preventing this marker being 
incorporated into virion-containing vesicles, or could be due to tight apposition of the virion ‘cargo’ 
with the transport vesicle membrane excluding sufficient HRP so that it is below the detection 
sensitivity in such small tightly bound vesicles. The origin of these vesicles is evidently key to 
determining the pathway by which BKPyV is being secreted. Colocalisation observed through 
immunofluorescence of GORASP1 and GORASP2, both Golgi cisternae tethers whose tethering 
abilities are regulated via phosphorylation by CDK1 and other kinases (Lowe et al., 1998, Preisinger et 
al., 2005), with BKPyV conformation-dependent antibodies suggests that the transport of virus-
containing vesicles could be mediated by these tethers. One note of caution regarding the observed 
virion containing vesicles near the cell periphery is the possibility of these vesicles representing 
incoming virus that have undergone endocytosis, although experiments with neutralising antibodies 
conducted for this thesis suggests this isn’t the case. To further address this concern, TEM experiments 
could be conducted where the extracellular media and/or plasma membrane is labelled, with a HRP 
marker for example, from 24-48 hpi, to investigate whether these virion-containing vesicles are of 
plasma membrane origin. In addition, further understanding of the mechanism by which virions are 
neutralised by conformational-dependent VP1, whether they prevent BKPyV infection by inhibiting 
virion binding and entry, or simply inhibit uncoating, could address some of these concerns. 
The discovery that BKPyV can be released from infected cells by non-lytic secretion via an 
unconventional secretion pathway adds further to the growing number of viruses which hijack novel 
cellular pathways to aid their dissemination (Bird and Kirkegaard, 2015).  
 
6.3 The role of GORASPs in BKPyV secretion 
While the role of GORASPs as tethers for the Golgi cisternae is well studied there has been limited 
understanding in their role as tethers during unconventional secretion (Ramirez and Lowe, 2009). 
Upon ER stress GORASPs have been shown to relocalise to the ER and become associated with vesicles 
trafficking directly to the cell surface (Gee et al., 2011, Jung et al., 2016). The hypothesis that BKPyV 
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might also be trafficked in such a way is the first description of this pathway being used for viruses, 
having been only described previously for membrane bound proteins (Gee et al., 2011, Jung et al., 
2016). As such it is important to investigate the role which GORASPs might play during virus egress 
and unconventional secretion. siRNA knockdowns were complicated by the compensatory effect of 
alternative GORASPs in single knockdowns, where GORASP1 expression increased in GORAPS2 
knockdown cells and vice versa, while simultaneous knockdown of both GORASP1 and 2 appeared to 
affect cell viability in these studies, which has also been observed by other labs (Bekier et al., 2017). 
While undoubtedly a difficult process to optimise, more success to identify the source of the single–
membraned vesicles could be made through isolation and purification of them through fractionation 
experiments, followed by proteomic analysis to ascertain their composition. Another possibility would 
be immuno-isolation using GORASP1 and 2 antibodies to isolate those proteins and vesicles associated 
with GORASP1 and 2, comparing BKPyV infected and mock infected cells, as has been conducted 
previously with circulating exosomes (Caby et al., 2005). 
It is interesting to note that CDK1, active during mitosis, phosphorylates GORASPs leading to 
fragmentation of the Golgi that is important for even distribution of this organelle into the daughter 
cells, and this study has shown CDK1 expression is induced during BKPyV infection. Furthermore, 
inhibition of CDK1 by RO-3306 caused a specific reduction in the proportion of infectious virus 
secretion, in addition to an overall reduction in total production of infectious virus. Therefore, one 
hypothesis is that CDK1 overexpression during BKPyV infection leads to phosphorylation of GORASPs 
and untethering from the Golgi followed by their relocalisation to the ER, which could also be 
stimulated by the ER stress due to the presence of virions within the ER lumen. If so this may be an 
effect on just a small population of total GORASPs because the Golgi complex appears to remain intact 
in infected cells. Such a process may promote the formation of vesicles containing single virions, and 
subsequent trafficking to the plasma membrane. 
 
6.4 The proteomes of two primary cell types and BKPyV infection 
By implementing TMT-based MS3 mass spectrometry technology the proteomes of two primary 
epithelial human cell types have been revealed, highlighting changes induced by BKPyV infection in 
these two BKPyV permissive cells. Not only should this comprehensive study prove useful for the study 
of renourinary cell biology, but these data should also be invaluable as a resource for future BKPyV 
research. A wide variety of protein hits modified in infected cells were validated by immunoblot or 
immunofluorescence microscopy, giving confidence that our data set was robust and valid. 
Surprisingly few changes were identified, when taking p < 0.0005 significance as a cut off for proteins 
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of interest. Of course, with such a large data set generated there are different choices that can be 
made when considering significance of observed differences in protein abundance when analysing the 
data. Alternative thresholds for significance that could have been implemented, for example simply 
greater than 2-fold changes in abundance across all time points and both cells lines. This differs from 
the analysis in this thesis in that it would fail to take into account the signal:noise ratio for low 
abundance peptides. This might result in the inclusion of proteins which were identified as changing 
in abundance more than 2-fold, but in reality measured peptide abundance might change from 4 
individual peptides identified, to 9 peptides. Whilst this represents a greater than 2-fold increase, it is 
unlikely to be of interest. However, if this greater than 2-fold change cut off were implemented for 
this study the number of proteins analysed for their changes in abundance would nevertheless remain 
less than 5% of the total proteomes identified.  
Of more interest might be the experimental design, given the opportunity to repeat such an 
experiment further controls could be added. One example could be studying the two cell types 
independently of one another, allowing the inclusion of a greater range of time points and at later 
times. This could identify if, at very late times during BKPyV infection, cell responses to infection are 
reduced even further or new pathways are activated, such as apoptosis or other cell death pathways. 
Although the benefits of such a study might be limited, given our understanding of the limited 
responses made by these cell types even at 72 hpi. 
The detection of a novel TAg peptide could be an important discovery which needs further 
investigation. The identified peptide should not be generated by trypsin cleavage of the canonical 
BKPyV large T antigen, or the published splice variant Trunc-TAg (Abend et al., 2009b), because there 
are no lysine or arginine residues immediately upstream of the N-terminus of this peptide in the amino 
acid sequences of these known TAg proteins. The most logical explanation is the presence of a further 
TAg splice variant that places the identified peptide downstream of a trypsin cleavage site, although 
this requires experimental validation. TAg has been described to play a number of roles, ranging from 
cell cycle stimulation and p53 binding, to its role as a viral helicase (Lilyestrom et al., 2006). Both Trunc-
TAg and this potential novel splice variant of TAg may function in controlling these various TAg roles, 
with one or either of them modulating these activities due to alternative subcellular localisation or 
different binding affinities for cellular interactors. Generating recombinant viruses lacking these TAg 
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6.5 BKPyV infection induces limited and specific proteome changes 
Of those pathways identified as significantly altered by infection in both cell types, cell cycle and cell 
cycle related processes dominated, although the apparent lack of induction of innate immune 
responses was perhaps the most surprising. The apparent absence of any antiviral responses 
correlates with the lack of IRF3 phosphorylation and activation in BKPyV infected cells. Surprisingly, 
this does not appear to be due to any viral activity that directly antagonises the IRF3 activation because 
infection with BKPyV does not inhibit IRF3 phosphorylation in response to artificial DNA or RNA 
mimics. This suggests that BKPyV can completely hide itself from detection by pathogen recognition 
receptors that activate IRF3 despite causing cells to synthesise large amounts of foreign (viral) DNA, 
RNA and protein. This may reflect the extensive co-evolution of polyomaviruses with their hosts 
leading to these viruses developing a sophisticated mechanism to evade detection. Further 
investigation into NFκB activation in response to infection would be interesting to confirming whether 
lack of immune stimulation is true for other arms of innate immune response pathways. It is also worth 
noting that these experiments were conducted at high multiplicity of infections to ensure the majority 
of cells were infected for the proteomic analysis. Therefore, it is conceivable that a lower multiplicity 
of infection might lead to IFN signalling to neighbouring uninfected cells. However, the lack of any IRF3 
phosphorylation or translocation to the nucleus suggests that IFN expression would not be stimulated 
in the infected cells, and previous data have suggested little-to-no activation of ISGs in cells infected 
with BKPyV at low multiplicity of infection. Furthermore, studies of global transcriptome changes in 
RPTE cells with low multiplicity (0.03) BKPyV infections show that even by 9 dpi few innate immune 
protein changes were observed (Assetta et al., 2016).  
 It is, however, clear that BKPyV is detected by the adaptive immune system, patients show 
seroconversion for VP1 epitopes (Kean et al., 2009, Viscidi et al., 2011) and infection is controlled by 
CD8+ T cells and antibody-secreting B cells, without which greatly increased levels of viral replication 
are seen, often leading to PVAN and renal failure (Binggeli et al., 2007, Comoli et al., 2008, Egli et al., 
2009). This activity would rely heavily on APCs and associated peptide presentation and is clearly 
inefficient as BKPyV is rarely cleared by even healthy patients, as such it would be interesting to 
undertake plasma membrane profiling of BKPyV infected cells, compared with mock infected, to 
observe any effects on immune-related receptors such as MHC-I and NK receptors. Such localisation 
canges would not be detected by our whole cell proteome analysis. Indeed certain MHC mutations 
have been implicated in BKPyV reactivation in transplant patients suggesting that MHC play a role in 
viral restriction (Tonnerre et al., 2016).   
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One observation that could be worth investigating further is the small (< 2-fold) changes in the 
expression of IFIT proteins observed in HU cells, which may suggest a low level of IFN signalling in 
these cells. This was not studied further at the time, partly due to the difficulties in culturing HU cells, 
and also because relatively small changes in total peptide expression were observed which were only 
for IFIT proteins and not for other ISGs. It would be interesting to investigate activation of IRF3 and 
NFκB and IFN production in these cells response to BKPyV infection and sensing of exogenous nucleic 
acid. 
Compared to the lack of any antiviral responses, the observed changes to cell cycle modulation causing 
a pseudo-G2/M-like arrest was less surprising. It has been well established that both TAg and tAg 
induce cell cycle progression through the G1/S checkpoint due to their actions on Rb and PP2A 
(Stubdal et al., 1997, Sowd and Fanning, 2012, Pallas et al., 1990), and further that members of the 
closely related papillomaviridae cause cells to undergo G2 arrested during infection (Davy et al., 2002). 
The benefit of G2 arrest for the virus is intriguing; arrest in S phase, a phase which favours DNA 
synthesis, would appear more beneficial for virus genome replication. However, G2 phase proteins 
where more highly upregulated than S-phase proteins. This suggest that certain properties of G2 
phase proteins may play a role in efficient viral replication.  
The data in this thesis has also shed more light on the mechanism of p53 regulation during BKPyV 
infection. While TAg has been suggested to be the main effector on p53 activity (Doherty and Freund, 
1997), when validating observed proteomic changes on Mdm2 and p53 it became evident that TAg 
expression alone is insufficient to drive the increase in p53 expression that is observed during 
infection. Interestingly, TAg expression by transfection, combined with G2 arrest through CDK1 
inhibition, increased p53 expression similar to that elicited by full BKPyV infection. This not only 
suggests that interaction of TAg with p53 to displace Mdm2 stabilises existing p53, but that another 
activity that is stimulated in G2 causes increased p53 synthesis which can also be stabilised by TAg. 
This may be related to ATM/ATR kinase activation as it is expected that a viral induced DNA damage 
response might also induce an equivalent response (Verhalen et al., 2015). Effects of ATM/ATR kinase 
activation by DNA damage on p53 levels in TAg expressing cells (by transfection) could be investigated; 
subjecting TAg transfected cells to DNA damage by ionising radiation would mimic the DDR induced 
during viral infection and may induce p53 levels to increase in cells much like CDK1 inhibition attained. 
This might help elucidate the various cellular states necessary for increased p53 synthesis during 
infection, as TAg expression alone is not sufficient to greatly increase p53 levels. 
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6.6 The importance of CDK1 activity in BKPyV infection 
Inhibition of CDK1 and CDK2 by Roscovitine prevents cells from progressing through S phase blocking 
DNA synthesis, primarily due to CDK2 inhibition, and so it is unsurprising that BKPyV infected cells 
which were treated with Roscovitine showed a dramatic reduction in progeny virus synthesis. These 
effects may also be partly due to inhibition of viral protein synthesis because of the known “off-target” 
effects of Roscovitine on CDK7 and CDK9, which have important roles in protein transcription initiation 
and elongation (Holcakova et al., 2014).  
CDK1 inhibition alone by RO-3306 afforded some interesting insights into the importance of BKPyV-
induced G2 arrest. CDK1 inhibition causes cells to accumulate in G2/M, while BKPyV infection also 
induces G2 cell cycle arrest, so it was therefore surprising that inhibition of CDK1 was detrimental to 
viral replication, causing a significant reduction in genome replication and infectious virus production. 
It is possible that there may also be off-target effects of RO-3306 as yet undescribed, although this 
inhibitor is used regularly to induce cell synchronisation with no noted off-target complications (Ma 
and Poon, 2011). To understand better the effects of CDK1 inhibition on virus replication through TAg 
helicase regulation phosphorylation of TAg could be studied. Phosphorylation of TAg is known to be 
important for protein function as a helicase (Moarefi et al., 1993), thus mutation of the suspected 
CDK1 phosphorylation site, T126, could be conducted although similar experiments have already been 
undertaken with JCPyV and SV40 so may not further the field of study greatly (Swenson et al., 1996, 
McVey et al., 1996).  
The data in this thesis also suggest that CDK1 activity may be important to enhance viral secretion. It 
is known that conventional secretion is reduced to a minimum as G2 phase ends and mitosis starts to 
occur (Farmaki et al., 1999), and that this is mediated by CDK1 phosphorylation of GORASPs and the 
GORASP1 binding protein GM130 (Lowe et al., 1998, Preisinger et al., 2005). The activity of 
unconventional secretion in G2/M has not been investigated and it is conceivable that some 
unconventional secretion pathways could be unaffected or even enhanced during this cell cycle phase, 
for example by releasing GORASPs from the Golgi enabling them to participate in Golgi-bypass-type 
secretion. This may provide another example of potential pro-viral effects of G2 arrest and increased 
CDK1 levels during BKPyV infection, enhancement of non-lytic egress of virions. We therefore 
hypothesise that not only is cell cycle modulation important for ensuring cells are in the correct state 
for efficient viral DNA synthesis, but G2 arrest and the activity of proteins such as CDK1 are important 
for efficient virus assembly and non-lytic exit from cells. 
 
 
Chapter 6. Concluding Remarks 
169 
 
6.7 A proposed mechanism for viral latency 
The observations that BKPyV genomes can remain in cells without viral gene expression, at least for 
24 hours, might suggest a mechanism by which BKPyV can remain silently persistent within kidneys. 
One hypothesis is that after virus entry viral DNA can exist in differentiated cells in an inactive state, 
but when such a cell is induced by an exogenous signal to re-enter the cell cycle this stimulates early 
virus gene expression, promoting rapid progression of the cell into S phase and turning it into a virus-
producing cell that becomes stalled in a G2 state. This could also help explain why high levels of BKPyV 
replication are associated with kidney transplantation, where the tubular epithelium is known to 
undergo extensive damage, which would lead to high levels of tubular epithelial cell division to repair 
this region of tissue, thus promoting BKPyV replication and shedding. Many questions remain, such as 
the nature of the stimulus that is required to initiate early viral gene expression when a cell re-enters 
the cell cycle and exits senescence, necessitating further investigation. Understanding this stimulus 
might provide novel drug targets in those patients who are seronegative but receiving a kidney from 
a seropositive donor. Furthermore, this may provide evidence for true viral latency during BKPyV 
infection (maintenance of silenced viral genome from which viral gene expression and can be 
reinitiated), rather than simply subclinical replication (continual low level virus gene expression and 
replication). 
 
6.8 Future work 
6.8.1 Viral trafficking 
A variety of important questions remain regarding the mechanisms underlying the non-lytic secretion 
of BKPyV. The potential role of GORASPs could be addressed by gene knockout using CRISPR/Cas9 
technology rather than depletion by siRNA, although this would inevitably require the use of an 
immortalised RPTE cell line because of the very low passage limit of primary RPTE cells. Cas9 
expressing immortalised RPTE cells could be transduced with guide RNAs to each GORASP, creating a 
knockout cell type for each individual GORASP or a knockout of both proteins. If deletion of both 
GORASP1 and 2 is deleterious to cells, siRNA knock down could be used to suppress the remaining 
GORASP in each single knockout cell line. This may allow cells to survive long enough for any effect on 
secretion of virus to be observed before potential cytotoxic effects of lacking both GORASPs. In 
addition analysis of global protein secretion (the secretome) in mock and BKPyV-infected cells, may 
shed light on whether unconventional secretion pathways are upregulated and/or conventional 
secretion is down regulated. Given the possible effect of G2 arrest on secretion pathways extending 
these analyses to cells treated with RO-3306 and other cell cycle inhibitors would be interesting 
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comparison. Furthermore, the effects of DIDS on cellular secretion pathways in the presence or 
absence of BKPyV infection may shed more light on the disruption caused by this anion channel 
inhibitor. 
 
6.8.2 Proteomic analysis of BKPyV infection 
While the proteomic analysis presented here has given substantial information on global protein 
abundance, it hasn’t provided information of phosphoproteome or compartment specific proteome 
changes. Such investigations might reveal subtler changes to infected cells such as activation of 
transporters or changes in catalytic activity of proteins. Furthermore, plasma membrane proteome 
profiling might also determine up or down regulated cell surface proteins affecting immune responses. 
Also interesting would be further investigation into the newly discovered novel TAg splice variant. By 
using site directed mutagenesis to knock out known and suspected splice donor sites within TAg the 
properties and phenotypes of such splice mutants can be studied.  These TAg variants might have 
differential effects on global TAg expression levels, subcellular localisation, Rb modulation, p53 
binding ability and helicase activity, all of which should be investigated. Of particular interest is 
whether such splice variants are all phosphorylated, in doing so becoming the viral helicase, to the 
same extent.  
 
6.8.3 Latency and the cell cycle  
The importance of the role cell cycle status plays in the establishment of infection needs to be better 
understood. The employment of EdU labelled viruses could be applied. 5-Ethynyl-2’-deoxyuridine 
(EdU) is a thymidine analogue which is incorporated into newly synthesised DNA, when used during 
viral synthesis EdU is incorporated into the viral genome. These viruses can be used to infect fresh 
(non-EdU treated) cells. The presence of viral EdU can then be detected with click chemistry; a 
fluorescent azide will form a covalent bond with EdU allowing detection by immunofluorescence 
microscopy (Strang et al., 2012). Using this method non-replicating, non-viral protein expressing, input 
viral genomes could be detected in cells, detecting the presence of ‘latent’ input viral genomes in 
contact inhibited non-replicating cells would advise how long BKPyV is able to remain in fully confluent 
cells before any gene expression can be stimulated. In addition, the use of cell cycle stimulation by 
extracellular stimulus such as scratch assay, addition of growth factors or overexpression of CDK1, 
might inform the factors which drive initial early gene expression.  
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This thesis has uncovered details of BKPyV lifecycle in persistently infected individuals; the non-lytic 
unconventional secretion of BKPyV offers a method of transmission which would elicit minimal 
inflammatory responses, while the minimal detected innate immune responses of kidney epithelial 
cells suggests initial infection is unlikely to be recognised by cytosolic viral DNA sensors. In addition, a 
hypothesis for viral latency is proposed whereby viral proteins are not transcribed, and genome not 
replicated, in non-dividing cells. 
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7. Materials and Methods 
7.1 Materials 
7.1.1 General Reagents 
Plasticware and tissue culture flasks were obtained from BD Biosciences, Gibco and Techno Plastic 
Products (TPP).  
Biochemical reagents were obtained from the following companies; Amersham Bioscience, BDH 
Chemicals, Clontech, Invitrogen, New England Biolabs, Promega, Roche, Sigma-Aldrich, and Thermo 
Fisher Scientific, unless otherwise stated. 
 
7.1.2 Solutions, Buffers and Media 
Table 7.1 General solutions, buffers, and media used in this study. 
Bacterial Culture  
2TY 1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl. Prepared by 
Department of Pathology lab technicians, University of Cambridge. 
2TY Agar 1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl, 1.5% 
technical grade agar. Prepared by Department of Pathology lab 
technicians, University of Cambridge. 
Kanamycin Used to select for bacteria containing plasmids that code for kanamycin 
resistance.  Used at 30µg/ml final concentration. 
Mammalian Tissue Culture  
Freezing Medium 90% fetal calf serum (FCS), 10% dimethyl sulfoxide (DMSO). 
Renal Epithelium General 
Medium (REGM) 
Primary RPTEC tissue culture medium. 
Renal Epithelial Basal Medium (REBM) (Lonza), supplemented with 
SingleQuots Bulletkit containing 0.5ml rhEGF, 0.5ml insulin, 0.5ml 
hydrocortisone, 0.5ml GA-1000, 2.5ml FCS, 0.5ml epinephrine, 0.5ml T3, 
0.5ml transferrin (Lonza). 
Supplemented Dulbecco’s 
Modified Eagle’s Medium 
(DMEM) 
HeLa and Vero cell tissue culture medium.  DMEM (GE Healthcare), 
supplemented with 10% FCS, 2mM L-glutamine, 100 U/ml penicillin and 
100µg/ml streptomycin. 
Urothelial Cell Medium 
(UCM) 
HUC tissue culture medium. UCM (ScienCell) supplemented with 5ml 
Urothelial Cell Growth Supplements (UCGS) (ScienCell), 100 U/ml 
penicillin and 100µg/ml streptomycin. 
RPTEC/TERT1 Growth 
Medium (HRGM) 
RPTEC/TERT1 tissue culture medium. 50% DMEM (GE Healthcare), 50% 
Ham’s Nutrient Mixture F-12 with L-glutamine and sodium bicarbonate 
(Sigma), supplemented with SingleQuots Bulletkit containing 0.5ml rhEGF, 
0.5ml insulin, 0.5ml hydrocortisone, 0.5ml GA-1000, 2.5ml FCS, 0.5ml 
epinephrine, 0.5ml T3, 0.5ml transferrin (Lonza). 
Trypsin/EDTA 0.05% trypsin, 0.02% EDTA in PBS. 
Trypsin/EDTA Neutralisation 
Solution (TNS) 
Used to neutralise trypsin and EDTA in HUC tissue culture, supplied by 
ScienCell. 
Poly-L-Lysine 10mg/ml stock used at 2µg/cm2 in HUC tissue culture, supplied by 
ScienCell 
Protein Manipulation  
5% Stacking Gel 0.67ml stock acrylamide solution, 0.5ml 1.0M Tris-HCl (pH 6.8), 40Pl 10% 
SDS, 40Pl 10% ammonium persulfate (APS), 4Pl N,N,N’,N’-
tetramethylethylenediamene (TEMED), made up to 4ml with dH2O. 
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8/10/12% Resolving Gel 2.7/3.3/4.0ml stock acrylamide solution, 2.5ml 1.5M Tris-HCl (pH 8.8), 
100Pl 10% SDS, 100Pl 10% APS, 4Pl TEMED, made up to 10ml with dH2O. 
Blocking Buffer 5% (w/v) non-fat powdered milk (Marvel Original) in PBS-T. 
Loading Buffer (5X) 250mM Tris-HCl (pH 6.8), 10% SDS, 50% glycerol, 0.05% bromophenol 
blue, 3.5% β-mercaptoethanol. 
Lysis Buffer (mRIPA) 50mM Tris (pH 7.5), 150mM NaCl, 1% Triton X-100, 1% sodium 
deoxycholate, Complete Protease Inhibitors without EDTA (Roche). 
PBS-T 0.1% (v/v) Tween 20 in PBS. 
Protein Marker Broad range prestained protein markers (New England Biolabs). 
SDS-PAGE Running Buffer 25mM Tris base, 200mM glycine, 0.1% SDS. 
Stock Acrylamide Solution 30% (w/v) acrylamide/methylene bisacrylamide solution (ProtoGel). 
Immunoblot Transfer Buffer 25mM Tris base, 200mM glycine, 10% methanol. 
Virus Preparation  
Buffer A 10mM HEPES (pH 8.0), 1mM CaCl2, 1mM MgCl2, 5mM KCl. 
20% Sucrose  200mg/ml sucrose in Buffer A. 
CsCl Gradient Heavy 548.3mg/ml CsCl in Buffer A. 




Blocking Solution 0.2% gelatin, 0.01% Triton X-100, 0.02% NaN3 in PBS. 
Fixative 3% formaldehyde (methanol free) in PBS. 
Permeabilisation and Quench 
Solution 
50mM NH4Cl, 0.1% Triton X-100 in PBS. 
Non-Permeabilising Quench 2% FCS in PBS. 




Fixative 0.5% glutaraldehyde in 200mM sodium cacodylate. 
Buffer 200mM sodium cacodylate. 
Flow Cytometry  
Fixative 100% ethanol. 
Blocking Buffer 3% BSA, 0.05% NaN3 in PBS. 
DNA Stain 50Pl/ml propidium iodide (PI). 
RNA Protease  0.2mg/ml RNAse A. 
Transfection  
siRNA Transfection Reagent Santa Cruz siRNA transfection reagent (Santa Cruz). 
Plasmid Transfection Reagent TransIT LT1 (Mirus). 
Serum Free Media OptiMEM reduced serum media (Gibco). 
Tandem Mass Tagging  
Lysis Buffer 6M guanidine HCl, 5mM HEPES in proteomic grade water (Bio-Rad).  
DNA Extraction  
Lysis Buffer 4M guanidine thiocyanate, 25mM Tris pH 7, 134mM E-mercaptoethanol. 
Wash Buffer 1 1M guanidine thiocyanate, 25mM Tris pH7, 10% ethanol. 
Wash Buffer 2 25mM Tris pH 7, 70% ethanol. 
Elution Buffer Nuclease free water. 
Miscellaneous  
PBS 138nM NaCl, 2.7mM KCl, 8mM Na2HPO4, 1.5mM KH2PO4 (pH 7.4). 
Prepared by Department of Pathology lab technicians, University of 
Cambridge. 
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7.1.3 Mammalian Cells 
Table 7.2 Mammalian cell lines and types used in this study. 
Cell Line/Type Description 
Renal Proximal Tubule 
Epithelial Cells (RPTEC) 
Primary human kidney epithelium cell, used experimentally from passage 
5-7. RPTECs are the closest model that is currently available for BKPyV 
primary infection site ex vivo (Li et al., 2013) (Lonza). 
hTERT Immortalised Renal 
Proximal Tubule Epithelial 
Cells (RPTEC/TERT1) 
Human telomerase reverse transcriptase (hTERT) immortalised RPTEC 
line, obtained from (American Type Culture Collection (ATCC)). 
Human Urothelial Cells (HUC) Primary human bladder epithelium cell, used experimentally from 
passage 4-10. HUCs are the only other natural host cell culture system 
other than RPTECs available for BKPyV infection ex vivo. 
HeLa Human cervical cancer epithelial cell line originally isolated from patient 
Henrietta Lacks in 1951 (kindly provided by Prof. Paul Lehner, CIMR). 
Vero African green monkey kidney epithelial cells. 
 
7.1.4 Bacterial Cell Lines 
Escherichia coli strain DH5D was used for propagating plasmids and cloning virus. 
 
7.1.5 Viruses 




Lab adapted BKPyV virus shown by this group to grow most efficiently in 
RPTE cells due, in part, to an extremely strong early promoter activity 
(Barcena-Panero et al., 2012). This viral strain was very kindly donated by 
M. Imperiale (University of Michigan). 
SC16 WT Herpes Simplex 
Virus-1 (HSV-1) 
A clinical HSV-1 strain isolated from human oral lesions (Hill et al, 1975). 
 
7.1.6 DNA Plasmids 
Table 7.4 DNA plasmids used in this study.   
Gene Plasmid Description  Source 
BKPyV–D pGEM-BKPyV-D BKPYV-Dunlop in a pGEM vector.  MJI 
KDEL-HRP  pGEM-KDEL-HRP pGEM vector based plasmid containing horse radish 
peroxidase (HRP) conjugated to a KDEL endoplasmic 
reticulum (ER) retention motif. 
MH 
TAg pcDNA3-TAg Large T antigen in pcDNA3 vector. GE 
Plasmids were kindly donated by M. Imperiale, University of Michigan (MJI), Gareth Evans (GE) and 
M. Hollinshead, Dept. of Pathology (MH) 
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7.1.7 Antibodies  
7.1.7.1 Primary Antibodies 
Table 7.5 Primary antibodies used in immunofluoresence microscopy (IF), neutralisation assays (N) and 




Applications and Dilution Source 
BST2 11721 Rabbit IB 1:20,000 NIH 
BK Agno GB17043 Rabbit IF purified 1:500, IB unpurified 1:500 EG 
BK VP1 B5 Mouse IgM IF 1:50 N.Ch 
 C1 Mouse IgG2a N 1:100 N.Ch 
 D11 Mouse IgG2a IF 1:50 N.Ch 
 L5 Mouse IgM IF 1:50 N.Ch 
 P5G6 Mouse IF 1:1000, IB 1:5000 D.Gall 
 PAb597 Mouse IF 1:10 W.At 
Calnexin MAB3126 Mouse IgG2a IF 1:200 MP 
CDK1 MA5-11472 Mouse IgG2a IF 1:100, IB 1:200 TFS 
cFos ab190289 Rabbit IF 1:100 AC 
Cyclin A2 
[Y193] 
ab32386 Rabbit IF 1:100, IB 1:1000 AC 
Cyclin B1 
[Y106] 
ab32053 Rabbit IF 1:100, IB 1:5000 AC 
Cyclin D2 ab207604 Rabbit IF 1:100, IB 1:1000 AC 
EEA1 ab2900 Rabbit IF 1:1000 AC 
Geminin GTX116125 Rabbit IB 1:2000 GT 
GM130 610882 Mouse IgG1 IF 1:1000 BDB 
GORASP1 
[Grasp65] 
ab30315 Rabbit IF 1:5000, IB 1:1000 AC 
GORASP2 
[Grasp55] 
Ab204335 Rabbit IF 1:150, IB 1:500 AC 
HSV-1 gD LP2 Mouse IgG2a N 1:100 A.Min 
IFIT1 PA3-848 Rabbit IB 1:2000 TFS 
IFIT2 12604-1-AP Rabbit IB 1:1000 PT 
IFIT3 SAB1410691 Rabbit IB 1:750 SA 
IFI16 ac-8023 Mouse IB 1:800 SC 
IRF3 11904 Rabbit IB 1:1000 CST 
IRF3 (S386)  ab76493 Rabbit IB 1:5000 AC 
ISG15 2758 Rabbit IB 1:1000 CST 
LAMP1 H4A3 Mouse IF 1:100 DSHB 
LC3B ab51520 Rabbit IB 1:2000 AC 
MDM2 
 
ab16895 Mouse IgG2a IF 1:100 AC 
86934 Rabbit IF 1:400 CST 
MX1 37849 Rabbit IB 1:1000 CST 
p53 ab1101 Mouse IgG2a IF 1:500, IB 1:1000 AC 
SV40 TAg PAb416 Mouse IgG2a IF 1:200, IB 1:1000.  Cross reacts with 
BKPyV TAg 
AC 
SV40 VP2/3 ab53983 Rabbit IF 1:1500, IB 1:5000.  Cross reacts 
with BKPyV VP2/3 
AC 
TGN46 AHP500G Sheep IF 1:200 BR 
Tubulin ab6160 Rat IB 1:2000 AC 
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All antibodies were purchased from AbCam (AC), BD Biosciences (BDB), Bio-Rad (BR), Cell Signalling 
Technologies (CST), Developmental Studies Hybridoma Bank (DSHB), Eurogentec (EG), Gene-Tex (GT), 
MilliPore (MP), National Institutes of Health, USA (NIH), Protein Tech (PT), Santa-Cruz (SC), Sigma-
Aldrich (SA), Thermo Fisher Scientific (TFS) or kindly donated by N. Christensen, John Hopkins (N.Ch), 
W. Atwood, Brown University (W.At), D. Galloway, University of Washington (D.Gall) and A. Minson, 
University of Cambridge (A.Min). 
 
7.1.7.2 Secondary Antibodies 




Applications and Dilution Source 
Anti-Mouse 
488 
A21202 Donkey IF 1:1000 LT 
Anti-Mouse 
568 
A10037 Donkey IF 1:1000 LT 
Anti-Mouse 
647 
A21236 Goat IF 1:1000 LT 
Anti-Mouse 
IgG1 488 
A21121 Goat IF 1:1000 LT 
Anti-Mouse 
IgG1 568 
A21124 Goat IF 1:1000 LT 
Anti-Mouse 
IgG2a 488 
A21131 Goat IF 1:1000 LT 
Anti-Mouse 
IgG2a 568 
A21134 Goat IF 1:1000 LT 
Anti-Mouse 
IgG2a 647 
A21241 Goat IF 1:1000 LT 
Anti-Mouse 
IgM 488 
A21042 Goat IF 1:1000 LT 
Anti-Mouse 
IgM 568 
A21043 Goat IF 1:1000 LT 
Anti-Rabbit 
488 
A21206 Donkey IF 1:1000 LT 
Anti-Rabbit 
568 
A11011 Goat IF 1:1000 LT 
Anti-Rabbit 
647 
A21245 Goat IF 1:1000 LT 
Anti-Sheep 
568 
A21099 Donkey IF 1:1000 LT 
Anti-Goat 
800 
925-32214 Donkey IB 1:10000 LI-COR 
Anti-Mouse 
680 
925-68020 Goat IB 1:10000 LI-COR 
Anti-Mouse 
800 
925-32350 Goat IB 1:10000 LI-COR 
Anti-Rabbit 
680 
925-68073 Donkey IB 1:5000 LI-COR 





925-32213 Donkey IB 1:5000 LI-COR 
Anti-Rat 
680 
925-68076 Goat IB 1:10000 LI-COR 
Anti-Mouse 
HRP 
62-6520 Goat IPer 1:1000 LT 
Secondary antibodies were purchased from Life Technologies (LT) or LI-COR Biosciences (LI-COR). 
 
7.1.8 siRNA 
Table 7.7 siRNA oligonucleotide sequences.   


































siRNA oligonucelotides were sourced from Dharmacon (D). 
 
7.1.9 Active Drugs and Inhibitors 
Table 7.8 Drugs and inhibitors used. 
Drug Description Source 
4,4'-Diisothiocyano-2,2'-
stilbenedisulfonic acid (DIDS) 
A broadly specific anion channel inhibitor. Solubilised in 
DMSO. 
LT 
Brefeldin A (BFA) Inhibits transport from ER to Golgi, induces retrograde 
transport from golgi to ER leading to apoptosis. 
Solubilised in DMSO. 
ELS 
Cidofovir Selective inhibition of viral DNA polymerase, inhibiting 
viral DNA replication. Solubilised in dH2O. 
SA 
Cycloheximide (CHX) Inhibitor of protein synthesis. Solubilised in ethanol. SA 
Monensin Sodium ionophore, secretion of proteins via disruption of 








acetoethyl ester (MQAE) 
Fluorescent intracellular indicator for Cl- used to 
determine changes to chloride anion homeostasis. 
Solubilised in dH2O. 
TFS 
Nutlin-3 Inhibitor of Mdm2:p53 interaction SA 
PD0133922 Inhibitor CDK4 and CDK6. Solubilised in dH2O. SA 
Roscovitine Inhibitor of CDK1, CDK2 and CDK5. Solubilised in DMSO. SA 
RO-3306 Inhibitor of CDK1. Solubilised in DMSO. SA 
Wortmannin PI3K inhibitor. Inhibits autophagosome formation from 
0.1-10μM. Solubilised in DMSO. 
SA 
Inhibitors were purchased from Enzo Life Sciences (ELS), Life Technologies (LT), Sigma-Aldrich (SA), 
Thermo Fisher Scientific (TFS). 
 
7.1.10 Immune Stimulation 
Table 7.9 Immune stimulation materials. 
Stimulator Description Source 
DNA Stimulation Oligo GGGTATATATATGCATATATATAGGG 
dsDNA palindromic oligomer with GGG overhangs. Shown 
to strongly stimulate a cGAS/STING mediated innate 
immune response (Herzner et al., 2015). 
GE 
Poly I:C Double-stranded polyribonucleotide poly(I):poly(C). SA 
IFNα2A Human interferon alpha-2, Type I secreted interferon 
produced during viral infection.   
GL 
Materials supplied by GE Healthcare (GE), Sigma-Aldrich, and kindly donated by the Goodfellow Lab, 
University of Cambridge (GL). 
 
7.1.11 qPCR  
Table 7.10 Primer and probe sequences. 
Primer or Probe Sequence Source 
PolyF (BKPyV Forward) TGTCACGWMARGCTTCWGTGAAAGTT TM 
BKR (BKPyV Reverse) AGAGTCTTTTACAGCAGGTAAAGCAG TM 





Hu TNF Sense (TNFα 
Forward) 
AGGAACAGCACAGGCCTTAGTG TM 
Hu TNF Antisense (TNFα 
Reverse) 
AAGACCCCTCCCAGATAGATGG TM 
TNFα Cy5 Taqman (TNFα 
Probe) 
CCAGGATGTGGAGAGTGAACCGACATG TM 










7.2.1 Eukaryotic Tissue Culture and Manipulation Techniques      
7.2.1.1 Cell Culture Maintenance 
RPTE cells were cultured for use from passage 5-7 only in Renal Epithelial Basal Medium (REBM) 
supplemented with Clonetics REGM SingleQuots containing 0.5ml rhEGF, 0.5ml insulin, 0.5ml 
hydrocortisone, 0.5ml GA-1000 (gentamycin and amphotericin), 2.5ml FCS, 0.5ml epinephrine, 0.5ml 
transferring, 0.5ml T3 (triiodothyronine) all supplied by Lonza. RPTEC/TERT1 cells were maintained in 
50% DMEM (GE Healthcare), 50% Ham’s Nutrient Mixture F-12 with L-glutamine and sodium 
bicarbonate (Sigma), supplemented with SingleQuots Bulletkit containing 0.5ml rhEGF, 0.5ml insulin, 
0.5ml hydrocortisone, 0.5ml GA-1000, 2.5ml FCS, 0.5ml epinephrine, 0.5ml T3, 0.5ml transferrin 
(Lonza). HU cells were cultured for use from passage 4-10 in Urothelial Cell Medium (UCM) 
supplemented with 5ml Urothelial Cell Growth Supplements (UCGS), 100 U/ml penicillin and 100µg/ml 
streptomycin all supplied by ScienCell. HeLa and Vero cells were maintained in DMEM (GE Healthcare), 
supplemented with 10% FCS, 2mM L-glutamine, 100 U/ml penicillin and 100µg/ml streptomycin. In all 
HU cell culturing flasks and plates were coated with 5Pg/cm2 poly-L-lysine (ScienCell). All cells were 
maintained in a humidified atmosphere at 37qC containing 5% CO2.  
 
7.2.1.2 Cell Freezing and Resuscitation 
Cells were harvested, re-suspended in freezing medium and aliquotted to 1x106 cells per freezing vial. 
After slow freezing at -80qC vials were transferred to liquid nitrogen for long-term storage. Individual 
vials of cells were resuscitated at 37qC, and then transferred to a T150 tissue culture flask containing 
appropriate media pre-warmed to 37qC. 24h later any remaining DMSO was removed by replacing the 
medium with fresh culture medium. 
 
7.2.1.3 Cell Culture Subculturing 
RPTE, RPTEC and HU cells were passaged and subcultured on a weekly basis, HeLa and Vero cells were 
passaged and subcultured on a biweekly basis. For RPTE, RPTEC-TERT1, HeLa and Vero cells the culture 
medium was removed from the cell monolayer, which was washed gently with PBS. Trypsin/EDTA was 
then used to detach all cells from the culture flask, incubating for approximately 10 minutes at 37qC. 
The trypsin was then neutralised with 10ml of media and cells harvested then centrifuged (1,400rpm, 
5 minutes at room temperature).   
For HU cells the culture medium was removed from the cell monolayer, which was washed gently with 
PBS. 16ml PBS was added to the flask, along with 4ml Trypsin/EDTA and incubated at 37qC for 1-2 
minutes or until the cells completely rounded up. The Trypsin/EDTA solution was transferred to 5ml 
Chapter 7. Materials and Methods 
180 
 
FCS, while the flask containing cells was incubated at 37qC for a further 1 minute with no solution. 
Cells were then detached with a sharp knock to the flask, and 5ml of trypsin neutralisation solution 
(ScienCell) added. This solution was added to the Trypsin/EDTA and FCS solution. Harvested cells were 
then centrifuged (1,000rpm, 5 minutes at room temperature). 
All cells were resuspended in fresh media and 5x105 cells used to reseed a new passage, or used for 
individual experiments by seeding at varying concentrations diluted further in fresh media. 
 
7.2.1.4 Cell DNA Staining for Analysis by Flow Cytometry 
In order to analyse cellular DNA content of RPTE cells set up in 6 well plates; all media was removed, 
cells were washed once in PBS and detached from wells by adding 1ml trypsin/EDTA, incubating at 
37qC for approximately 15 minutes. After detachment, the cells were pelleted by centrifugation 
(5,000rpm, 5 minutes at room temperature) and the supernatant discarded. The cell pellet was 
resuspended in 1ml PBS, further pelleted by centrifugation (5,000rpm, 5 minutes at room 
temperature) and the supernatant discarded.  Finally the cell pellet was resuspended in 300Pl PBS, 
before 700Pl ice cold 100% ethanol was added and the sample inverted several times to ensure 
thorough mixing.  The sample was then stored at -20qC for at least 24hrs to ensure membrane 
permeabilisation. 
The ethanol fixed and permeabilised samples were then centrifuged (5,000rpm, 5 minutes at 4qC) and 
the ethanol supernatant carefully removed.  The remaining cell pellet was washed twice with ice cold 
PBS and resuspended in 1ml PBS containing 0.2mg RNAse A and 50Pg/ml propidium iodide, then 
incubated at 37qC for 3 hours. The sample was then centrifuged (5,000rpm, 5 minutes at room 
temperature), the supernatant discarded and cell pellet resuspended in 500Pl PBS. 
 
7.2.1.5 Flow Cytometry 
The BD FACSCalibur Flow Cytometry System (BD Biosciences) was used to collect a minimum of 10,000 
cells per sample. Doublets and debris were discriminated against using forward and side light scatter 
gates. Fluorescence intensity corresponding to DNA content was collected in linear mode.  FlowJo 
(v10.5.0) was used to analyse collected flow cytometry data, utilising the Cell Cycle analysis function. 
 
7.2.1.6 siRNA Transfection  
For each transfection two solutions were created, solution A contained 50nM of siRNA and 100Pl 
OptiMEM, while solution B contained 6Pl Santa Cruz siRNA Transfection Reagent and 100Pl OptiMEM. 
The solutions were combined and gently mixed by pipetting. The final mixture was allowed to incubate 
at room temperature for 45 minutes, once incubated 800Pl of appropriate media was added. 
Chapter 7. Materials and Methods 
181 
 
The media on the cells being transfected was removed and cells were washed gently with OptiMEM. 
All OptiMEM was fully aspirated before the prepared siRNA mixture was added to the cells and 
incubated at 37qC for 5-7 hours, after which time a further 1ml of media was added. 
 
7.2.1.7 Plasmid Transfection   
Prior to transfecting the cells media in wells was changed to include 10% FCS and antibiotics were 
removed. For each single well transfection of a 24 well plate 0.2Pg of plasmid DNA was placed in an 
eppendorf tube, to which 0.6Pl Trans-IT LT1 incubated with 20Pl OptiMEM was added. After 20 
minutes incubation plasmid transfection mix was added to each well and further incubated at 37qC. 
 
7.2.1.8 Cell Viability Assay 
Trypsinised cells were incubated in trypan blue (Sigma) for 5 to 15 mins and then counted using a 
haemocytometer. Those cells that were blue and could not exclude the dye were scored as non-viable, 
while those that excluded the dye were scored as viable. 
 
7.2.1.9 MQAE Assay 
In order to test for intracellular chloride cells were incubated with 5mM MQAE for 1 hour. Cells were 
then washed with PBS at least five times and immediately imaged by immunofluorescence with MQAE 
fluorescing in 488nM channel, unless quenched in the presence of chloride. 
 
7.2.1.10 Immune Stimulation  
RPTE cells were plated at 2x105 cells per will in a six well plate. To stimulate with synthetic RNA (Poly 
I:C) or synthetic DNA (DNA Oligo) 24 hours after plating cells were transfected with 2Pg/ml of synthetic 
RNA/DNA, using 7Pl Lipofectamine diluted in 240Pl OptiMEM. To stimulate with IFNα2A 24 hours after 
plating 104 U/ml was added directly to cells. 
 
7.2.2 Virus Techniques    
7.2.2.1 Production of BKPyV Stocks  
BKPyV working stocks were produced using BKPyV pcDNA transfection into RPTE cells, which were 
60% confluent at the time of transfection. In a T150 flask, 16.6Pg of BKPyV genome was added to 10Pl 
TransIT LT-1 (Mirus) and 1600Pl OptiMEM. The resulting transfection mixture was incubated at room 
temperature for 15 minutes. Fresh REGM media supplemented with 5% FCS was added to the RPTE 
cells and the transfection mixture added. The T150 flask was incubated in a humidified atmosphere at 
37qC with 5% CO2 for 1 week to allow cells to grow and propagate infection between cells. After 1 
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week the cells were scraped up into the media, frozen and thawed 3 times. The lysed cells and released 
virus was then transferred to 3 new T150 flasks containing 5% FCS REGM, seeded with 1x106 RPTE 
cells. These T150 were then incubated (37qC, 5% CO2) for a further 3-5 weeks, after which time the 
cells were harvested by scraping up into the media. The media and cell harvest was then frozen to -
80qC, then thawed at 37qC (freeze/thawed) 3 times to release virus.  
 
7.2.2.2 Purification of BKPyV Stocks  
Viral lysates were adjusted to pH 7.4 with HEPES pH 8.0 then centrifuged at 8,000 x g or 30 minutes at 
4qC. Once centrifuged the supernatant was saved on ice and the remaining pellet resuspended in 10ml 
Buffer A. The resuspended pellets were then sonicated at 50-60A for 1 minute in a cup horn sonicator. 
The suspension was then centrifuged at 16,000 x g for 5 minutes at 4qC. Once again the supernatant 
was saved on ice and the remaining pellet resuspended in 10ml Buffer A and 0.1% sodium 
deoxycholate and then incubated at room temperature for 15 minutes. After incubation the 
suspension was centrifuged again at 16,000 x g for 5 minutes at 4qC. The supernatant was saved and 
the pellet discarded. The saved supernatants were then combined and centrifuged over a 20% sucrose 
cushion at 100,000 x g for 3 hrs at 4qC. Upon centrifugation supernatant and sucrose should be 
discarded and a milky pellet residue remain. The milky pellet should be resuspended in 1ml of Buffer 
A and layered over a heavy and light CsCl gradient. The CsCl gradient should be spun at 200,000 x g 
for at least 17 hours at 16qC.  
The top band will contain empty capsids, while the bottom band is infectious virus (Fig. 7.1). This is 
harvested and dialysed against Buffer A for at least 24 hours. The virus stock was then aliquoted and 
stored at -80qC. The sample was subsequently assayed to determine the titre of infectious virus 












Figure 7.1: Typical CsCL 
gradient composition after 
centrifugation.   
The top band (indicated with a 
blue arrow) contains empty 
capsids. The bottom band 
(indicated with a red arrow) 
contains infectious virus and 
must be harvested with a 
needle and dialysed to remove 
any CsCl from the virus 
preparation. 
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7.2.2.3 Fluorescent Focus Unit (FFU) Assay 
In order to titre BKPyV virus in experimental samples RPTE cells were seeded at 5x104 cells per well in 
24 well plates, and then infected with samples in a range of appropriate dilutions. At 48 hpi cells were 
fixed, permeabilised, quenched and blocked, then antibody stained for VP1 (PAb597 antibody). 
Infectious units (IU) were then calculated by counting infected cell numbers using immunofluoresence 
microscopy, multiplying by 341.9 fields of view at x10 magnification, thus giving an IU/ml value. 
 
7.2.2.4 Immunoperoxidase Monolayer Assay 
In order to titre HSV-1 virus in experimental samples RPTE cells were seeded at 5x104 cells per well in 
24 well plates, and then infected with samples in a range of appropriate dilutions. Cells were fixed at 
16 hpi in 4% formaldehyde in PBS for 10 minutes. Cells were then blocked with 5% FBS, 0.5% Tween 
20 in PBS for 30 minutes. Cell monolayer was then incubated with HSV-1 LP2 primary antibody for 1 
hour, washed thoroughly with blocking buffer and then incubated with anti-mouse HRP for a further 
hour. After final incubation cells were washed thoroughly with blocking buffer and then PBS. Cells 
were then developed with DAB peroxidase substrate (ImmPACT DAB HRP peroxidase substrate; 
Vector).  
 
7.2.2.5 Infection of Cells for Fluorescence Microscopy 
Cells were grown on 13mm glass coverslips in a 24 well plate, at 5x104 cells per well, and incubated at 
37qC with 5% CO2. The following day the cells were infected at 1 IU/cell. At varying time points post 
infection cells were fixed, permeabilised, quenched and blocked, preparing them for antibody staining 
and fluorescence microscopy. Slide were images   
 
7.2.2.6 Infection of Cells for SDS-PAGE Analysis 
Cells were seeded in a 6 well plate, at 2x105 cells per well, and incubated at 37qC with 5% CO2. The 
following day the cells were infected at 1, 3 or 5 IU/cell. Cells were harvested at varying time points 
and processed for SDS-PAGE analysis. 
 
7.2.2.7 Virus Growth Curves 
To ascertain rate of viral replication in RPTE and HU cells a growth curve was conducted. Cells were 
seeded in a 6 well plate, at 2x105 cells per well, and incubated at 37qC with 5% CO2. The following day 
the cells were infected at 1 IU/cell. Cells were harvested at 12, 24, 36, 48, 60, 72, 84 and 96 hpi and 
processed for titre analysis by FFU. 
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7.2.2.8 Virus Release Assay 
Cells were seeded in a 6 well plate, at 2x105 cells per well, and incubated at 37qC with 5% CO2. The 
following day the cells were infected at 1 IU/cell. Supernatant containing released virus was harvested 
and centrifuged (5,000rpm, 5 minutes at room temperature) to remove cell debris. Supernatant was 
then transferred to a new eppendorf, taking care not to disturb the pellet, and once again centrifuged 
(5,000rpm, 5 minutes at room temperature). The supernatant was then transferred to Microfuge 
Tubes TLA55 ultracentrifuge tubes (Beckman) and centrifuged in Beckman-Coulter Optima MAX-E 
Ultracentrifuge (100,000 x g, 2 hours at 4qC) using the TLA55 rotor. After centrifugation the 
supernatant was removed from the pelleted virus, and the pellet was resuspended in 70Pl PBS. 
Cells were harvested by scraping up into in 1ml media and to release the cellular associated virus 
samples were freeze/thawed 3 times. FFU assays were conducted on prepared samples. 
 
7.2.2.9 Virus Cell Surface Binding Assay 
RPTE cells were grown on 13mm glass coverslips in a 24 well plate, at 5x104 cells per well, and 
incubated at 37qC with 5% CO2. The following day cells were brought to 4qC and infected at 1 IU/cell 
and incubated for 1 hour at 4qC. 500Pl of chilled media was then added to cells and incubated at 4qC 
for a further 2 hours. At 3 hpi cells were washed gently with PBS and then blocked in 2% FCS for 45 
minutes. Cells were then stained with primary antibodies diluted in 2% FCS for 1 hour. Cells were then 
washed gently again in 2% FCS, then secondary antibodies in 2% FCS added. After a further one hour 
incubation cells were washed with 2% FCS and then fixed in 4% paraformaldehyde. Fixed slides were 
then attached to microscope slides. 
 
7.2.2.10 Inhibitor Assays on Infected Cells 
RPTE cells were seeded in a 6 well plate, at 2x105 cells per well, and incubated at 37qC with 5% CO2. 
Cells were infected with 1 IU/cell the following day and at 1 hpi cells were washed gently with PBS and 
2ml of REGM added 1 hpi cells were washed gently with PBS and 2ml of REGM added. Inhibitors were 
introduced at varying concentrations at 24 hpi. Cells were harvested at 48 h pi by scraping cells into 
the media and prepared for FFU assay, qPCR or immunoblot.  
 
7.2.2.11 Autophagy Assays on Infected Cells 
RPTE cells were seeded in a 6 well plate, at 2x105 cells per well, and incubated at 37qC with 5% CO2. 
Cells were infected with 1 IU/cell the following day and at 1 hpi cells were washed gently with PBS and 
2ml of REGM added 1 hpi cells were washed gently with PBS and 2ml of REGM added. 10nM of the 
autophagy inhibitor wortmannin, or 3Pg/ml Brefeldin A in optiMEM to induce autophagy were 
Chapter 7. Materials and Methods 
185 
 
introduced at a range of times points prior to harvest. Cells and supernatant were harvested 
separately at 48 h pi and prepared for virus release assay or immunolot. 
 
7.2.2.12 Virus Protein Stability Assay  
RPTE cells were seeded in a 6 well plate, at 2x105 cells per well, and incubated at 37qC with 5% CO2. 
Cells were infected with 1 IU/cell the following day and at 1 hpi cells were washed gently with PBS and 
2ml of REGM added 1 hpi cells were washed gently with PBS and 2ml of REGM added. 50ug/ml 
Cyclohexamide (CHX) was added at 0, 12, 24 and 36 hpi. Cells were harvested at 48 h pi by scraping 
cells into the media and prepared for immunoblot.  
 
7.2.2.13 Sample Preparation for Transmission Electron Microscopy (TEM)  
RPTE cells were seeded in a 35mm tissue culture dish at 4x105 cells per well, and incubated at 37qC 
with 5% CO2. Cells were infected at 3 IU/cell and at 72 hpi were fixed for TEM. To fix cells were brought 
to 4qC and washed twice with chilled PBS. Fixative was added for 30 minutes, over which time cells 
were slowly brought up to room temperature. Once fixed cells were washed twice with buffer, then 
incubated at 4qC for 4 hours. Where necessary cells were developed with DAB peroxidase substrate 
(ImmPACT DAB HRP peroxidase substrate; Vector). The cells were then secondarily fixed with 1% 
osmium tetroxide, 1.5% potassium ferricyanide for 1 hour, before being washed in dH2O and treated 
with 0.5% magnesium uranyl acetate overnight at 4qC. After incubation the samples were rinsed again 
in dH2O before being dehydrated in graded ethanol, the samples were then embedded in epoxy resin. 
Ultrathin 50-70nm sections were examined with a FEI Technai G2 Transmission electron microscope 
operated at 120Kv using AMT XR60B digital camera running Deben software. Samples were processed 
by M. Hollinshead of University of Cambridge, Pathology Department. 
 
7.2.2.14 Scratch Assays 
RPTE cells were grown on 13mm glass coverslips in a 24 well plate, at 5x104 or 2x105 cells per well, 
and incubated at 37qC with 5% CO2. The following day cells were infected at 1 IU/cell and incubated 
for 1 hour at 37qC, after which time cells were thoroughly washed with PBS and fresh media added. 
Coverslips were then either left unscratched, scratched immediately or scratched at 24 hpi. At 48 hpi 
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7.2.3 Protein Expression Analysis Techniques 
7.2.3.1 Cell Lysate Preparation for SDS-PAGE Analysis 
Cells were washed gently with PBS and then scraped into 1ml of fresh PBS.  The cells were pelleted by 
centrifugation (5,000rpm, 5 minutes at room temperature) and the supernatant discarded. The cell 
pellets were lysed and resuspended in protease and phosphatase inhibitor supplemented mRIPA (lysis 
buffer) and incubated for 20 minutes on ice.  Centrifugation (13,000rpm, 15minutes at 4qC) was used 
to remove cell debris and the supernatant protein samples were made up in 1x loading buffer. Each 
sample was then boiled for 5 minutes, or left unboiled if staining for TAg. 
 
7.2.3.2 SDS-PAGE Electrophoresis 
Once prepared the protein samples were resolved in SDS-polyacrylamide gels comprising resolving 
and stacking gels using the Bio-Rad Mini-PROTEAN System. In SDS-PAGE running buffer, gels were run 
at 170V for 1 hour. Broad range prestained protein markers (NEB) were used to identify molecular 
weight standards. 
 
7.2.3.3 Immunoblot Analysis 
After separation by SDS-PAGE electrophoresis proteins were transferred onto nitrocellulose 
membranes (0.45Pm) via the ‘wet transfer’ method, using Mini Trans-Blot Electrophoretic Transfer 
Cells (Bio-Rad).  These transfers were completed at 70V for 2 hours at room temperature, or overnight 
at 18V at 4qC.  Once transferred, membranes were placed in immunoblot blocking buffer for at least 
30 minutes at room temperature, followed by incubation in primary antibody for at least 1 hour at 
room temperature. Primary antibodies were diluted in blocking buffer.  After primary antibody 
incubation 3x 5 minute washes with PBS-T were carried out before incubation with infrared-
fluorescent conjugated secondary antibodies at room temperature for 1 hour. Secondary antibodies 
were diluted in PBS-T.  Membranes were finally washed 6x in PBS-T for 5 minutes each, before 
scanning and visualization on the LI-COR Odyssey Infrared Imager. Densitometry analysis of visualised 
bands was conducted on LI-COR Image Studio Software (v5.2.5). 
 
7.2.4 Fluorescence Microscopy Techniques  
For standard fluorescence microscopy images were acquired using either a 60x oil immersion objective 
or 10x objective of an Olympus IX81 wide field microscope in conjunction with Image-Pro Plus 
software. Confocal fluorescence microscopy images were acquired using a 63x oil immersion objective 
of a Leica TCS SP5 II inverted confocal microscope in conjunction with Leica Application Suite software. 
Acquired images were processed using Adobe Photoshop. 
Chapter 7. Materials and Methods 
187 
 
7.2.5 Tandem Mass Tagging Spectrometry 
7.2.5.1 Infection and Harvest of Cells for TMT Analysis 
Either RPTE of HU cells set up at 3x105 cells per well in a 12 well plate. At 24 hpi cells were infected at 
5 IU/cell. After 1 hour cells were washed with proteomic grade PBS thoroughly and fresh media added. 
Cells were harvested for TMT at 24, 48 and 72 hpi. To harvest cells were washed with ice-cold 
proteomic grade PBS, and 75Pl of lysis buffer added. Cells were scraped up into an eppendorf and 
vortexed extensively. After 10 minutes at room temperature the lysates were sonicated on ice using 
the probe sonicator at 25W for 30 seconds. Lysates were then spun at 16,000 x g for 10 minutes, 
supernatant was carefully transferred to a fresh Eppendorf tube and centrifuged again at 16,000 x g 
for 10 minutes. Sample supernatants were then snap frozen in liquid nitrogen. 
 
7.2.5.2 Whole cell lysate protein digestion  
(Details provided by Weekes Lab, where this procedure was conducted) 
Dithiothreitol (DTT) was added to a final concentration of 5 mM and samples were incubated for 20 
mins. Cysteines were alkylated with 14 mM iodoacetamide and incubated 20 min at room 
temperature in the dark. Excess iodoacetamide was quenched with DTT for 15 mins. Samples were 
diluted with 200 mM HEPES pH 8.5 to 1.5 M guanidine followed by digestion at room temperature for 
3 h with LysC protease at a 1:100 protease-to-protein ratio. Samples were further diluted with 200 
mM HEPES pH 8.5 to 0.5 M guanidine. Trypsin was then added at a 1:100 protease-to-protein ratio 
followed by overnight incubation at 37°C. The reaction was quenched with 5% formic acid, then 
centrifuged at 21,000 g for 10 min to remove undigested protein. Peptides were subjected to C18 
solid-phase extraction (SPE, Sep-Pak, Waters) and vacuum-centrifuged to near-dryness. 
 
7.2.5.3 Peptide labelling with tandem mass tags and fractionation 
(Details provided by Weekes Lab, where this procedure was conducted) 
Desalted peptides were dissolved in 200 mM HEPES pH 8.5. Peptide concentration was measured by 
microBCA (Pierce), and 25 JRISHSWLGHlabeled with TMT reagent. TMT reagents (0.8 mg) were 
dissolved in 43 μl anhydrous acetonitrile and 3 μl added to peptide at a final acetonitrile concentration 
of 30% (v/v). Samples were labelled as follows; 
126 – HU cells mock infection 24 hpi, 127N – HU cells mock infection 72 hpi, 127C – HU cells BKPyV 
infection 24 hpi, 128N – HU cells BKPyV infection 48 hpi, 128C – HU cells BKPyV infection 72 hpi, 129N 
– RPTE cells mock infection 24 hpi, 129C – RPTE cells mock infection 72 hpi, 130N – RPTE cells BKPyV 
infection 24 hpi, 130C – RPTE cells BKPyV infection 48 hpi, 131N – RPTE cells BKPyV infection 72 hpi. 
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Following incubation at room temperature for 1 h, the reaction was quenched with hydroxylamine to 
a final concentration of 0.3% (v/v). TMT-labelled samples were combined at a 1:1:1:1:1:1:1:1:1:1 ratio. 
The sample was vacuum-centrifuged to near dryness and subjected to C18 SPE (Sep-Pak, Waters). 
After an unfractionated singleshot quantities of each TMT labelled sample were adjusted prior to high 
pH reversed-phase (HpRP) so that normalisation factors were >0.25 and <1.5. TMT-labelled tryptic 
peptides were subjected to HpRP fractionation using an Ultimate 3000 RSLC UHPLC system (Thermo 
Fisher Scientific) equipped with a 2.1 mm internal diameter (ID) x 25 cm long, 1.7 µm particle Kinetix 
Evo C18 column (Phenomenex). This yielded combined fractions which were dried in a vacuum 
centrifuge and resuspended in 10 µl MS solvent (4% MeCN / 5% formic acid) prior to LC-MS3.  
 
7.2.5.4 LC-MS3 
(Details provided by Dr. Robin Antrobus, who conducted the mass spectrometry) 
Mass spectrometry data was acquired using an Orbitrap Lumos (Thermo Fisher Scientific, San Jose, 
CA). An Ultimate 3000 RSLC nano UHPLC equipped with a 300 µm ID x 5 mm Acclaim PepMap µ-
Precolumn (Thermo Fisher Scientific) and a 75 µm ID x 50 cm 2.1 µm particle Acclaim PepMap RSLC 
analytical column was used. 
Loading solvent was 0.1% FA, analytical solvent A: 0.1% FA and B: 80% MeCN + 0.1% FA. All separations 
were carried out at 55°C. Samples were loaded at 5 µL/minute for 5 minutes in loading solvent before 
beginning the analytical gradient. The following gradient was used: 3-7% B over 3 minutes, 7-37% B 
over 173 minutes, followed by a 4 minute wash at 95% B and equilibration at 3% B for 15 minutes. 
Each analysis used a MultiNotch MS3-based TMT method (McAlister et al., 2012, McAlister et al., 
2014). The following settings were used Th, 120,000 Resolution, 2x105 automatic gain control (AGC) 
target, 50 ms maximum injection time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, 
CID fragmentation (normalised collision energy (NCE) 35) with ion trap scanning in turbo mode from 
m/z 120, 1.5x104 AGC target, 120 ms maximum injection time. MS3: In Synchronous Precursor 
Selection mode the top 6 MS2 ions were selected for HCD fragmentation (NCE 65) and scanned in the 
Orbitrap at 60,000 resolution with an AGC target of 1x105 and a maximum accumulation time of 150 
ms. Ions were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target 
time of 3 s. Dynamic exclusion was set to +/- 10 ppm for 70 s. MS2 fragmentation was trigged on 
precursors 5x103 counts and above. 
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7.2.5.5 Data analysis 
(Details provided by Weekes Lab, where this procedure was conducted) 
Mass spectra were processed Sequest-based “MassPike” software pipeline for quantitative 
proteomics, through a collaborative arrangement with Professor Steve Gygi’s laboratory at Harvard 
Medical School.  
A combined database was constructed from (a) the human Uniprot database (4th February, 2014), (b) 
the BK polyomavirus database (6th October, 2014). The combined database was concatenated with a 
reverse database composed of all protein sequences in reversed order. Searches were performed 
using a 20 ppm precursor ion tolerance (Haas et al., 2006). Product ion tolerance was set to 0.03 Th. 
Peptide spectral matches (PSMs) were filtered to an initial peptide-level false discovery rate (FDR) of 
1% with subsequent filtering to attain a final protein-level FDR of 1% (Kim et al., 2011, Wu et al., 2011). 
Proteins were quantified by summing TMT reporter ion counts across all matching peptide-spectral 
matches using ”MassPike”, as described previously (McAlister et al., 2012, McAlister et al., 2014). 
Peptides meeting the criteria for reliable quantitation were then summed by parent protein, in effect 
weighting the contributions of individual peptides to the total protein signal based on their individual 
TMT reporter ion yields. Protein quantitation values were exported for further analysis in Excel. 
 
7.2.6 DNA Manipulation Techniques 
7.2.6.1 Transformation of DNA into competent E. coli 
For the growth of pGEM-BKPyV plasmid volumes, heat shock was used to transform DH5D E. coli. 3Pl 
of DNA was mixed with 50Pl of competent E. coli and incubated on ice for 30 minutes, followed by 
heat shock at 42qC for 30 seconds. The transformed E. coli were then incubated on ice for a further 2 
minutes. After incubation transformed cells were added to 200Pl 2TY and shaken at 37qC for 1 hour. 
Samples could then be grown up to larger volumes overnight in 2TY at 37qC while shaken. 
 
7.2.6.2 Plasmid Vector Removal 
DNA plasmids were harvested from E. coli using the Plasmid DNA purification NucleoBond Xtra Midi 
kit (Macher-Nagel) as per the manufacturers instructions. BKPyV genome was cleaved from its pGEM 
vector backbone in 50Pl reactions of 20Pg DNA, 2Pl BamH1 and 2Pl BSA1 in BufferB incubated 
overnight at 37qC. After incubation pGEM vector was separated from BKPyV by 0.8% agarose gel 
(dissolved in TBE) with ethidium bromide, run at 100V for 2 hours in 1x TBE running buffer. 1kB plus 
DNA ladder (Invitrogen) was used to determine molecular weight standards. Bands were then 
visualised on the UV transilluminator and 5kB BKPyV bands were cut from agarose and purified using 
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QUAQuick Gel extraction kit (Qiagen) as per the manufacturers instructions. Genomes were then 
ligated in 20Pl aliquots of T4 Ligase Buffer with 1PL T4 Ligase (NEB) and 17Pl purified BKPyV. 
 
7.2.6.3 Cellular DNA Harvest and Extraction 
Cells were pelleted and 200Pl lysis buffer added. Once incubated at 56qC for 10 minutes 200Pl of 100% 
ethanol was added, then centrifuged through silica columns (Epoch Lifescience) at 13,000rom for 1 
minute. The flow through was discarded and column washed with Wash Buffer 1 by centrifuging at 
13,000rpm for 1 minute. Once again the flow through was discarded and the column washed with 
Wash Buffer 2 by centrifuging at 13,000rpm for 2 minutes. The column was then moved to a nuclease 
free eppendorf and 200Pl of Elution Buffer added to the column. The DNA was then eluted by 
centrifuging at 13,000rpm for 1 minute. Samples were stored at -20qC. 
 
7.2.6.4 qPCR 
BKPyV genome and TNFD loads were measured by quantitative real-time PCR using HotStarTaq kits 
(Qiagen). Assays were performed in 20Pl total reaction mixtures that contained 8Pl extracted DNA 
sample and 12Pl mastermix (Table 7.11). 
 
Table 7.11: Mastermix total final concentrations made in MiiliQ water. 
Optimised Ingredient BKPyV TNFD 
PCR Buffer (Qiagen) 1x 1x 
MgCl2 2.5mM 10mM 
DMSO N/A N/A 
dNTPs 2.5mM 250PM 
HotStartTaq DNA 
Polymerase (Qiagen) 
0.04 U/Pl 0.04 U/Pl 
Forward Primer (Poly F) 300nM (Hu TNF sense) 50nM 
Reverse Primer (BKR) 300nM (Hu TNF antisense) 900nM 
Probe (BK Taqman Probe FAM) 
50nM 
(TNFD Cy5 Taqman) 50nM 
 
Amplifications and detection were performed on a Rotor Gene RG-3000 (Corbett Research). Initial 
denaturation and polymerase activation was at 95qC for 15 minutes, followed by 45 cycles of 
denaturation at 95qC for 15 seconds, and elongation at 60qC for 1 minute. Each experiment was 
conducted in triplicate, with the threshold cycle value for each sample and copies per sample obtained 
using Rotor Gene Software v.6 (Corbett Research). 







































Figure S1:  Infectious BKPyV release from RPTE cells conducted by Dr G Evans.  
The levels of BKPyV secretion in uninhibited cells was determined prior to the start of this PhD. RPTE cells were 
BKPyV infected at 1 IU/cell. At 48 hpi supernatant media and cell associated virus were harvested 
independently. To determine the virus concentration in each harvest an FFU assay was conducted (a). The 







































Figure S2: BKPyV genome release from 
RPTE cells conducted by Dr. G Evans.  
The effect of DIDS on BKPyV genome 
secretion was determined prior to the 
start of this PhD. RPTE cells were BKPyV 
infected at 1 IU/cell and treated with 
DIDS at increasing concentrations, or 
DMSO as a control, at 24 hpi. At 48 hpi 
supernatant media and cells were 
harvested independently. Genome levels 
were detected from each sample using 
qPCR and analysed using Rotor-Gene (a). 
Percentage of BKPyV genomes released 












Figure S3: GORASP siRNA knockdown; individual experiment data.  
RPTE cells were treated with double 100mM siRNA knockdowns of GORASP1, GORASP2, a combination of GORASP1 
and 2, or ConX as a control for 96 h. Cells were infected with BKPyV (1 IU/cell) after 48 h of siRNA treatment and at 
48 hpi cells and supernatant were harvested separately for FFU assay of viral titre. (a & b) Experiment 1; (c & d) 











    
Figure S4: STRING analysis of most significantly (p < 0.0005) down regulated proteins in RPTE and HU cells. 
Those proteins that were observed to be decreased in abundance RPTE (a, c & e) or HU (b, d & f) cells at each time 
point (as shown in Fig. 4.4) were analysed using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). 
STRING analysis shows each protein represented as a spot, with connections made between proteins representing 
known and predicted protein-protein interactions, the heavier the connecting line, the more confidence in the 
interaction based on experimental, co-expression, co-occurrence, gene fusion, textmining or neighbourhood 




(a) RPTE cells; 24 h. (d) HU cells; 24 h. 
(b) RPTE cells; 48 h. (e) HU cells; 48 h. 
(c) RPTE cells; 72 h. (f) HU cells; 72 h. 




(a) RPTE cells; 24 h. 
(b) RPTE cells; 48 h. 
(c) RPTE cells; 72 h. 






Figure S5: STRING analysis of most significantly (p < 0.0005) up regulated proteins in RPTE and HU cells. 
Those proteins that were observed to be increased in abundance RPTE (a, b & c) or HU (d, e & f) cells at each time point 
(as shown in Fig. 4.4) were analysed using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). STRING 
analysis shows each protein represented as a spot, with connections made between proteins representing known and 
predicted protein-protein interactions, the heavier the connecting line, the more confidence in the interaction based 
on experimental, co-expression, co-occurrence, gene fusion, textmining or neighbourhood evidence.   
 
 
(d) HU cells; 24 h. 
(e) HU cells; 48 h. 
(f) HU cells; 72 h. 


































Table S1: Inhibitor screen conducted by Dr G Evans.  
The effects of various trafficking and ClC inhibitors on BKPyV secretion were determined prior 
to the start of this PhD. RPTE or VERO cells were BKPyV infected at 1 IU/cell and treated with 
inhibitors at a variety of concentrations, or DMSO as a control, at 24 hpi. At 48 hpi supernatant 
media and cells were harvested independently. To determine the virus concentration in each 
harvest an FFU assay was conducted. The proportion of released BKPyV was determined, 
normalised to the uninhibited controls for each experiment.  
* = cell death was observed in these inhibitions; some caution must be given when analysing 
these data. 
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